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Is it I, or is it n o t!
It means nothing 
Yet it explains the world 
It achieves so little 
Yet does so much 
It cant go on 
Yet it fails to be stopped 
It grows, multiplies, progresses 
Yet it never changes 
It concentrates on a void 
Yet produces a masterpiece 
It is darkness 
Yet it lights up in us 
It is nothing 
But it is something 
It is death and life 
Yet it contradicts itself 
It is a paradox, an enigma 
Yet fully comprehensible 
It is I 
And it is not
March 8th, 1991, Declan P Bogan
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ABSTRACT
The research presented in this thesis has centered on the development of newer and better 
techniques for the determination of coumann, 7-hydroxycoumann and 7-hydroxycoumann- 
glucuromde The methods developed were applied to clinical studies of biological fluids 
including serum, plasma and urine and after in vitro metabolism of coumann and 7- 
hydroxycoumann The techniques employed include capillary electrophoresis (CE), high- 
performance liquid chromatography (HPLC) and antibody-based immunoanalytical 
techniques
A separation based on capillary electrophoresis (CE) was developed for determining free and 
total 7-hydroxycoumann in serum and unne after the in vivo metabolism of coumann The 
compound was extracted into ether, evaporated to dryness and reconstituted into phosphate 
buffer before analysis by CE The separation method developed was then applied to the 
determination of 7-hydroxycoumann, without sample clean-up, after in vitro metabolism of 
coumann by liver microsomal suspensions The inter-species and inter-individual variation in 
coumann metabolism was assessed A large variation within species (human microsomal 
preparations - n = 5) and between species (n = 10) was found Another CE method was 
developed for the direct determination of free 7-hydroxycoumann and conjugated 7- 
hydroxycoumann in unne after in vivo metabolism of coumann This method was also 
applied to the determination of 7-hydroxycoumann-glucuronide after in vitro metabolism of 
7-hydroxycoumann by undine diphosphate glucuronyl transferase in a crude enzymatic 
preparation from liver
High-performance liquid chromatography was used for the determination of coumann, 7- 
hydroxycoumann and 7-hydroxycoumann-glucuronide in unne, plasma and serum An 
isocratic separation method was utilised for the determination of total 7-hydroxycoumann 
after the administration of 7-hydroxycoumann to patients diagnosed with a range of cancers 
The method was used to determine the pharmacokinetic profile of serum levels of the drug 
A range of 7-hydroxycoumann doses were given (100 mg - 7000 mg) and the mtenndividual 
variations in 7-hydroxycoumann metabolism were determined Separations were based on 
enzymatic deconjugation of 7-hydroxycoumann from the glucuromde form, followed by 
extraction into ether, evaporation to dryness, and reconstitution into methanol before analysis
v
by HPLC A gradient separation method was also developed for the direct determination of 
coumann, 7-hydroxycoumann, and 7-hydroxycoumann-glucuromde in urine, plasma and 
serum after the in vivo metabolism of coumann and 7-hydroxycoumann The method was 
also used for the determination of 7-hydroxycoumann-glucuromde after the in vitro 
metabolism of 7-hydroxycoumann by a crude enzymatic preparation from liver
A 7-hydroxycoumann-thyroglobuhn protem-drug conjugate was prepared It was used in 
the generation of rabbit polyclonal antibodies Antibodies raised against the protein-drug 
conjugate were screened against another protein-drug conjugate (bovine serum albuimn-7- 
hydroxycoumann) to determine the antibody titre The antibodies raised were purified from 
rabbit serum, characterised and utilised in an enzyme-linked immunosorbent assay
VI
ABBREVIATIONS
Ab antibody
Ag antigen
Ag/AgCl silver silver chlonde reference electrode
BIAcore bio specific interaction analysis
BSA bovine serum albumin
ca approximately
CE capillary electrophoresis
CMC critical rmcellar concentration
CZE capillary zone electrophoresis
ELISA enzyme-linked immunosorbent assay
EOF electroosmotic flow
Fab variable portion of IgG molecule
Fc constant portion of IgG molecule
GC gas chromatography
GC-MS gas chromatography with mass spectral detection
H202 hydrogen peroxide
HPLC high performance liquid chromatography
HRP horse-radish peroxidase
IgG immunoglobulin of the G class
IR infrared analysis
MECC rmcellar electrokinetic capillary chromatography
NADPH nicotinamide adenine dinucleotide phosphate
NMR nuclear magnetic resonance
7-OHC 7-hydroxycoumann
7-OHCG 7-hydroxycoumann-glucuronide
7-OHC-BSA 7 - hydroxycoumann- bovine serum albumin protein conjugate
pNPP paramtrophenol phosphate
% R S D orRSD percentage relative standard deviation
S D or St Dev standard deviation
TLC thin layer chromatography
UV ultraviolet
UDPGA undine diphosphate glucuronic acid
UDPGT undine diphospahte glucuronyl transferase
vu
UNITS
jag/ml or ug/ml micrograms per millilitre
mA rmlliamperes
mg milligrams
kDa Kilodaltons
Da Daltons
0 C degrees centigrade
Kg kilogram
cm centimetre
jam micron, micrometre
cm1 wavenumber per centimetre
jLil microlitre
jiamps rmcroamperes
L litre
mol mole
M  molar
jiM micromolar
m M  nullimolar
ppm parts per million
min minutes
h hour
A U absorbance units
RU response units
nm nanometres
MHz megahertz
pH log hydrogen ion concentration
V volts
kV kilovolts
rpm revolutions per minute
p s 1 pounds per square inch
g times gravity
A/Ao absorbance divided by the maximal absorbance
v/v, w/v dilution percentage as volume or weight per volume
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1.0 INTRODUCTION
The ubiquitous nature of coumann and its many derivatives, in industry, medicine, and 
in the environment, have led many investigators to search for methods of analysis of 
coumann and its denvatives (Casley-Smith and Casley Smith, 1986, Murray, 1989, Egan 
et a l, 1990, Keating and O’Kennedy, 1996) The methods thus far developed cover a wide 
range of analytical techniques, encompassing more traditional methods, eg paper 
chromatography, or colounmetnc approaches, and currently available general techniques, 
e g high-performance liquid chromatography, capillary electrophoresis, and 
immunochemical, and some specific methods e g centrifugal partition chromatography 
There is a need to determine coumann and its denvatives m assessing their clinical efficacy, 
their effects on foodstuffs, and their industrial applications The methods used need to be 
applicable to a vanety of matnces, to a range of concentrations, sensitive, and they need to 
be reproducible, reliable, and accurate In this chapter structures, nomenclature and 
occurrence of coumanns are descnbed The principle section deals with the broad range of 
analytical methods available for coumann analysis These are cntically examined m relation 
to their application to the analysis of coumann, and some of its denvatives, with special 
reference to 7-hydroxycoumann
4
1 0 1  The Structure of the Coumanns
The coumanns belong to a group of compounds known as the benzopyrones, all of which 
consist of a benzene ring joined to a pyrone ring - a six-membered heterocyclic ring 
containing one oxygen atom and five sp2-hybndised carbons Both g- and a- pyrones exist, 
with the prefixes referring to the position at which the oxygen atom is found Figure 
10 11 shows the structure of a-pyrone
F i g u r e  1 0 1 1
0 ^ 0  
T h e  s t r u c t u r e  o f  a - p y r o n e
Coumann (Figure 10 12) and the other members of the coumann family are benzo-a- 
pyrones, while the other main members of the group - the flavonoids - contain the g-pyrone 
group
F i g u r e  1 0 1 2 T h e  s t r u c t u r e  o f  c o u m a n n
The coumanns display a characteristic fluorescence upon excitation with ultra-violet light, 
in addition to having a large range of physiological activity Many coumanns are comprised 
of isoprenoid chains joined to one of the carbons of the nucleus, or to an oxygen atom, for 
example, a phenolic oxygen The isoprenoid chains may consist of one, two or three units, 
and many variations of this type of structure are to be found among the coumanns 
Interactions of the phenyl group with an ortho-phenolic group can lead to the formation of 
another heterocyclic ring Oxidative interaction may also occur As the vast majonty of the 
coumanns are oxygenated at C-7, 7-hydroxycoumann (Figure 1013) is frequently 
considered to be the parent compound for the more structurally complex members of the 
family Coumanns may also be found in nature in combination with sugars, as glycosides
5
The coumanns can be roughly categorised as follows
a) Simple
These members of the coumann family are the hydroxylated, alkoxylated and alkylated 
derivatives of the parent compound, coumann, along with their glycosides 7- 
hydroxycoumann (Figure 1 0 1 3 ) is a member of this group
F i g u r e  1 0 1 3  T h e  s t r u c tu r e  o f 7 - h y d r o x y c o u m a n n
b) Furanocoumanns
These compounds consist of a five-membered furan nng attached to the coumann nucleus 
Most of the members of this group are denvatives of the linear furanocoumann psoralen 
(Figure 1 0 1 4 ), or its more stable angular isomer, angelicin (Figure 1015)
F i g u r e  1 0 1 4  T h e  s t r u c t u r e  o f  p s o r a le n
The terms “linear” and “angular” refer to the onentation of the furan nng with respect to 
the coumann nucleus The dihydrofuranocoumanns are also members of this group
F i g u r e  1 0 1 5  T h e  s t r u c t u r e  o f  a n g e lic in
6
c) Pyranocoumanns
Members of this group are analogous to the furanocoumanns, and contain a six-membered 
nng As with the furanocoumanns, linear and angular types exist (Figure 1016 and 
1017)
0
F i g u r e  1 0 1 6  T h e  s t r u c t u r e  o f  x a n t h y le t in  ( l in e a r )
F i g u r e  1 0 1 7 T h e  s t r u c t u r e  o f  s e s e lin  ( a n g u la r )
d) Coumanns substituted in the pyrone nng
Examples of this group include 4-hydroxycoumann (Figure 1 0 1 8 ) and the 3-methyl-4- 
hydroxycoumanns, such as autumnanol (Figure 1019)
OH
F i g u r e  1 0 1 8  T h e  s t r u c t u r e  o f  4 - h y d r o x y c o u m a n n
F i g u r e  1 0 1 9 T h e  s t r u c t u r e  o f  a u t u m n a n o l
1
1 0  2 Nomenclature
Coumann compounds are known by their common generic titles, generally related to their 
source, as well as their standard IUPAC names This is illustrated with the nomenclature of 
coumann itself The parent compound, coumann, is vanously known as 2-oxo-l,2-benzo- 
pyran, 5,6-benzo-a-pyrone, 5,6-benzo-2-pyrone, 1,2-benzopyrone, 2H-l-benzopyran-2- 
one, cis-o-coumanc acid lactone, 2H-benzo[6]pyran-2-one, coumanmc anhydride and 2H- 
chromen-2-one and coumann Members of the coumann family have been isolated from 
hundreds of species of plants and microorganisms, giving rise to another problem in the 
naming of the compounds Many of the coumanns that have been isolated are known by 
common names, which are generally based upon the latin or colloquial name of the plant in 
which they have been discovered, or from the place where the plant grows, resulting in the 
same compound having several different trivial names Frequently, the tnvial names which 
have been assigned to these compounds give little or no information as to its structural 
composition, and in some cases may even be misleading For example, 7-hydroxycoumann 
(Figure 1 0 1 3 ) is also known as umbelhferone, skimmetin, hydrangin and Dichnn A
1 0  3 Occurrence
Although some have been discovered in animals and microorganisms, most of the naturally 
occurring coumanns have been extracted from higher plants The nchest sources have 
been the Rutaceae and Umbelhferae, where all parts of the plant have been discovered to 
contain coumanns The coumanns belong to a group known as the secondary products of 
plant metabolism, the exact roles of which in plant physiology are not clearly understood 
While being distnbuted throughout all parts of the plant, the coumanns occur at the highest 
levels in the fruits, followed - in order of decreasing occurrence - by the roots, stems and 
leaves In addition, seasonal changes and environmental conditions may affect the 
occurrence in vanous parts of the plant
Of the lower plants, neither algae or mosses have been reported to contain coumanns 
Complex coumanns such as novobiocin and chartreusm have, however, been discovered in
8
bacteria Several coumanns - most notably, perhaps, the aflatoxins - have been extracted 
from fungi
The Castoreum pigments have been isolated from the yellow secretions of beaver sweat 
glands Murray et al (1988) and Keating and O’Kennedy (1996) gave a comprehensive 
overview of the chemistry and occurrence of natural coumanns, including a table of the 
botanical sources of all of the coumann compounds known at time of publication
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1 1 THE ANALYSIS OF COUMARINS -
AN HISTORICAL BACKGROUND
The presence of coumann in plant extracts or as a flavouring component was of interest to 
the early coumann analysts Paper chromatography, thin layer chromatography, 
colounmetnc assays and polarography were all used These more traditional analytical 
methods were applied to the analysis of chocolate (Gardner, 1954), sweet clover (Ferencz 
and Veres, 1953), flavourings (Nivoli, 1950, Ensrmnger, 1952, Stoll and Bouteville, 1954, 
ted Heide and Lemmens, 1954) and plant extracts (Patzak and Neugebauer, 1952, Riedl 
and Neugebauer, 1952, Svedsen, 1952, FofFam, 1953) The majonty of these techniques 
were applied primarily for the qualitative determination of coumann and/or its denvatives
The concentration of coumann and denvatives was determined by colounmetnc assays 
(Ensminger, 1952) or by using the ultraviolet (UV) absorption spectra of the denvative of 
interest after chromatographic separation (Nivoli, 1950) Coumann was treated with p- 
annnophenol to selectively determine it in the presence of vanillin (Nivoli, 1950)
Paper chromatography was also used for the separation of coumanns Separation with 
butanol acetone water (Swain, 1953), acetic acid butylene glycol water (Berhngozzi and 
Fabbnm, 1954), or ammonia butanol water (ted Heide and Lemmens, 1954), were some 
examples of mobile phases used for the separation of coumann and its denvatives in 
organic flavourings or in plants After separation of coumann from other endogenous 
species present in the matrix of interest it is possible to visualise coumann after treatment 
with an alkali or after photocatalysis Coumann can be visualised by treating the 
chromatogram, after separation, with alkali eg KOH, or Na2C0 3 (Mitchell, 1953, 
Berhngozzi and Fabbnm, 1954, ted Heide and Lemmens, 1954, Stoll and Bouteville, 1954) 
The coumanmc salt produced is fluorescent and the intensity can be used to determine 
coumann concentrations Photocatalysis was another technique (Feigl et a l, 1955) utilised 
for coumann and 7-hydroxycoumann detection after paper chromatographic separation 
Here the chromatogram was treated with an alkali, irradiated to form a trans isomer that
1 0
fluoresces blue for 7-hydroxycoumann and yellow-green for coumann under UV light 
The limit of detection of the method was 5 ng
Denvatisation of coumann was also investigated for use in qualitative and quantitative 
analysis (Glenn and Peake, 1955, Wild, 1964, Anger and Richter, 1965) The analysis was 
based on the formation of acidic products, amides of ethylenediamine, or coloured 
products After coumann was dissolved in ethylenediamine, a rapid visual indicator, or the 
potentiometnc response of the denvative, was utilised for its determination (Glenn and 
Peake, 1955) The coloured diazocoupled product (Wild, 1964), formed between 
diazotised sulfamhc acid and coumann (Wild, 1964), had a linear detection range between 
01 -07 g/L The sodium salt of coumanmc acid (formed by reaction of coumann and 
alkali) was reacted with 2,6-dichloroquinone-4-chloroimide to form a blue indophenol dye 
(Anger and Richter, 1965) Their method had a linear detection range between 2-10 
mg/ml
The emergence of more sophisticated analytical technology in the nineteen sixties and 
seventies led to its application for the determination of coumann and its denvatives Gas 
chromatography was applied to the determination of coumann as a contaminant of 
flavourings (Bucci et a l , 1965, Johansen, 1965) Limits of detection were in the order of 
0 2 mg, or 0 01% of sample with an electron capture detector
Today high performance liquid chromatography, gas chromatography, biosensors, and, 
capillary electrophoresis are routinely used for the analysis of coumann and its analogues 
Method development, data handling and the applicability of these techniques are made 
more straightforward by the development of computer controlled systems
1 1
12 CHROMATOGRAPHIC ANALYSIS OF COUMARINS
One of the most widespread analytical tools is chromatography The basis of 
chromatography is the separation of components in a mixture and their selective detection 
Table 1 2 1 is a table summarising some of the chromatographic techniques available that 
have been used for the determination of coumann and 7-hydroxycoumann
1.2.1 Thin-Layer Chromatography
The principle of thin-layer chromatography (TLC) is the separation of compounds on a 
coated solid surface with a liquid earner phase, typically a silica coated stationary phase, 
with an organic mobile phase The compound is applied to the solid surface and interaction 
with the earner phase, in which the components migrate along the solid surface, enables 
separation A range of solid and mobile phases have been assessed for their applicability to 
the separation of coumann and its denvatives Typically, TLC was used as a purely 
qualitative method but it is possible to use TLC in quantitative analysis
1 2 1 1  M e t a b o lis m  o f  u m b e U if e r o n e  a n d  H e r m a n n
The metabolism of 7-hydroxycoumann (umbeUiferone) and 7-methoxycoumann (hemiann) 
was followed by TLC (Indahl and Scheline, 1971) Separation of the principle metabolites 
was achieved with benzene-glacial acetic acid-water (6 7 3, v/v/v), and with, potassium 
chlonde-glacial acetic acid (100 1 v/v), on thin layer cellulose plates (Sigmacell type 19, 
and Macherey, Nagel & Co M N  300 plates) After separation, the spots on the TLC 
plates were observed under UV light (fluorescence at 254 nra) or by spraying with fast blue 
B salt The different compounds gave a vanety of different colours eg 7- 
hydroxycoumann (purplish-white), 7-methoxycoumann (pinkish-white), 6,7- 
dihydroxycoumann (greenish-yellow), and 3,4-dihydro-7-hydroxycoumann (reddish- 
violet) The method was used for studying the metabolism of 7-hydroxycoumann in rats 
after oral and intrapentoneal administration
1 2
Method & 
Application
Mode of Detection Limit of 
Detection
Reference
Thin layer 
chrom atography
In vivo 7-OHC Colounmetnc 1 ng/ml Johansen et al (1965)
metabolism Fluorescence 5 ng Cholerton et al (1992)
Vanilla flavouring Fluorescence 500 ng Indah let al (1971)
High perform ance 
liquid chrom atography
UV absorbance (Coumann) Sherma et al (1987) 
Poole et al (1993)
In vivo coumann 
metabolism
UV absorbance 500 ng/ml (7-OHC)
0 3 ng/ml (7-OHC & 
7-OHCG)
Moran et al (1987), 
Egan et al (1992) 
Shanfi et al (1993)
In vitro metabolism UV absorbance Fentem et al (1991)
Coumann Radiochemical Lake et al (1992), van 
Iersel et al (1994), 
S teensm aeia/ (1994)
Coumann in 
Foodstuffs
UV absorbance 0 6 ng/ml Thompson et al 
(1988) Mazza (1984),
Plant extracts
Gas chrom atography
Coumann in
1 ng/ml Gam achee/tf/ (1993) 
Archer (1988),Nykolov 
et al (1993)
Hawthorne et al
Flavours/Fragrances Mass Spec 
FTIR
7 7 ng/ml (1988), Grundschober 
(1991)
Tobacco FID/ Mass Spec 0 05 mg/g Chnstakopoulus et al 
(1992)
Table 121 Summary o f the chromatographic methods of analysis o f 
coumanns Table o f method o f separation, detection, the limits o f detection (where 
available) and the reference
12 12 TLC o f vanilla flavourings
High performance silica gel TLC was used to qualitatively and quantitatively determine 
coumann in real and artificial vanilla flavourings (Sherma et a l, 1987) Samples and 
standards were spotted onto Whatman LHPKD preadsorbent silica gel plates Separation 
was earned out with toluene-methanol (97 3, v/v) and visualised under UV light by 
spraying with NaOH Coumann was detected as a fluorescent or coloured zone and
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quantified by scanning with a densitometer The limit of detection was 5 ng for 
fluorescence and 500 ng for absorbance Belay et al (1993) determined vanillin and the 
adulterant, coumann, in a variety of natural vanilla beans, by TLC They employed an 
automated multiple development (AMD) system which optimises the separation selectivity 
throughout the chromatogram for mixtures of a wide polanty range The whole process is 
automated which ensures a high degree of reproducibility Separation was earned out with 
a stepwise mobile phase change between chloroform, ethyl acetate, 1-propanol, acetic acid 
and hexane They were (Belay et a l, 1993) able to separate and identify coumann from 
other vanilla extracts eg vanillin, ethyl vanillin, vamllyl alcohol, vanillic acid, 4- 
hydroxybenzyl alcohol 3,4-dihydroxybenzaldehyde, 4-hydroxybenzoic acid, and piperonaL
A chloroform, ethyl acetate, propan-l-ol (96 2 2, v/v/v) mobile phase was also used for the 
separation of vanilla extracts (Poole et a l, 1993) by TLC The method allowed the 
determination of the authenticity of natural vamlla extracts as opposed to synthetic flavour 
compounds which can only be found in counterfeit vanilla flavourings (coumann is 
considered as an adulterant in counterfeit vanilla flavouring) Whatman HP-K high 
performance silica gel plates were used for the separation of coumann from the other 
species present in the flavourings Plates were analysed at 280 nm or as 2,4- 
dimtrophenylhydrazone denvatives at 500 nm with a scanning densitometer
1 2 1 3  T L C  a n a ly s is  o f  7 - h y d r o x y c o u m a n n  in  u n n e
TLC was also used for the analysis of 7-hydroxycoumann after in vivo metabolism of 
coumann (Cholerton et a l, 1992) 64 patients were treated with 2 mg of coumann
Samples were treated with (3-glucuromdase, and extracted into chloroform. Separation 
was earned out on silica plates (precoated high-performance TLC glass-backed silica gel 60 
F254) with a mobile phase of chloroform-water-ethyl acetate-acetic acid (24 1 2 6 0  5 v/v) 
Quantitative results were obtained by fluorescence densitometry The chromatographic 
lanes were scanned at a wavelength of 313 nm using a mercury lamp in the reflection mode 
in the presence of a K400 secondary filter Peak heights were compared to those of 7- 
hydroxycoumann standards The limit of detection was 1 ng/ml with a linear range of 5 
ng/ml - 4000 ng/ml
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12 2. High Performance Liquid Chromatography
High-performance liquid chromatography (HPLC) is a technique whereby molecules can be 
separated by exploiting their physical and / or chemical differences (Knox, 1980, Willard et 
a l, 1988, and Meyer, 1988) For a review on the different modes of HPLC available see 
section 4 0 HPLC has been applied to the analysis of coumann in flavourings, in plant 
extracts and in in vivo, and in vitro metabolism studies Separation was achieved on a 
variety of stationary phases eg Cig, Cg with many different mobile phases e g based on 
methanol, or acetomtnle Detection systems utilised included, UV detection, radiochemical 
detection, mass spectral detection, fluorescence detection, and, electrochemical detection 
An excellent review on the determination of many coumann denvatives by HPLC between 
1983 and 1990 are covered by Shkarenda et al (1993) The conditions for the separation 
of complex mixtures of coumanns and the use of coumanns in the HPLC analysis of natural 
and synthetic compounds are discussed The coumann denvatives analysed include 
furanocoumanns, hydroxycoumanns, pyranocoumanns, and isocoumanns Detection 
wavelengths, column selection, mobile phases, sources and the presence of an internal 
standard are all included
1 2 2 1  M e t a b o lis m  s t u d ie s
Hepatic microsomes play a major role m role in the metabolism of coumann to a vanety of 
metabolites (see Figure 3 2 11) The metabolic pathway is dependent on the species 
(Cohen, 1979, Kaipainen et a l, 1985, Egan et a l, 1990, Pelkonen et a l, 1996) HPLC has 
been adapted to determine the many metabolites both for studies on the in vivo and in vitro 
metabolism of coumann This is achieved by determining coumann metabolites after in vivo 
or in vitro metabolism (Figure 12 2 1)
1 2 2 1 1  M e t a b o lis m  in v iv o
Moran et al (1987) and Egan and O’Kennedy (1992) both descnbed methods for the 
determination of 7-hydroxycoumann in unne after the in vivo metabolism of coumann in 
man Initial sample preparation steps and long incubation steps made the method of Moran
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et al (1987) very time consuming Large samples of unne were required, and large 
amounts of (3-glucuronidase were also needed to liberate the glucuromde conjugate from 7- 
hydroxycoumann The method of Egan and O’Kennedy (1992) made major improvements 
on this method It shortened the total time of preparation by at least 16 hours The amount 
of (i-glucuronidase was reduced from 20,000 Umts/ml to 5000 Umts/ml and the incubation 
time was reduced from 16 hours for the method of Moran et al (1987) to 0 5 hours for the 
method of Egan and O ’Kennedy (1992)
Direct extraction into diethyl ether (Egan and O’Kennedy, 1992), rather then freeze drying 
(Moran et a l , 1987), was the preferred method of sample preparation before the 
application of the sample onto the HPLC Samples were separated with mobile phases 
based on a methanol water acetic acid mix [300 700 2 (v/v/v), Egan and O’Kennedy,
(1992), and 200 300 1 (v/v/v) for Moran et al (1987)] The limit of detection of the 
method of Egan and O’Kennedy (1992) was 500 ng/ml with a linear detection range 
between 0 - 100 mg/ml Sharifi et al (1993) developed a method that avoided the 
deconjugation step entirely for the determination of coumann and some of its metabolites 
(7-hydroxycoumann, 7-hydroxycoumarm-glucuromde, 3-hydroxycoumann) in unne
Extraction of the glucuromde conjugate from rabbit urine, giving a pure standard to work 
with, allowed the study of samples containing 7-hydroxycoumann-glucuromde without 
having to deconjugate The urine was prepared by altering its pH to 4 5 and then diluting 
the sample with water and methanol Separation was achieved with a 
methanol water tetrahydrofuran acetic acid (45 40 10 5 v/v/v/v) mobile phase Sharifi et al
(1993) used a Cg reverse phase column to separate the individual components of interest 
whereas Moran et al (1987) and Egan and O’Kennedy (1992) both used Cig reverse phase 
columns
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Coumann
NADPH Cytochrome P450
COOH
7-hydroxycoumann UDP-glucuronic acid
beta-glucuronidase UDPGT
COOH
+ UDP
7-hydroxycoumann-glucuromde
F i g u r e  1 2 2 1  T h e  r e a c t io n  s h e m e  f o r  a n  i n  v it r o  o r  in  v iv o  p a t h w a y  o f
c o u m a n n  m e t a b o l is m  to  7 - h y d r o x y c o u m a n n  a n d  7 - h y d r o x y  c o u m a n n - g l u c u r o n i d e  
r e s p e c t iv e ly  T h e  F i g u r e  s h o w s  b o t h  t h e  P h a s e  I  m e t a b o l is m  (s e e  s e c t io n  3  2 1 )  a n d  
t h e  P h a s e  I I  m e t a b o lis m  o f  c o u m a n n  (s e e  s e c t io n  3  2  3 ) ,  t h e  m e t a b o lis m  o f  7- 
h y d r o x y c o u m a n n  to  7 - h y d r o x y c o u m a n n - g l u c u r o m d e , a n d  t h e  s p e c ie s  n e c e s s a r y  f o r  
t h e  m e t a b o l is m  o f  b o t h  c o u m a n n  a n d  7 - h y d r o x y c o u m a n n  to  t h e ir  r e s p e c t iv e  
m e t a b o lit e s  T h e  p a t h w a y  i l lu s t r a t e d  is  t h e  p n n c i p l e  m e t a b o l ic  f a t e  o f  c o u m a n n  in  
m a n
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The limits of detection for the method of Shanfi et al (1993) were far superior to those of 
Egan and O’Kennedy (1992) or Moran et al (1987) They were able to detect down to 
0 3 ng/ml with a linear range between 0 6 and 26 ng/ml (250 - 10000 nmol/ml) for 7- 
hydroxycoumann-glucuromde, and similarly for coumann and 7-hydroxycoumann 
Laimable et al (1993) utilised a different mobile phase (acetomtnle phosphate buffer), 
extraction into hexane, and reconstitution into hydrochloric acid for the determination of 
coumann in plasma (limit of detection of 0 3 ng/ml) They used a Cg column as compared 
with the methods of Egan and O’Kennedy (1992) and Moran et al (1993) who used Qg 
columns All the above methods used UV detection at 280 nm or 320 im
Hiller and Cole (1995) described a method for the determination of 7-ethoxycoumann and 
its metabolites after phase I and phase II metabolism Their method utilised short-column 
gradient elution HPLC for the separation of 7-ethoxycoumann, 7-hydroxycoumann, 7- 
hydroxycoumann-glucuromde and 7~hydroxycoumann-sulphate in liver-slice incubates 
Separation was earned out on a 33 mm X 4 6 mm -hd , 3 |im particle size, LC-8 HPLC 
column The mobile phases used for the gradient elution consisted of acetomtnle, 
tetrabutyl ammonium phosphate and acetic acid The different compounds were prepared 
in Krebs-Henseleit buffer containing human or mouse hver-shces and analysed directly by 
HPLC without any sample clean-up
1 2 2 1 2  M e t a b o lis m  in  v itro
High-performance liquid chromatography has also been used to follow the in vitro 
metabolism of coumann by hepatic microsomes Fentem et al (1992) showed the 
complete separation of a standard mixture of the majonty of coumann metabolites 
Separation was earned out on a 250 mm X 4 6 mm Sphensorb 5 ODS-2 column using a 
linear gradient elution of formic acid water methanol, and detection at 280 nm O- 
hydroxyphenylacetaldehyde was found to be a major metabolite of coumann formed by rat, 
human, and gerbil liver microsomes (Fentem et a l} 1991) This was determined by 
separation as above (Fentem et a l, 1992) but with mass spectral analysis of the metabolite 
isolated from the rat liver microsomal incubation HPLC has been used for the
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determination of cytochrome P-4502A6 activity, as well as for the determination of other 
coumann metabolites
Metabolism of radiochemical labelled [3-14C]coumann by hepatic microsomes from vanous 
species was also studied by HPLC (Lake et a l , 1992, van Iersel et a l , 1994, Steensma et 
a l , 1994) The metabolites were determined by comparison of retention times with known 
standards The concentration of metabolite was quantified by measurement of the 
radioactivity present in the appropriate HPLC fractions At specific timed intervals the 
metabolic reaction was terminated by the addition of ice-cold methanol, followed by 
centrifugation It was possible to monitor the majonty of metabolites produced over time 
to give a pharmacokinetic profile of coumann metabolism in vitro
Evans and Relling (1992) descnbed 7-ethoxycoumann O-deethylase activity by analysing 7- 
hydroxycoumann using fluorescence detection (excitation at 360 nm and an emission at 
470 nm) Separation was earned out on a (lBondapak phenyl column (300 mm x 3 9 mm 
I D ) Separation was achieved with an isocratic mobile phase of (55 45, v/v) methanol and 
0 05 M acetate buffer (pH 4 7) The limit of detection was 70 ng/mL 7-hydroxycoumann 
was extracted into chloroform and this was evaporated to dryness followed by 
reconstitution into methanol-water (70 30, v/v) before HPLC separation and analysis
1 2 2 2  Coumann in foodstuffs
Coumann is the most common adulterant of vanilla extract (Thompson and Hoffmann, 
1988) The method of Thompson and Hoffmann (1988) utilised a methanol water acetic 
acid mobile phase (40/60/0 1 v/v/v), on a Cig column, with UV detection and a limit of 
detection of 0 6 ng/ml (from 3 X signal-to-noise ratio) It was possible to separate 
coumann from vanillin as well as other endogenous species in bean extracts Thus, it was 
possible to use HPLC in the assessment of quality Phenohcs and flavanoids are common 
substituents of plant-denved beverages (Gamache et a l , 1993), playing a role in the 
stability, colouration, nutntional value, etc Many coumann denvatives, including 7- 
hydroxycoumann, were separated by HPLC with coulomemc array detection Limits of 
detection were in the order of 1 ng/mL Electrochemical detection provides selectivity and
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sensitivity to the study of trace amounts of these compounds in such matrices Mazza 
(1984) also describes the separation and determination of coumann m alcoholic beverages 
Separation was earned out on a LiChrosorb RP-18 column with a l l  water methanol 
mobile phase
1 2 2 3  Plant extract analysis
Many of the reported HPLC analyses of coumann, and its denvatives, involved some form 
of sample preparation The method might require organic solvent extraction (Moran et a l, 
1987, Lander et a l , 1990, Egan and O’Kennedy, 1992, Nykolov et a l , 1993, Shanfi et a l , 
1993), precipitation of any protein present (Fentem et a l , 1991), or filtration (Archer, 
1988)
Nykolov et al (1993) determined numerous hydroxycoumanns present in the bark of 
Fraxinus ornus, which is a major source of esculin, an anti-inflammatory and vitamm-P-hke 
agent Climatic conditions, and the stage of plant growth will lead to great variations in 
hydroxycoumann content The samples were extracted into ethanol, and analysed on a C8 
column, with gradient elution of the components (mobile phases were water phosphonc 
acid, pH 3 0, and methanol) and UV detection at 210 nra Preparative HPLC was used to 
purify the individual components Fractions were taken and analysed separately by thin 
layer chromatography, and by mass spectrometry to characterise each of the 
hydroxycoumanns
The determination of coumann in cinnamon and cassia (Archer, 1988) was achieved by 
separation on a LiChrosorb RP-8 reversed-phase column with a water, methanol, 
acetomtnle, tetrahydrofuran (60 12 20 8 v/v/v/v) mobile phase Vanillin was used as an 
internal standard
1.2 3 Gas Chromatography
Gas chromatography (GC) is a technique that allows the separation of thermally stable and 
volatile organic and inorganic confounds (Willard et a l , 1988) The early work on 
coumann analysis (Johansen, 1965) centred on the separation of coumann as an adulterant
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in flavourings More recent work has focused on coumann as a flavouring (Hawthorne et 
a l , 1988, Grundschober, 1991), as a fragrance (Hawthorne et a l , 1988, Jirovetz et a l , 
1992), in tobacco and in vegetables (Chnstakopoulus et a l , 1992) Separations were 
typically earned out on fiised-silica capillanes with helium as the earner gas The 
temperature gradients for the different methods vaned from 8 °C/wm or 10 °C/rmn up to a 
final temperature of 300 °C (Chnstakopoulus et a l , 1992, Weinberg et a l , 1993)
m/z Range of relative abundance
147 7-12
146 66-100
119 8-10
118 82-100
90 28-41
64 30-40
63 8-12
62 5-15
59 8-15
44 7-11
43 5-14
39 11-16
Table 1 2 3 1  Mass spectral analysis data for relative abundances of coumann ions 
The results are given as the mass!charge ratio (mfz) and the relative abundances of 
each ion
12 31 Flavours and fragrances
Supercntical fluid extraction (SEE) was used as the preparation step to determine coumann 
in some natural flavour and fragrance compounds (Hawthorne et a l , 1988) The samples 
were extracted into 300 atmospheres of supercntical carbon dioxide at 45 °C The 
extraction chamber outlet restnctor capillary was connected to the standard on-column 
injection port of the gas chromatogram allowing for an on-line purification and separation 
This reduces sample loss due to sample transfer after extraction The sample is then 
separated and detected by either mass spectrometry or flame ionisation (FID) The 
method was used for the determination of coumann in cinnamon and in rosemary and 
for the analysis of spices, chewing gum, spruce needles, and cedar wood Separation
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was earned out on the GC with a gradient temperature program from 70 °C to 320 °C 
at 8 °C/min 1 14 ± 12% mg of coumann was detected per g of rosemary
The efficacy of using GC was also assessed as a tool for the accurate identification of 
coumann, and other flavourings (Grundschober, 1991) In the report by Grundschober 
(1991) coumann is separated by GC with mass spectral (MS) and Founer transform infra­
red (FUR) detection to distinguish coumann from other flavourings present in the species 
of interest Infra-red bands and their intensity and mass spectral coumann ion relative 
abundances are included The relative abundances for coumann ion profile after mass 
spectral analysis are given in Table 12 3 1 and the infra red bands observed for coumann 
are given in Table 12 3 2
The effective blood concentration of coumann in mice, after the inhalation of coumann, is 
desenbed by Jirovetz et al (1992) Sandalwood oil was added into the cages of mice, and 
blood samples were taken and assessed for coumann content The levels of coumann 
found in the blood were 7 7 ng/ml (± 2 ng/ml), after the addition of coumann (3 0 g) into 
the mouse cage Samples were separated and detected by a vanety of methods, including 
FTIR, MS and atom emission detection
Infra-red bands (cm
825 (w)877 (w)
919 (w)
1096 (m)
1173 (w)1265 (w)1451 (w)1608 (w)1778 (w)
3079 (w)
Table 1 2  3 2  A list o f  the infra-red bands (c m o b s e r v e d  fo r  coumann as analysed by 
Founer transform infra-red analysis, (w = weak band, m = medium band)
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12 32 Tobacco and vegetable juice analysis
Thin-layer chromatography and high-performance liquid chromatography were used to 
purify coumann from tobacco samples before their analysis by gas chromatography 
(Chnstakopoulus et a l , 1992) A chloroform-hexane (25 75, v/v) solution was used to 
extract the coumann from the vanous tobacco leaf samples chosen The HPLC mobile 
phase was based on a chloroform-hexane gradient [6 94, (v/v) at T0, 40 60 at Tig, and at 
T24 6 94] Coumann was separated on a silica gel TLC plate, with a pentane-ethyl acetate 
(70 30, v/v) mobile phase The coumann fraction from the HPLC and the coumann TLC 
spot were then analysed by GC-MS The limit of detection of the method was 0 05 mg/g 
tobacco The identity and punty of coumann were confirmed by nuclear magnetic 
resonance (NMR), and mass spectrometry (MS) Radiolabelled 13C-coumann was used as 
an internal standard for mass spectral determination of coumann Weinberg et al (1993) 
descnbe the analysis of coumanns in vegetable juices The coumanns present in vegetablef
juices includes umbelliferone, psoralen, and bergapten The coumanns were extracted into 
methylene chlonde, and analysed by GC-MS
1.2 4 Capillary Electrophoresis Analysis
There has only been a limited amount of work reported on the analysis of coumann and its 
denvatives by capillary electrophoresis This powerful analytical technique is a relatively 
new addition to the analyst and it is gaining in widescale acceptance for the determination 
of many species in a multitude of areas (Li, 1992, Landers, 1993, Weinberger, 1993) 
Several researchers have applied this tool to the separation of coumann, 7- 
hydroxycoumann and warfarin in a vanety of matrices For a review on the different 
modes of CE separation see section 3 0
12 41 Separation of coumanns in plant extracts
Seven coumanns were separated by rmcellar electrokinetic capillary chromatography 
[MECC] (Monn and Dreux, 1993) Coumann, and several of its hydroxy- and methyl- 
denvatives were separated by a phosphate-borate (pH 7 0) and sodium dodecyl sulphate 
(SDS, anionic surfactant) as electrolyte The eluent was monitored at 195 nm The 
samples were analysed on a 70 cm untreated capillary with an applied voltage of 18 kV
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These neutral coumanns are separated based upon the differential partitioning between the 
SDS micelle hydrophobic interior and the aqueous mobile phase
12 41 Using 7-hydroxycoumann to determine separation efficiencies
The electroosmotic velocity occurring in capillaries made from polyfluorocarbon, 
polyethylene or polyvinylchlonde was determined by the use of electrically neutral marker 
substances in dependence on the pH in aqueous solutions (Schutzner and Kenndler, 1992) 
The fluorescent characteristic of 7-hydroxycoumann was exploited 7-hydroxycoumann is 
determined as it is neutral in the acidic pH range up to 5 8 The pH and composition of 
electrolyte solutions are changed and the effective influence of the coating at the capillary 
surface was assessed
12 43 Warfarin determination in plasma
3-(-a-acetonylbenzyl)-4-hydroxycoumann (warfarin) is widely used as an anticoagulant 
As a racemic compound it was necessary to develop the separation of the two forms of 
warfarin based on chiral capillary electrophoresis (Ganel el a l , 1993) A methylated b- 
cyclodextnn-containmg electrolyte was used to successfully resolve the two isomers 
Plasma samples were analysed on a 72 cm fused silica capillanes The limit of detection 
was 0 65 mM for each enantiomer The optimisation of the separation is descnbed 
Varying of voltage, electrolyte ionic strength and content has a dramatic effect on 
separation
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13 SPECTROSCOPY
Absorbance, fluorescence, and luminescence of any compound is dependent on the 
interaction of electromagnetic waves and matter (Banwell, 1983) Interactions are 
dependent on the molecular structure of the compound and unique for all compounds 
Coumann and all its denvatives have their own unique spectroscopic properties that can be 
exploited for their determination Table 13 1 summarises the spectroscopic methods 
available for the determination of 7-hydroxycoumann or denvansed coumann
Method & Application Mode of Detection Reference
Spectrofluonmetry 
Pharmacokinetics of coumann 
metabolism
Glucuromdation of 7-OHC 
In vivo metabolism of coumann
Fluorescence of 7-OHC 
& denvaased coumann
Fluorescence of 7-OHC
Fluorescence of 7-OHC
Microplate-assay 
TLC separation
Tan et al (1976), Ritschell et 
a/, (1977,1981), 
Kaipainenera/ (1985)
Conway e ta l (1984)
RauUo et al (1992), Merkel et 
al (1993, 1994), Iscan et al 
(1994)
Egan and O’Kennedy (1993a) 
Cholerton et al (1993)
Table 131  Summary of the spectroscopic methods of analysis of coumanns Table 
of the methods of detection, the application and the references
13.1 Spectrofluonmetry
1 3 1 1  Pharmacokinetic and biopharmaceutical studies
Tan et al (1976) descnbed a method for the quantitative analysis of coumann and 7- 
hydroxycoumann, and mixtures thereof, in whole blood Coumann and 7- 
hydroxycoumann were selectively isolated from blood by solvent extraction and analysis 
was based on the measurement of fluorescence of the coumann fluorophore or 7- 
hydroxycoumann (which is fluorescent) The coumann is extracted into ether and
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evaporateci to almost dryness with a constant nitrogen flow at low heat 1 ml of methanol 
is added and the evaporation of the ether is completed 5 0 ml of 2 N methanolic KOH is 
then added to the solution Coumann under alkali conditions is then exposed to UV light 
The fluorescence is determined at activation and emission wavelengths of 361 nm and 491 
nm, respectively The linear range for coumann determination is 0 02 jig/ml - 0 2 jig/ml 7- 
hydroxycoumann is extracted into ether also However, a second extraction step is then 
used to isolate 7-hydroxycoumann before fluorescence detection Glycine buffer (pH 10 0) 
is added to the ether layer and centrifuged The glycine layer is removed and fluorescence 
is determined at activation and emission wavelengths of 370 nm and 450 nm, respectively 
The linear range for 7-hydroxycoumann was 1 ng/ml - 10 ng/mL For the analysis of a 
mixture of coumann and 7-hydroxycoumann the procedure is as just descnbed with the 
ether layer used for coumann determination and 7-hydroxycoumann determined by its the 
fluorescence in glycine buffer The method was shown to be sensitive, and reproducible 
with little interference from other constituents m blood and there was no need to precipiate 
out the proteins in the blood Other umbelliferone conjugates or other hydroxycoumanns 
do not interfere
The spectrofluonmetnc method of Tan et al (1976) was used to determine the 
pharmacokinetics of coumann after peroral and intravenous administration (Ritschel et a l , 
1977) in man Levels of 7-hydroxycoumann and 7-hydroxycoumann-glucuronide were 
determined by spectrofluonmetry Samples were analysed after extraction for free 7- 
hydroxycoumann and after treatment with (3-glucuronidase to liberate 7-hydroxycoumann 
from the glucuromde conjugate for total 7-hydroxycoumann content determination
Coumann must be denvatised and irradiated with UV light before it can be analysed by 
fluonmetry (Ritschel et a l , 1981) Coumann was firstly extracted into anhydrous ether, 
then evaporated to dryness, and finally reconstituted into methanoL An alkali solution of 
2N KOH was added to the reconstituted sample and irradiated with UV light After 
irradiation, it was analysed by fluonmetry with an excitation wavelength at 361 nm and 
emission at 491 nm. 7-hydroxycoumann can be analysed after clean-up without the need 
for denvatisation The excitation and emission wavelengths for 7-hydroxycoumann are
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370 nm and 450 nm respectively This procedure was utilised for determining binding of 
coumann and 7-hydroxycoumann to proteins (in human serum) and to erythrocytes and for 
assessing their solubility in water, phosphate buffer, and human serum.
Coumann 7-hydroxylation activity in the liver microsomes of 8 different species was 
investigated by Kaipainen et al (1985) An incubation solution containing coumann, 
NADPH, MgCfe, and the microsomal preparation was prepared At predefined times the 
reaction was stopped by precipitating the solution with tnchloroacetic acid NaOH-glycine 
buffer, (pH 10 3), was added to the solution and fluorescence was determined at excitation 
and emission wavelengths of 390 nm and 440 nm, respectively Antibodies were raised, in 
mice, against cytochrome P450, with high activity against coumann 7-hydroxylation The 
microsomes were preincubated with the antibody Inhibition of coumann 7-hydroxylase 
activity was assessed in the microsomes from the different species There was almost 100 
% inhibition of coumann 7-hydroxylation in some species and little if any in the rat or rabbit 
microsomes
1 3 1 2  Glucuronidation studies
The major site of glucuronidation (a detoxification pathway that makes compounds more 
hydrophilic and more readily excretable in unne) is the liver (see section 3 2 3) The 
majonty of coumann administered in man is excreted as 7-hydroxycoumann-glucuromde 
(Egan and O’Kennedy, 1992) A novel method was developed that allowed the monitoring 
of the decrease in 7-hydroxycoumann content (Conway et a l , 1984) A fluonmeter is 
connected via optical fibres to micro-light guides that were placed on the surface of liver 
tissue samples It was possible to monitor the fluorescence of 7-hydroxycoumann As the 
7-hydroxycoumann was converted to 7-hydroxycoumann-glucuromde the decrease in 
fluorescence could be observed (Conway et a l , 1984) One strand of the micro-light guide 
is connected to a 100-W mercury arc lamp and the other strand to a photomultiplier 
Excitation and emission wavelengths were at 366 nm and 450 nm, respectively Different 
parameters were changed to assess the differences in glucuronidation in the different liver 
regions Glucuronosyltransferase activity was determined by measuring 7- 
hydroxycoumann-glucuromde spectrofluonmetncally after treating it with (J-glucuromdase
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in a fluonmeter Maximal rates of glucuromdation in periportal and pericentral regions of 
the liver lobule were 9 6 and 35 jimoles/g/hr, respectively
1 3 1 3  Urine analysis
Several investigators have used the fluorescence characteristics of 7-hydroxycoumann for 
its determination in unne A spectrofluonmetnc assay was used to assess intenndividual 
variability in coumann 7-hydroxylation by Rautio et al (1992) and Iscan et al (1994) 
Samples of urine were treated with (3-glucuronidase before extraction into chloroform and 
analysis Results were compared to analysis of the same samples by a HPLC method 
(Rautio et a l , 1992) Samples were analysed on a Interchrom Nucleosil Qg column with 
UV detection at 313 nm. Samples were separated by gradient elution [buffer A - 20 % of a 
1 5 % acetic acid (pH 4 85, adjusted with NH4OH) and 80 % buffer B buffer B - 50 % 
buffer A -1- 50 % acetomtrile] Different doses of coumann were used in a preliminary 
experiment to study the relationship between the dose and the 7-hydroxycoumann 
excretion (Rautio et a l , 1992) However, both groups administered a single 5 mg dose of 
coumann for the intenndividual variability study
In the two studies 100 (Rautio et a l , 1992) and 110 people (Iscan et a l , 1994), 
respectively, were administered coumann and the production of total 7-hydroxycoumann 
was determined There was a large intenndividual variability in the metabolism of coumann 
to 7-hydroxycoumann Up to 80 % of the 7-hydroxycoumann formed was excreted in the 
first two hours 59 8 % (± 21 5 %) of the administered coumann was denvatised to 7- 
hydroxycoumann or 7-hydroxycoumann-glucuromde (Iscan et a l , 1994) Coumann 7- 
hydroxylation was found to be lower in males and m cigarette smokers (Iscan et a l , 1994), 
however, Rautio et al found no statistical difference between male and female coumann 7- 
hydroxylase activity
Merkel et al (1993, 1994) also investigated 7-hydroxycoumann production by analysing 
unnary excretion of the coumann metabolite Samples were prepared by a similar method 
to that of Rautio et al (1992) Merkel et al (1994) report that grapefruit juice flavanoids 
inhibit cytochrome P450 2A-dependent metabolic pathways They report that coumann 7-
2 8
hydro xlation was significantly decreased with 7-hydroxycoumann excretion delayed by up 
to 6 hours 13 volunteers were assessed for the effect of the grapefruit juice on their 
production of 7-hydroxycoumann in vivo
Egan and O’Kennedy (1993a) developed a spectrofluonmetnc irncroassay for the 
determination of 7-hydroxycoumann in unne and plasma. The samples were initially 
analysed without sample clean-up The samples were then treated with p-glucuromdase, 
extracted into diethyl ether, evaporated to dryness and reconstituted into methanol The 
linear range for detection of 7-hydroxycoumann, before or after extraction, in unne and 
plasma was 0 5 -10 (ig/ml and 10 - 100 |ag/ml, respectively, and the limit of quantification 
was 0 5 |ig/ml The excitation wavelength chosen was 370 nm and emission was 
monitored at 450 nm. The assay was earned out in 96 well Dynatech rrncrotitre plates
13 2. Total Luminescence Spectroscopy
Coumann is added as a marker compound to separate rebated and unrebated kerosene for 
the purpose of customs excise duty (Shanahan et a l , 1991) A quick method of analysis of 
the fuel oils is to convert the coumann present into the potassium salt of c/s-coumanc acid, 
and, furthermore, into the trans isomer by irradiation with UV light at 365 nm. This isomer 
is fluorescent and coumann can be qualitatively determined Coumann is quantified by 
measuring the fluorescence obtained by excitation at 365 nm and emission at 500 nm. 
Total luminescence spectra of the fuel samples are obtained by examining all the 
fluorescence spectra across a range of wavelengths (300 nm to 600 nm)
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1 4 ANTIBODY-BASED IMMUNOANALYTICAL TECHNIQUES
The antibody-antigen interaction can be used as an analytical tool for selective and sensitive 
determinations (Tijssen, 1985, Killard e ta l , 1995) of drug, hormones etc The production 
of antibodies, their functions and their applications are reviewed by Killard et al (1995) 
The specificity of an antibody determines its suitability as a potential tool for sensitive, 
accurate analysis of coumann and its derivatives Table 1 4 1 summarises the antibody 
based unmunoanalytical techniques available for coumann and 7-hydroxycoumann 
determination discussed in the section below Chapter 5 gives an introduction to 
antibodies, to the antigen-antibody interaction and to an enzyme-linked immunosorbent 
assay (ELISA)
Method ¿^Application Mode of 
Detection
Limit of 
Detection
Reference
ELISA
Analysis of Coumann or 7-hydroxycoumann - Antigen 
mhibiUon ELISA with anti- 
coumann / 7-OHC antibody
OPD as substrate with detection at 405 nm 
pNPP as substrate 
with detection at 414 
nm
0 5 (ig/ml 
40 ng/ml
Egan (1993) and Egan / 
O’Kennedy, (1993b) 
Remartz e ta l (1996)
7-hydroxycoumarin-alkaline- phosphatase-bispecific 
antibody assay
pNPP as substrate with detection at 414 
nm
6 ng/ml Reinartz et al (1996)
Electroanalytical Analysis Direct analysis of 7-OHC 
Indirect analysis of 7-OHC
Electrochemistry of 
7-OHCElectrochemistry of HRP
10 \iM  
24 |oM
Dempsey et al (1993a) 
Deasye ta l (1994)
Biospecific Interaction 
Analysis7-hydroxycoumann assay Surface plasmon resonance 0 5 ng/ml Keating e ta l (1995)
Table 1 4 1  Summary of the immunoanalyUcal methods o f analysis of coumarins. 
Table of the methods of analysis, detection, application, limit of detection and 
reference
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1 4 1  Enzyme-linked immunosorbent assay (ELISA)
An enzyme-linked immunosorbent assay (ELISA) is an antibody-based method for the 
detection of drugs in body fluids (also see section 5 14 1) A large variation of assay 
designs have been used for the detection of antibodies and antigens (Catty and Raykundalia, 
1989, Kemeny, 1991, Killard et a l , 1995) Immunoassays can be divided into 
heterogenous and homogenous assays In a heterogenous assay, a separation step is 
required where the free antibody and antigen is separated from the solid phase bound 
antibody-antigen complex The quantifiable signal from the complex does not differ from 
the free entity and therefore without this separation, interference would occur In a 
homogenous assay, this separation step is not required The binding of antigen and 
antibody results in a change in the activity of the label and therefore this activity can be 
detected without the problems of interference An heterogenous immunoassay will have the 
following steps common to all variations
1 Immobilisation of antigen or antibody on a solid surface (usually a microtiter plate)
2 Incubation with a sample containing the corresponding antigen or antibody
3 Detection of specifically bound antibody or antigen by binding an enzyme-linked 
antibody or antigen, using a colounmetnc reaction employing the enzyme
The method most frequently used for the quantification of haptens (e g drugs, hormones 
etc) is the antigen-inhibition ELISA (Egan and O’Kennedy, 1993b)
1 4 1 1  Determination of coumann and 7-hydroxycoumann by antigen
inhibition enzyme-linked immunosorbent assay
Antigen inhibition ELISA has been used to detect both coumann and 7-hydroxycoumann 
in unne (Egan, 1993, Egan and O’Kennedy, 1993b, Reinartz and O’Kennedy, 1995) For 
the detection of coumann (Egan, 1993), a coumann-thyroglobulin-conjugate was 
immobilised on an ELISA microtiter plate Coumann standards and unknowns (n=4) were 
incubated with purified polyclonal anti-bovine serum albumin-coumann IgG antibodies 
raised in rabbits at 37 °C for 2 hours A competition occurs between the free coumann in 
solution and the coumann coated on the plate surface for the antibody Unbound antibody 
and free coumann-antibody complexes are washed off leaving bound coumann-antibody 
complexes behind on the plate Bound antibody was detected using HRP-labelled
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secondary goat anti-rabbit IgG, with o-phenylene diamine (OPD) as the substrate The 
linear range of the assay is from 10-100 |ig/mL A similar protocol is followed for the 
determination of 7 - hydroxycoumann by ELISA (Egan and O’Kennedy, 1993b) The 
antibody was raised against BSA-7-hydroxycoumann and screened with ovalburmn-7- 
hydroxycoumann The linear range of this assay is from 5-100 |!g/ml with a limit of 
detection of 0 5 |ig/ml
A similar system, employing a BSA-7-hydroxycoumann-conjugate immobilised at the 
microtiter plate surface, an anti-7-hydroxycoumann IgG raised in rabbits, and alkaline 
phosphatase-labelled goat anti-rabbit IgG as detection antibody with paramtrophenol 
phosphate (pNPP) as substrate, was found to be more sensitive (Reinartz and O’Kennedy, 
1996) The linear range was from 50 ng/ml to 5 fig/ml, with a limit of detection of 40 
ng/ml
1 4 1 2  Antigen inhibition ELISA employing a bispecific antibody 
Bispecific antibodies are antibodies, which, in contrast to natural antibodies, can bind to 
two different antigens simultaneously Bispecific antibodies have been produced chemically 
by crosshnking whole antibodies (bispecific multivalent antibodies, bsMab) or fragments 
(Fab - bs(Fab’)2), biologically using hybndoma technology, or through genetic engineering 
Their production, potential, and advantages in enzyme immunoassays are reviewed by 
Nolan and O’Kennedy (1992)
bsMab's can be rapidly synthesised by the heterobiiunctional cross-linkage of two parental
antibodies (Cook and Wood, 1994) Such a bispecific antibody was produced from an anti-
thyroglobuhn-7-hydroxycoumann and an anti-alkaline phosphatase antibody, using the
method of Cook and Wood (1994) The product was used to develop a one-step antigen
inhibition ELISA for the detection of 7-hydroxycoumann in unne (Reinartz and 
*
O’Kennedy, 1995) The plate was coated with BSA-7-hydroxycoumann 25 jil of 7- 
hydroxycoumann standard or unknown, 50 ¡Lil of bsMab at its working dilution, and 25 |xl 
of alkaline phosphatase, at a well concentration of 100 jig/ml, were added and incubated
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for 90 rran at 37 °C Colour was developed with paramtrophenol phosphate as substrate 
and absorbance at 414 nm
Free 7-hydroxycoumann was determined in urine using this method, and had a linear range 
between 20 ng/ml and 4 |ig/ml Total 7-hydroxycoumann determination required the 
deconjugation of 7-hydroxycoumann-gIucuromde by the addition of p-glucuromdase All 
samples were diluted 1 10 in 60 mM PBS-Tween 20 and the samples were analysed as 
above The linear range for the determination of total 7-hydroxycoumann was from 100 
ng/ml and 1 |J.g/ml with a limit of detection of 30 ng/ml Accuracy and precision was 
determined by spiking 7-hydroxycoumann and 7-hydroxycoumann-glucuromde into 
control unne Samples were also analysed after sample clean-up Samples were extracted 
into diethyl ether, evaporated off and reconstituted into PBS-Tween 20 The limit of 
detection was 6 ng/ml with a linear range between 6 ng/ml and 800 ng/mL Samples were 
analysed by this method and by HPLC (Egan and O’Kennedy, 1992) There was no 
statistical difference between the different methods
1.4.2 Immunoelectroanalytical Analysis
Dempsey et al (1993a), Deasy et al (1994) and Lu et al (1996) have investigated the use 
of anti-7-hydroxycoumann antibodies for the determination of 7-hydroxycoumann A 
biosensor based on the immobilisation of anti-7-hydroxycoumann antibodies at the surface 
of a glassy carbon electrode behind a permeable cellulose dialysis membrane was developed 
by Dempsey et al (1993a) The electrochemical behaviour of 7-hydroxycoumann at a bare 
glassy carbon electrode is documented (Dempsey et a l , 1993b) However, when the 
antibody is present at the electrode surface there is a 90% decrease in 7-hydroxycoumann 
electrochemical response The binding of the 7-hydroxycoumann to the antibody is believed 
to occur at its electroactive site which would explain the decrease in the response at the 
electrode surface Anodic detection of the oxidised product was achieved at 0 6 V using 
DC amperometry The limit of detection was 10 jjM Antibody-antigen kinetics were also 
investigated A first-order reaction was observed with k= 0 0329 mA/rmn
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An enzyme-linked electrochemical competitive immunoassay was developed by Deasy et 
al (1994) The anti-7-hydroxycoumann antibodies were labelled with horseradish
peroxidase The electrochemical character of horseradish peroxidase is utilised for the 
indirect determination of 7-hydroxycoumann The glassy carbon surface was coated with 
thyroglobulm-7-hydroxycoumann Different concentrations of 7-hydroxycoumann were 
added together with antibodies raised, in rabbits, against bovine serum albuimn-7- 
hydroxycoumarm A competition, similar to the competitive ELISA above occurs, 
between free 7-hydroxycoumann and 7-hydroxycoumann at the electrode surface After 
antibody-antigen interaction all unbound solutions are removed by washing leaving labelled 
antibody at the surface The electrochemical activity of the horseradish peroxidase on the 
labelled antibody at the electrode surface is then determined The current is measured after 
the addition of 1 mM hydrogen peroxide (enzyme substrate), in the presence of 2 mM 
hydroquinone The current output was inversely proportional to the concentration of free 
7-hydroxycoumann in solution The limit of detection was 24 jiM and 7-hydroxycoumann 
concentrations could be determined up to 1 mM
Lu et al (1996) developed a regeneratable enzyme immunosensor for 7-hydroxycoumann 
based on electrochemical detection B S A-7 - hydroxycoumann is chemically immobilised at 
the surface of a glassy carbon electrode A competition is set-up between free 7- 
hydroxycoumann in solution and BSA-7-hydroxycoumann coated at the electrode surface 
for binding of a horseradish peroxidase labelled anti-7-hydroxycoumann antibody The 
reduction of hydrogen peroxide in the presence of potassium ferrocyanide (a mediator in 
the reaction) was used for the determination of 7-hydroxycoumann After binding of the 
antibody to the BSA-7-hydroxycoumann conjugate the excess antibody and free 7- 
hydroxycoumann were removed and the reduction of hydrogen peroxide is determined by 
DC voltammetry at a potential at 0 0 V vs Ag/AgCL The surface of the electrode was 
regenerated by immersing the electrode in 10 mM HC1 to dissociate the antibody-hapten 
complex The regenerated electrode was then washed with phosphate buffered saline, 
ready for the next analysis
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14 3 Biospecific Interaction Analysis
A competitive immunoassay for the analysis of 7-hydroxycoumann in biological samples 
has been developed, based on a commercial biosensor system - the BIAcore™ from 
Pharmacia Biosensor (Keating and O’Kennedy, 1995) The BIAcore (real-time Biospecific 
Interaction Analysis) makes use of the phenomenon of surface plasmon resonance (SPR) to 
directly monitor biomolecular binding events without the need to label interactants 
(Fagerstam and O'Shannessy, 1993)
The BIAcore sensor system utilises a combination of optical and continuous-flow 
technologies to facilitate label-free interaction analysis Biomolecular binding is studied by 
immobilising one of the components on the surface of a specialised sensor chip within the 
biosensor, and allowing the other to flow over the surface in solution Mass changes at the 
biosensor chip surface due to the binding of two or more components causes a change in 
resonance angle directly proportional to the mass change An indirect competitive 
immunoassay was developed for the determination of 7-hydroxycoumann in serum 
(Keating and O’Kennedy, 1995)
The assay consists of the following steps
1 Immobilisation of 7-hydroxycoumann-protein conjugate on sensor surface
2 Samples/standards mixed with P-glucuromdase to deconjugate 7- 
hydroxycoumann-glucuromde to 7-hydroxycoumann
3 Incubation for 2 hours at 37 °C
4 Addition of antibody (0 5 mg/ml) to samples/standards
5 Incubation for 5 minutes
6 Injection over sensor chip surface
7 Regeneration of sensor surface
A 7-hydroxycoumann-bovine serum albumin (7-OHC-BSA) is first immobilised on the 
sensor chip surface This is done by denvatisation with N-hydroxysuccimmide (NHS), 
mediated by N-ethyl-N’-(dimethylammopropyl)carbodiimide hydrochloride (EDC) The 
immobilisation procedure is highly reproducible, resulting in the covalent binding of about
10,000 response units (RU) of 7-OHC-BSA The antibody used in the assay is a rabbit 
polyclonal anti-7-hydroxycoumann purified from serum. 20ml of antibody-sample mixture
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is injected The 7-OHC-BSA on the sensor surface and the 7-OHC in the sample compete 
for antibody binding The resulting signal - due to unbound antibody binding to the drug- 
protein conjugate immobilised on the sensor chip - is inversely proportional to the amount 
of 7-hydroxycoumann present in the sample
A standard curve of concentration versus relative signal is prepared In this assay, 
regeneration of the 7-OHC-BSA surface is achieved by injection of a 1 minute pulse of 
5mM NaOH, a pulse of 20mM HC1, and another pulse of 5 mM NaOH Following the 
regeneration of the surface the next sample or standard is then analysed All the steps in the 
assay, including the addition of, and incubation of, both enzyme and antibody, are 
automated and earned out on the BIAcore The assay is suitable for the analysis of 7- 
hydroxycoumann in neat serum and plasma, without the need for extraction of the drug 
Neat urine samples may also be analysed, although variations in salt content and pH are 
problematic The range of the assay is from 0 5 |ig/ml to 80 |ig/ml
1.5 ELECTROANALYTICAL AND OTHER
CHROMATOGRAPHIC TECHNIQUES
1 5.1 Electroanalytical Analysis
Cyclic voltammetry was earned out on 7-hydroxycoumann prepared in phosphate buffer at 
an electrochemically pre-treated glassy carbon electrode (Dempsey et a l , 1993b) The 
potential was cycled between -15 V and +1 5 V From this the electrochemical 
characteristics of 7-hydroxycoumann were found An electroanalytical assay was then 
developed using differential pulse voltammetry as the method of detection Samples of 7- 
hydoxycoumann were prepared in unne, treated with p-glucuronidase and extracted 
according to Egan and O’Kennedy (1992) and reconstituted into methanol The sample 
was then analysed by determining the electrochemical response at an anodic detection at 
0 66 V The method was found to be linear between 0 and 15 mM The method was also 
applied to the determination of 7-hydroxycoumann in patient unne samples
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Differential pulse voltammetry was also used to analyse 7-hydroxycoumann and 7-armno-
4-methyl-coumann in rmcellar and emulsified media (Carrazon et a l , 1989) Carrazon et 
al (1989) analysed the coumanns by differential pulse voltammetry (DPV) and by linear 
sweep voltammetry (LSV) with a rotating and stationary glassy carbon electrode (GCE) 
The detection limits for 7-hydroxycoumann were DPV 0 87 (iM for a stationary GCE, and 
0 28 |iM for the rotating GCE The limit of detection for LSV at a stationary GCE was 4 9 
jiiM, and 0 63 \lM  for a rotating GCE The above values were determined in a micellar 
solution (0 08% Tnton X-405, 0 2 M acetate buffer, pH 4 8) The samples were prepared 
in micellar solution or as emulsions to avoid the use of organic solvents and to allow their 
dissolution into aqueous media.
Polarography was used to determine coumann in sweet clover and in preparation FIBS 
(Orlov, 1988, and Orlov et a l , 1992) Coumann from samples of white and yellow sweet 
clover was extracted into boiling ethanol After distilling off the ethanol a 1 ml 
reconstituted sample, in ethanol, was added to 4 ml of ethanol and 1 ml of a 1 % solution 
of tetraethylammomum iodide Polarography was earned out with a dropping mercury 
electrode Coumann is used as a stabiliser in the injection solution of FIBS and 
polarography is used as a selective detector to separate it from cinnamic acid, also present 
as a stabiliser Samples of coumann were analysed by polarography with cathodic 
polarisation in the interval 1 20 V - 2 00 V (E1/2 = 1 67 V)
1.5 2 Other Chromatographic Techniques
Planar chromatography (Betti et a l , 1993), centrifugal partition chromatography (Marston 
et a l , 1993), and high speed countercurrent chromatography (Schaufelberger, 1989) have 
all been used for the determination of coumanns Betti et al (1993) report on a planar 
chromatography method utilising a senes of different stationary phases and mobile phases 
in order to discover the best separation technique for the different compounds of interest 
including umbelliferone, quercetin, and psoralene The stationary phases include C18, 
cyano-, silica, phenyl, ammo, diol, and C2 Mobile phases include mixtures of methanol, 
acetic acid, acetone, toluene, ethyl acetate, or formic acid
r
37
Centrifugal liquid-liquid partition chromatography (Marston et a l, 1988) relies on the 
separation of compounds between two immiscible phases and the application of a 
centrifugal force during that separation Samples of umbelliferone, hermann, and 
scopoletin were separated in a light petroleum-ethyl acetate-methanol-water system 
Fractions are collected and analysed by UV detection A chloroform-methanol-water 
mobile phase was used for the separation of coumanns by high-speed analytical counter- 
current chromatography (Schaufelberger, 1989) with photodiode array detection
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Summary
The analytical approaches used to detect coumann and its derivatives are many and vaned 
The choice of method is dependent on the particular coumann of interest, and the matnx in 
which it is a component The ideal method is obviously one which will involve minimal 
sample preparation, short analysis time, be relatively inexpensive, and have excellent 
accuracy and precision for a vanety of applications Separation and detection of the 
coumann in its particular matnx, is dependent on many factors These methods are 
dependent on whether it fluoresces or not, whether it has a strong UY absorbance or not, 
and whether there are antibodies available against that particular coumann Migration on 
CE, retention on a HPLC column, or its volatility for GC analysis will vary for each 
coumann and determine its resolution from other species present The selectivity of
antibody-based systems may be needed to isolate the analyte of interest from complex
!
endogenous species present that may interfere with analysis However, it is now clear that 
there are a vanety of methods now available with good analytical characteristics which may 
be applied to complex matrices and these may be modified to suit the requirements of a 
particular coumann or coumanns or specific applications
MATERIALS AND METHODS
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M A T E R I A L S
A list of the equipment and reagents used and their suppliers are given in Table 2 1 1 
and Table 2 12, respectively All reagents used were of analytical grade All organic 
solvents used were of HPLC grade The water used for all buffers and mobile phases 
was of Ultrapure Grade
2.1 REAGENTS AND EQUIPMENT
Equipment Suppliers
Nicolet IR  Spectrometer
Heraeus Sepatech Biofuge 13, and Heraues 
Labofuge GL, Titretek Twmreader-plus
System Gold solvent module 126, detector 
module 166, photodiode array 168, autosampler 
507, P/ACE System 2050 and System 5500, 
Beckman L8-70M  Ultracentnfuge,
400 MHz NMR spectrometer
U V -160A Spectrometer
3015 pH meter
Hetosicc, Hetofhg and Hetovac freeze dryer 
Ultra-pure water
Ultra-Turrax, Kika-Werk Homogemser
Nicolet Instr Corp , Madison, WI, USA  
Medlabs, Dublin Ireland
Beckman Instruments Limited, Fullerton, 
CA, USA
Brucker, Coventry, England
Shimadzu Corp , Kyoto, Japan
Jenway Ltd , Essex, England
Heto Lab equipment A /S, Allerod, Denmark
Millipore, Bedford, MA, USA
Lennox, Dublin, Ireland
Table 2 1 1  Equipment and Suppliers
43
Reagent Company
Bovine serum albumin, thyroglobulin, o-phenylene diamine (OPDA), 
ammonium sulphate ((NH4)2S0 4), sodium chloride, deoxycholic acid, 
7-hydroxycoumann, sodium and potassium hydrogen phosphate 
(N aH P04, KHPO4), sodium and potassium phosphate (Na2P 0 4, 
K2P 0 4), mcoune adenine dihydrogen phosphate, goat anti-rabbit 
peroxidase labelled antibody, gIucose-6-phosphate, glucose-6- 
phosphate dehydrogenase, sucrose, sodium acetate, UDP-glucuromc 
acid, 4-hydroxycoumann, magnesium chloride, saccharic acid 1,4- 
lactone, (3-glucuromdase, dithiothreitol, Freunds complete and 
incomplete adjuvant, protein molecular weight standards
Sigma Chemical C o , St 
Louis, MO, USA
Trichloroacetic acid, tns-HCl, Hydrogen peroxide BDH Chemicals L td , 
Poole, England, Carl 
Stuart, Dublin, Ireland
HPLC grade methanol, diethyl ether, acetom tnle, Petroleum-ether Labscan, Dublin, 
Ireland
1 6 ml plastic eppindorf tubes, 10 ml NH4-Hepann AH/10 treated 
tubes for blood collection
Sarstedt, Wexford, 
Ireland
Sodium hydroxide, Tween 20, hydrochloric acid, acetic acid, Silica  
TLC plates
Riedel de-Haen, Hannover, 
Germany
Coumann, 7-hydroxycoumann-glucuromde Schaper and Brummer, 
Salzgitter, Germany
1 1 ml screw cap HPLC vials, PTFE septa Carl Stuan, Dublin, Ireland
Untreated silica capillaries, 50 ml polyallomer quick-seal centrifuge 
tubes
Phosphate Buffered saline tablets
Beckman Instruments 
Limited, Fullenon, CA, 
USA
Unipath, Hampshire, 
England
Bicinchonmic acid (BCA) assay Pierce and W amnger, 
Cheshire, England
NUNC Maxisorb plates NUNC,Kam strup DK, 
Roskilde, Denmark
7-ammo-4-methyl coumann Aldrich, Dorset, England
Phenomenex Bondclone 10 C18 HPLC column, Phenomenex, Macclesfield, 
England
10 ml screw cap untreated blood tubes, 12 mm X  75 mm glass tubes Medlabs, Dublin Ireland
Table 2 1 2  Reagents and Suppliers
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METHODS
2 2 HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
(HPLC)
All HPLC analysis was earned out on system Gold HPLC apparatus (see Table 2 1) 
The system consisted of a dual pump/solvent delivery system and solvent mixer 
[module 1261, an autosampler injection system [module 507], a UV detector [module 
166], a solvent waste bottle and data processing unit (computer- Dell Dimension 486) 
-see Figure 4 01 The system was controlled by System Gold™ software (version 8 0)
2 2.1 Preparation of HPLC mobile phase
The mobile phases utilised for the separation and determination of coumanns in the 
various areas studied consisted of a water methanol acetic acid mix Analysis of 
serum samples from a Phase I drug trial of 7-hydroxycoumann used the method of 
Egan and O’Kennedy (1992) Separation was based on an isocratic method with a 
water methanol acetic acid mobile phase (700 300 2 v/v/v) The method developed 
for the determination of 7-hydroxycoumann and 7-hydroxycoumann-glucuromde after 
in vivo and in vitro metabolism of coumann or 7-hydroxycoumann used gradient 
elution The mobile phases were (A) water methanol acetic acid (950 50 2 v/v/v) 
and (B) methanol (100 %) The mobile phase used for the analysis of proteins was 0 1 
M  phosphate buffer, pH 7 4 The mobile phases prepared were mixed thoroughly and 
degassed by somcation for 20 min (organic solvents) or filtered and degassed under 
vacuum (phosphate buffer)
2.2 2 Preparation of samples for HPLC analysis
2 2 2 1  The collection and preparation of serum, unne and plasma
2 2 2 1 1  The preparation of stripped serum
Control serum was obtained from St James’ Hospital (Dublin, Ireland) For every 200
ml of serum 10 g of activated charcoal was added, mixed and mcubated at 45 °C for 
20 min This was then removed and centnfuged at 3000 rpm for 15 min and the
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supernatant was collected For each ml of supernatant, 50 mg of activated charcoal 
was added and incubated in the water bath for a further 20 min and then centrifuged 
This was repeated a further two times Following this the supernatant was filtered 
through 0 45 (im disposable sterile filters and stored at -20 °C until required
2 2 2 1 2  Patient serum collection and preparation
59 patients were treated orally with 7-hydroxycoumann as part of a Phase I clinical 
tnal 29 male and 30 female patients were diagnosed with a range of advanced 
malignancies (Table 2 2), and their ages varied from 27 to 83 years (see section 4 3)
Diagnosis No. of Patients
Renal cell carcinoma 15
Colon 15
Prostate 8
Carcinoid 6
Non-small cell 5
Hepatoma 2
Small cell carcinoma 1
Adrenal 1
Parotid 1
Gallbladder 1
Rectal 1
Neurosarcoma 1
Bronchial carcinoma 1
Bladder 1
Table 2 2 Patient diagnosis and the number of patients diagnosed with a 
particular malignancy Serum samples were obtained from the patients as part of 
the metabolism study tnal of 7-hydroxycoumann in patients with advanced 
malignancies
The range of doses investigated were from 100 mg to 7,000 mg (each of 3 patients 
were administered 100 mg, 300 mg, 500 mg, 700 mg, 900 mg, 1200 mg, 1500 mg, 
2000 mg, 2500 mg, 3000 mg, 3500 mg, 4000 mg, 4500 mg, 5000 mg, 5500 mg (2 
patients only), 6000 mg, and each of 6 patients were administered 6500 mg and 7000 
mg respectively) Blood samples were taken pre-administration and at 5, 15, 30, 45, 
60 min and 2, 4, 8, and 24 hr after drug administration The drug was readrmmstered
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14 days later and samples were taken at the above times again The blood was allowed 
to clot and stored immediately, after the removal of the clot, at -80 °C until analysis
2 2 2 1 3  Control unne and plasma collection and preparation
Blank unne and plasma was obtained from healthy volunteers who had not been 
treated with coumann and / or 7-hydroxycoumann The unne was collected into a 
stenle glass bottle, centnfuged and filtered through a 0 22 Jim stenle filter Control 
plasma was kindly donated by Professor R D Thornes
2 2 2 1 4  Volunteer unne and plasma samples collection and preparation
In two different studies volunteers were adminstered 100 mg and 250 mg of coumann 
respectively Unne samples were taken before the administration of coumann and at 2, 
6, 10, 14, and 24 hr after administration The samples were collected in stenle 500 ml 
bottles and the unnary volumes were recorded Before analysis the unne samples were 
centnfuged at 3000 rpm for 5 min to remove excess precipitated salts Blood samples 
were taken before the administration of 250 mg of coumann and at 1 hr and 4 hr after 
administration The blood was added into 10 ml screw cap tubes treated with NH4- 
Hepann to prevent clotting The samples were centnfuged at 3000 rpm for 20 min and 
the plasma removed Both unne and plasma control and samples were stored at -20 
°C until required
2 2 2  2 The preparation of samples for analysis
2 2 2 2 1  Determination of free and total 7-hydroxycoumann by HPLC
Deconjugation and extraction of 7-hydroxycoumarin
Senal dilutions of 7-hydroxycoumann were prepared in deionised water from a stock 1 
mg/ml solution prepared in 10 % methanol 90 % water Into a 10 ml stenle blood 
tube, 0 1 ml volume of 7-hydroxycoumann standard was added to 0 9 ml of control 
serum or unne giving a senes of calibration standards between 0 and 100 |ig/ml (0, 
0 5, 1 0, 5 0, 10 0,20 0, 50 0, 80 0 and 100 0 M.g/ml, respectively) Into a 10 ml stenle 
blood tube 1 ml samples of the patient serum or volunteer unne was added To both 
standard and unknown samples 0 05 ml of a 1 mg/ml internal standard (7-ammo-4- 
methyl-coumann, prepared in 100 % methanol) solution was added and vortex mixed
47
I(
To liberate conjugated 7-hydroxycoumann a 1 0 ml (3-glucuromdase solution was 
added (5000 units/ml prepared in 1M sodium acetate, pH 5 0) ,, gently mixed, and 
incubated for 30 mm at 37 °C After incubation the 7-hydroxycoumann present was
iextracted into diethyl ether 3 5 ml of diethyl ether was added into each tube and
i
rotary mixed for 10 mm The tubes were then centrifuged at 2000 rpm for 10 mm 1 8i
ml of the organic layer are removed into a 75 mm x 12 mm glass tube and evaporated 
to dryness at 60 °C The sample was then reconstituted into 0 2 ml of methanol,f
vortex mixed for 10 sec and centrifuged at 2,000 rpm for 2 min before analysis by
i
HPLC 160 |il of the reconstituted sample was added to a 1 1 ml screw cap vial before 
analysis (see section 4 0) Samples were analysed by the isocratic method (see section 
2 2 3 1) 1
2 2 2 2 2  Determination of total 7-hydroxycoumann by HPLC
Deconjugation and protein precipitation |
i
Unne samples 1
In a 1 6 ml eppendorf tube, 0 5 ml of (J-glucuronidase (5000 units/ml in 1 0 M  sodium
acetate, pH 5 0) was added to 0 5 ml of unne sample or standard and incubated at 37
t
°C for 30 min 100 |il of a 20 % (w/v) solution of tnchloroacetic acid was then added, 
to precipitate the protein solunon, and the samples were mixed and centnfuged at
i
13,000 rpm for 5 minutes 10 (il of a 1 mg/ml 4-hydroxycoumann, prepared in 100 % 
methanol, (the internal standard) was added to 190 \il of supernatant and vortex 
mixed Samples were analysed by the gradient method (see section 2 2 3 2)
Plasma samples
i
To 100 jo.1 of 7-hydroxycoumann or 7-hydroxycoumann-glucuromde standard, 
prepared in blank plasma, or 100 |il of plasma sample, 100 \il of P-glucuromdase 
(5000 units/ml in 0 5 M  sodium acetate, pH 5 0) was added and incubated at 37 °C for
t
60 min 20 (il of a 20 % (w/v) solution of trichloroacetic acid was added, mixed and 
centnfuged at 13000 rpm for 5 min To 150 ji.1 of supernatant 10 jil of a 1 mg/ml 4-
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IIII
hydroxycoumann, prepared in 100 % methanol, (the internal standard) was added and
i
vortex mixed Samples were analysed by the gradient method (see section 2 2 3 2)
if
I2 2 2 2 3  Determination of coumann, free 7-hydroxycoumann and conjugated 
7-hydroxycoumann by HPLC
Preparation of urine, serum and plasma samples for direct analysis of coumann, 7- 
hydroxycoumann and 7-hydroxycoumann-glucuronide
[i
iPreparation of 7-hydroxycoumarin-glucuromde
i
Rabbits were fed 7-hydroxycoumann and the unne of the animals was collected The 
glucuronide was punfied by liquid chromatography The separation column was filled 
with DEAE-cellulose M N  2100 (Macherey & Nagel) and the sample applied For 
elution ammoniumformate buffer, pH 9 0, was used After drying the 7- 
hydroxycoumann-glucuromde was extracted several times with methanol The 
resulting 7-hydroxy coumann-glucuromde was recrystallised from water andi
ethanol/water (The protocol and compound was kindly supplied by Dr M  
Tegtmeier, Schaper & Brummer, Salzgitter, Germany) !
Unne samples !
A senes of 7-hydroxycoumann, coumann and 7-hydroxycoumann-glucuromde 
standards were prepared in water from 1 mg/ml stock solutions (0, 20, 50, 100, 200, 
500, 800 and 1000 |ig/ml respectively) To 140 \il of blank unne, 20 [il each standard 
and 10 \i\ of internal standard (1 mg/ml 4-hydroxycoumann, prepared in 100 % 
methanol) was added and vortex mixed To 200 |il of sample 10 \il of the internal 
standard was added Samples were analysed by the gradient method (see section 
2232) iiii[tSerum and plasma samples
To 140 |ixl of control plasma or serum 20 (il of each of the standards was added and 
vortex mixed (the standards prepared were 0, 1, 5, 10, 20, 50, 80 and 100 (ig/ml) To 
200 Jixl of sample or the standard solution 40 jil of a 20 % solution of tnchloroacetic
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acid was added and vortex mixed This was then centrifuged at 13,000 ipm for 10 
min To 190 jxl of the supernatant 10 |xl of the internal standard (1 mg/ml 4- 
hydroxycoumann, prepared in 100 % methanol) was added, vortex ¡mixed and then 
analysed by the gradient HPLC method (see section 2 2 3 2) j
Calculation of total 7-hydroxy coumarin content in serum '
\
\
It was assumed that 99 % of the 7-hydroxycoumann in the sample was present as 7- 
hydroxycoumann-glucuronide and from this the total 7-hydroxycoumann content was 
calculated by multiplying the molar ratio (0 48, i e Molecular Weight 7-OHC / 
Molecular weight of 7-OHCG - 162 1/338 1 x 100/1) by the 7-hydroxycoumann- 
glucuronide concentration
i
2 2 2 2  4 Determination o f 7-hydroxycoumann-glucuronide after the in vitroi
metabolism o f 7-hydroxycoumann
Preparation o f samples and standards for the in vitro metabolism study of 7-
ihydroxycoumarin ,
Component Stock solution 
concentration
Volume
(ill)
Final
concentration
7-hydroxycoumann 6 2 mM 500 0 77 mMUDPGT enzyme preparauon 4 mg/ml 1000 i 1 mg/mlMagnesium Chlonde 1M 25 | 6 25 mMSacchanc acid 1,4-lactone 50 mM 500 t 6 25 mMUDP-glucuronic acid 10 mM 500 125 mMAbsolute Ethanol - 125 -Tns-HCl (pH 7 4) 1M 500 ; 125 mMDeionised water - 850 i
T able222  2 1  Concentrations and volumes o f the components o f the 
incubation mixture used in the in vitro production o f 7-hydroxycoumann
iii
The mixture (Table 2 2 2 2 1 ) was prepared for the in vitro production of 7- 
hydroxycoumann-glucuromde 7-hydroxycoumann was prepared by diluting a 62 
m M  (1 mg/ml) stock solution (prepared in 10 % ethanol water) with water All other
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components were prepared in water The reaction was earned out at 37 °C in an open 
10 ml glass tube and initiated by the addition of the enzyme solution 200 jil of the 
reaction mixture was removed at specific time intervals and added to 40 |il of a 20 % 
(w/v) solution of tnchloroacenc acid, mixed and centnfuged at 13,000 rpm for 5 rmn 
before analysis by HPLC
A senes of 7-hydroxycoumann-glucuronide (0 - 1000 |ig/ml) standards were prepared 
in water from a 1 mg/ml stock solution A standard curve was prepared as follows 20 
|il 7-OHCG standard, 40 \i\ enzyme solution, 40 |il water, 100 jlxI tns-HCl, and 40 |il 
tnchloroacetic acid were added together and centnfuged at 13000 rpm for 5 min The 
total volume was exacdy the same as that of the sample removed from the metabolic 
solution 190 (il of the sample or standard supernatant were added to 10 |il of a 1 
mg/ml solution of the internal standard (4-hydroxycoumann) in a 1 1 ml sample vial for 
analysis on HPLC Samples were analysed by the gradient method (see section 
2232)
2.2.2.2 5 Determination of proteins by HPLC
Qualitative determination of proteins
A 1 mg/ml solution of the protein-drug conjugates and controls (see section 2 5 1) 
were prepared in water The punfied antibody (section 2 5 3 ), prepared in 0 14 M  
PBS, pH 7 4 was diluted to 1 mg/ml
2.2.3 HPLC separation parameters
The HPLC system consisted of a System Gold solvent module 126, detector module 
166, photodiode array detector 168, and autosampler module 507 All of the 
components were controlled by System Gold Software Reverse-phase HPLC 
separations were earned on a 300 mm X 3 9 mm Phenomenex (Macclesfield, England) 
Bondclone 10 Ci8 column Protein samples were separated using a Protein Pak 
(Millipore) SW 300 column with a particle diameter of 10 (inx
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The mobile phase was a 700 300 2 water methanol acetic acid (v/v/v) solution 
The flow rate was 2 ml/min Detection was at 320 nm 20 ^ 1 samples were injected 
onto the column for analysis
2 2  3 2 Gradient method
Solvent A was a 950 50 2, water methanol acetic acid (v/v/v) solution Solvent B 
was 100 % methanol The flow rate was 1 ml/min Detection was at 320 nm The 1 
ml/min gradient was as follows
0 min -14 min Solvent A (100%) -»Solvent A (50 %) / Solvent B (50 %), 14 mm- 22 
min Solvent A (50 %) / Solvent B (50 %), 22 min-23 mm Solvent A (50 %) / Solvent 
B (50 %) -4 Solvent A (100 %), 23 min- 32 min Solvent A(100 %)
Detection was at 320 nm 20 |il samples were injected onto the column for analysis 
Figure 2 2 3 2 1 shows the gradient used for the separation of coumann, 7- 
hydroxycoumann, 7-hydroxycoumann-glucuromde and 4-hydroxycoumann
100 0 —
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Figure 2 2 3 2 1  Graphical representation of the HPLC gradient elution 
profile used for the separation of coumann, 7-hydroxycoumann, 7- 
hydroxycoumann-glucuronide, and 4-hydroxycoumann (see section 22  3 2 )
2 2 3 3 Analysis of proteins by HPLC
Protein-drug conjugates
2 2 31  Isocratic method
i 1— i— >— i— >— i— >— i— '— i— '— i— ■— i— '— i— -— i— '— j—  
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The mobile phase used for the separation of the BSA- and thyroglobulin-7- 
hydroxycoumann conjugates was 100 % ultra-pure water The mobile phase was 
filtered through a 0 45 |im filter and degassed by somcation for 20 min The flow rate 
was 0 5 ml/mm, with photo diode array detection 
Antibody Analysis
The purified annbody was separated by HPLC with the above mobile phase or with 0 1 
M  phosphate buffer, pH 7 4
2 3 CAPILLARY ELECTROPHORESIS
2 3 1 Preparation of CE electrolyte solutions
All buffers were prepared with deionised water (resistivity of 18 MQ), and HPLC 
grade organic solvents 
Phosphate Buffer
The various phosphate buffers used were prepared by mixing the acid and base salts 
(both prepared at the molanty required) of dipotassium hydrogen phosphate (K2HP04) 
and potassium dihydrogen phosphate (KH2PO4) or the equivalent sodium salts until the 
required pH is achieved The solution was then sonicated for 5 min and filtered 
through a 0 22 Jim sterile filter
90 % (100 mM phosphate Buffer I 11 mM deoxvchohc acid (sodium salt)) 10 % 
acetomtrile
100 m M  phosphate buffer was prepared in water and the 11 m M  deoxychohc acid 
(sodium salt) was then dissolved in this buffer and thoroughly mixed To 18 ml of the 
viscous solution 2 ml of acetomtrile was then added, vortex mixed and filtered through 
a 0 22 |im sterile filter
2 3 2 Preparation of samples and standards for analysis by CE.
2 3 2 1  Deconjugation and extraction
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The unne and serum samples and standards were prepared as outlined under Method 1 
in the preparation of samples for HPLC analysis above However, the samples were 
reconstituted into phosphate buffer instead of methanol before analysis
2 3 2  2 Preparation of unne samples and standards for direct analysis of
7-hydroxycoumann and 7-hydroxycoumann-glucuromde in unne
7-hydroxycoumann standards were prepared from a 1 mg/ml stock solution prepared 
in 20 80 (v/v) methanol deionised water 7-hydroxycoumann-glucuromde standards 
were also prepared from a 1 mg/ml stock solution prepared in deionised water 
Dilutions (20-800 Jig/ml) were then prepared in deionised water and 10 |il of each 
standard was spiked into 80 [i\ of unne Blank unne was also used, where necessary, 
for the dilution of samples with unknown metabolite levels to bring their values within 
the linear range of the assay The samples and standards were centnfuged at 13,000 
rpm for 5 min before analysis
2 3 2 3 Microsomal in vitro metabolism of coumann
Incubation solution
The incubation solution consisted of an NADPH regeneration system, coumann and a 
liver microsomal preparation (Table 2 3 2 1) The concentrations of the NADPH- 
generating system in all incubations were 4 umts/ml glucose-6-phosphate- 
dehydrogenase, 2 mg/ml D-glucose-6-phosphate, and 1 2 m M  NADP+ This was 
higher than that required to maintain maximum metabolic rates under the chosen in 
vitro conditions
Component Stock Concentration Volume added
Coumann 0 21 mM 195 |ilD-glucose-6-phosphate 50 mg/ml 10D-glucose-6-phosphate-dehydrogenase 200 units/ml 5 MlNADP+ 20 mM 15 piMicrosomal suspension vanous 25 pi
Table 2.3>2.1» Components of the incubation mixture for studying the in vitro 
metabolism of coumann by CE
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The coumann (substrate) concentration in the incubation solutions was always 0 16 
m M  The components (Table 2 3 2 1) were mixed together in an 1 6 ml eppendorf 
tube to give final concentrations as above The reaction was started by the addition of 
25 |il of microsomal suspension Following mixing the open Eppendorf tube was 
transferred immediately into the incubation bath (37 °C), and a 20 (il sample was 
taken and analysed The metabolite formation was monitored over a two hour period, 
taking samples at 0, 7, 14, 20, 30, 45, 60, 90, and 120 minutes, respectively In the 
case of analysis by HPLC, the incubation was first stopped by the addition of 50 |il of 
ice-cold trichloroacetic acid (20% w/v) and centrifuged at 13,000 rpm for 5 min before 
injection The HPLC analysis was earned out according to the method Egan and 
O’Kennedy (1992)
Preparation o f standard curve
Standards were prepared by spiking 2 jil of 7-hydroxycoumann and 4 [il of microsome 
preparation in 34 jil buffer The linear range was (0 - 308 5 jliM, 0-50 |!g/ml) with a 
limit of quantification of 6 17 (iM (1 (ig/ml) The concentration of 7-hydroxycoumann 
produced by the microsomes was calculated from a plot of absorbance versus 
concentration of 7-hydroxycoumann Standard curves were prepared in each of the 
microsomal preparations on the day on which the assay was earned out to allow for 
any day to day vanations
2 3 2 3 1  NADP+ i NADPH  Ratio Study
For this study, the concentration of glucose-6-phosphate-dehydrogenase was reduced 
to 0 1 units/ml The remainder of the incubation mixture was as above The study was 
earned out in the presence and in the absence of coumann, or the microsomal 
preparation
2 3 2 4  The in vitro glucurom dation o f  7-hydroxycoumann
The incubation solution consisted of 8 components (Table 2 3 2 4 1 ) The pnncipal 
components for the production of 7-hydroxycoumann-glucuromde are 7-
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hydroxycoumann, the enzymatic solution containing the UDP-glucuronyl transferase, 
and UDP-glucuronic acid A 1 mg/ml solution of 7-hydroxycoumann was prepared in 
10 % ethanol (Merck, Darmstadt, Germany) 90% deionised water All other solutions 
were prepared in deionised water
Component Stock solution Volume Final
concentration m concentration
7-hydroxycoumann 6 2 mM 200 0 77 mM
UDPGT enzyme preparauon 4 mg/ml 400 1 mg/mlMagnesium Chlonde 1M 10 6 25 mMSacchanc acid 1,4-lactone 50 mM 200 6 25 mMUDP-glucuronic acid 10 mM 200 125 mMAbsolute Ethanol - 50 -Tns-HCl (pH 7 4) 1 M 200 125 mMDeionised water - 340 -
Table2 3 2  41 Concentrations and volumes of the components of the 
incubation mixture used in the in vitro production of 7-hydroxycoumann- 
glucuromde
Reactions were earned out in open 2 0 ml plastic test tubes (Sarstedt Ltd, Wexford, 
Ireland) at 37 °C The reaction was initiated by the addition of the protein solution A 
sample was immediately removed and analysed by CE It was not necessary to add any 
matenal to stop the reaction as the application of the 30 kV separates the components 
of the reaction mixture thus stopping the opportunity for further reaction Samples 
were removed approximately every 12 minutes and analysed immediately The 
reaction was repeated 4 times Control studies were earned out in the absence of 7- 
hydroxycoumann, UDP-glucuronic acid and enzyme, respectively
Preparation of standard curve
0-1000 jLig/ml standards of 7-hydroxycoumann-glucuromde were prepared in water 
The standards were prepared by spiking 10 ^il of standard into 40 jil of denatured 
enzyme preparation, and 50 \i\ of 50 m M  tns-HCl, pH 7 4 It was necessary to 
denature the protein solution to remove any interference of endogenous P- 
glucuromdase present If undenatured enzyme preparation was used to prepare the
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standards it was possible to monitor the deconjugation reaction of 7-hydroxycoumann- 
glucuromde to 7-hydroxycoumann This was achieved by boiling the solution for 5 
minutes and utilising the supernatant after centrifuging the protein solution at 13,000 
rpm for 10 min Concentrations of 7-hydroxycoumann-glucuromde produced were 
determined from a mean standard curve (n=3) of concentration of 7-hydroxy coumann- 
glucuromde versus peak area
2.3.3 CE separation parameters
All capillanes were conditioned each day by 10 min nnses with 0 1 M  hydrochlonc 
acid, followed by 0 1 M  sodium hydroxide, then deionised water and finally electrolyte 
buffer
2 3 31  Determination of free and total 7-hydroxycoumann in unne and
serum
The capillary used was a 27 cm x 50 |xm fused silica column, with a capillary to 
detector distance of 19 3 cm The capillary was nnsed between runs with 0 1 M  
NaOH (1 min), followed by 25 m M  phosphate buffer, pH 7 5 (1 min) The sample was 
applied to the capillary by a 3 second pressunsed injection (0 5 p s i ) and separation 
achieved with an applied voltage of 20 kV (nse time 0 2 min) at 25 °C Typical 
running current was 100 [lamps The samples were analysed on a Beckman capillary 
electrophoresis P/ACE 2000 instrument and controlled with System Gold™ software
2 3 3 2 The direct determination of 7-hydroxycoumann-glucuromde and
7-hydroxycoumann in unne by capillary electrophoresis
Separations were earned out in a fused untreated silica capillary, 47 cm x 50 |im ID 
(Beckman Instruments, Fullerton, California, USA) with a capillary to detector 
distance of 39 3 cm The samples were analysed on a Beckman capillary 
electrophoresis P/ACE 5500 instrument and controlled with System Gold™ software 
Separation was optimised under the following conditions The capillary was 
reconditioned between each run with a 1 5 min 0 1 M  NaOH wash, followed by a 3 
min nnse with electrolyte buffer The electrolyte solution, for the separation of 7-
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hydroxycoumann and 7-hydroxycoumann-glucuromde in unne, was a 90 10 v/v [100 
m M  phosphate buffer (pH 7 0) 11 m M  deoxycholic acid (sodium salt)] [acetomtnle
(Labscan, Dublin, Ireland)] Samples were injected at 0 5 p s i for 5 sec The 
separation was earned out at 20 kV (nse time 0 2 min) and the typical running current 
was 160 |iamps Detection of the analytes was earned out at 320 nm with a fixed 
wavelength detector Calibration curves were prepared for each metabolite by plotting 
the concentration versus peak area Inter-assay and mtra-assay vanations were 
assessed to determine the accuracy and precision of the technique
2 3 3 3 The study of coumann metabolism by human liver microsomes
using CE
The capillary used was a 27 cm x 50 |im fused silica column, with a capillary to 
detector distance of 19 3 cm The preparation step for pnming of the capillary was a 1 
min nnse with 0 1 M  sodium hydroxide, followed by a 1 min nnse with electrolyte 
solution (25 m M  phosphate buffer, pH 7 0 or pH 7 5, depending on the separation 
required) The sample was applied to the capillary by a 3 second pressunsed injection 
(0 5 p s i ) and separation achieved with an applied voltage of 20 kV (nse time 0 2 
min) at 25 °C Typical running current was 100 |iamps The separation was earned 
out on a Beckman Capillary Electrophoresis Instrument (P/ACE System 2000) The 
resultant separation was monitored at 210 nm with a fixed wavelength detector using 
Beckman System Gold™ software
2 3 3 4 Interspecies differences in coumann metabolism in liver microsomes
examined by CE
The separation was earned out on a Beckman Capillary Electrophoresis Instrument 
(P/ACE System 5500) The capillary used was a 27 cm x 50 (im fused silica capillary 
with a capillary to detector distance of 19 3 cm The capillary was purged for 0 75 min 
with 0 1 M  sodium hydroxide Conditioning of the capillary was then achieved by a 1 
mm nnse with the 50 m M  phosphate buffer electrolyte solution (pH 6 8) The sample 
was applied by a 3 second pressunsed injection (0 5 p s 1 ) and the separation was
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earned out at 15 kV (rise time 0 2 min) at 25 °C with UV detection at 214 nm 50 
m M  phosphate buffer (pH 6 8) was found to be optimal, with a working current of 80 
(lamps
2 3 3 5 The use of CE for studying the in vitro glucuromdation of
7-hydroxy coumann.
Separation was earned out on a Beckman capillary electrophoresis instrument (P/ACE 
System 5500) The capillary used was a 57 cm X 50 |J.m i d untreated silica capillary 
with a capillary-to-detector distance of 50 cm Between each run the capillary was 
nnsed for 0 8 minutes with 0 1 M  NaOH, then a 2 5 minute rinse with electrolyte 
solution Samples were applied by 10 second pressurised injections at 0 5 p s l 
Separation was achieved at 30 kV (rise time 0 2 mm) at 25 °C with detection at 
320nm Typical running current was 170 jiAmps The same capillary was used 
without any deleterious effects on performance or reproducibility during the duration 
of the study
2.4 PREPARATION OF LIVER ENZYME HOMOGENATES AND
PROTEIN ASSAY
In order to prevent the introduction of contaminating species dunng the enzyme 
preparation, all glassware and solutions used for the preparations were autoclaved 
before use All solutions were prepared in deionised water Human liver microsomes 
were kindly donated by Dr Uwe Fuhr, University Hospital, Frankfurt am Main, 
Germany A kit consisting of microsomes of different species (Beagle dog, 
Cynomolgus monkey, male New Zealand white rabbit, female rat SD-OFA) was 
purchased from IFF A Credo (L’Arbresle Cedex, France) Protein concentrations of 
the microsomal preparations were included for each species Livers from other species 
(gerbil, mouse [Schofield, CD1], bovine, porcine) were obtained from freshly 
sacrificed animals and stored at -80 °C until required
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L Fragmentation of the sample
Approximately 1 g of frozen liver was cut into small pieces and washed with 0 9 %  
sodium chlonde until the supernatant remained clear The pieces were blotted dry and 
weighed
U_ Homogenisation
A 4 fold amount of 0 25 M  sucrose solution was then added to the liver pieces and the 
mixture was homogenised in a Potter homogemser with a teflon pestle using 5 strokes 
at 500 m m 1
/// Centrifugation
The solution was centrifuged at 4,000 rpm (1,900 g) for 10 min and 10,500 rpm 
(13,000 g) for 20 min to remove the nuclei, the mitochondria, unprocessed cells and 
extracellular matrix After centrifugation the upper lipid layer was removed and 
discarded The supernatant (including microsomes and cytosol) was then centrifuged 
at 50,000 rpm (190,000 g) for 80 min to separate out the micrsomes 
IV Wash and centrifuge
The supernatant was discarded and the pellet was resuspended in an 8 fold amount of 
0 15 M  KC1 and centrifuged at 50,000 rpm (190,000 g) for 80 min
V. Final preparation of microsomal suspension
The supernatant was discarded and the pellet was reconstituted into a tns (50 mM)- 
sucrose (0 25M) solution (pH 7 4) Aliquots of the microsomal suspension were then 
transferred into 2 ml cryotubes and frozen immediately in liquid nitrogen and stored at 
-80 °C until required Protein content was determined by the BCA assay
2.4 1 Preparation of liver microsomes
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Bovine liver was kindly donated by Kepak Ltd, Meath, Ireland from a freshly 
sacrificed cow It was immediately put on ice until it could be frozen It was stored at 
-80 °C until required The preparation was earned out at 0 °C
Approximately 40 g of frozen bovine liver was weighed out and cut into small pieces 
(0 5 cm X 1 cm X 0 1 cm approximately) It was washed with excess 0 9 % NaCl to 
remove blood from the liver This washing solution was discarded The liver was 
homogenised in 4 X weight of the liver of 0 25 M  sucrose solution in a 50 ml 
centnfuge tube The solution was then centrifuged at 4,000 rpm (1900 g) for 20 nun 
The pellet was discarded and the supernatant was added into Beckman quick-seal 
centnfuge tubes
The supernatant was centnfuged at 50,000 rpm (190,000 g) for 80 min Following 
centnfuganon the supernatant was discarded and the pellet was homogenised in a 0 1 
M  tns-HCl, 0 1 m M  dithiothreitol, and 0 75 % (w/v) sodium cholate solution The 
solution was centnfuged at 50,000 rpm (190,000 g) for 80 min The pellet was 
discarded To the supernatant saturated ammonium sulphate was added slowly with 
gentle stimng to give a 40 % (NH^SCX solution This was mixed for 20 min and then 
centnfuged at 4,000 rpm (1900 g) for 20 min The pellet was discarded To the 
supernatant saturated ammonium sulphate was added slowly with gentle stimng to 
give a 70 % solution and mixed for 20 min The solution was then centnfuged at
4,000 rpm (1900 g) for 20 mm
The supernatant was discarded and the pellet was resuspended in 50 m M  tns-HCl, pH 
7 4 and dialysed at 4 °C against 50 mM, tns-HCl, pH 7 4 After dialysis, the solution 
was aliquoted into 2 0 ml cryotubes and ‘snap-frozen’ in liquid nitrogen The crude 
UDP-glucuronyl transferase preparation was stored at -80 °C until required Protein 
content was determined by the BCA assay
2 4 2 Preparation of UDP-glucuronyl transferase
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2 4.3 Bicinchonmic acid (BCA) assay for protein determination
The BCA assay was earned out in a 96 well microtitre plate
1 The working reagent was prepared by combining 50 parts reagent A ( base 
reagent containing, sodium bicarbonate, bicinchonmic acid detection reagent and 
sodium tartrate in 0 2 N NaOH) with 1 part reagent B (4 % copper sulphate solution)
2 A set of BSA standards from 0 - 2 mg/ml were prepared by diluting stock BSA 
solution in the same diluent as the samples
3 To each respective well 10 fil of standard or unknown was added
4 200 |il of working reagent was then added to each well, mixed, covered and 
incubated at 37 °C for 30 mm
5 The absorbance was read at 562 nm on a microplate reader (Titretek 
Twmreader PLUS) Concentrations of proteins were determined from a plot of 
concentration versus absorbance
2.5. 7-HYDROXYCOUMARIN-PROTEIN CONJUGATES AND
PRODUCTION OF AN ANTI-7-HYDROXYCOUMARIN ANTIBODY 
2 5 1 Production of 7-hydroxycoumarin drug conjugates*
Preparation of diazomum salt of 7-hydroxycoumann Figure 2 5 11 is a schematic 
representation of the reaction involved in the production of BSA- and thyroglobulin- 
7-hydroxycoumann protein drug conjugates
Stage r  Synthesis and purification of 3-acetylamino-7-aceto-coumarin
8 1 g 2,4-dihydroxybenzaldehyde, 4 05 g of glycine, 10 g of sodium acetate, and 40 ml 
of acetic anhydnde were added into a 100 ml round bottomed flask and refluxed for 60 
min yielding a very dark brown solution which was allowed to cool to room 
temperature After cooling the semi-sohd substance was broken-up and added to 400 
ml of water and placed on ice for 30 min The water was poured off and 50 ml of 
warm methanol was added yielding a mustard coloured solution This was filtered and 
dned under vacuum The resultant filtrate was recrystallised from acetic acid (the 
com pound was dissolved in minimal acetic acid, with vigorous stim n g  over heat and 
the crystals were allowed to form overnight at 4 °C) The compound formed was
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filtered and dried under vacuum at 37 °C for several days to remove any remaining 
acetic acid The identity of the resultant yellow compound was determined from 
infrared analysis, TLC (the mobile phase used in the TLC separation was a 90 10 (v/v) 
diethyl ether petroleum ether) and melting point determination
Stage II Synthesis and purification of 3-amino-7-hydroxycoumarin
4 0 g of 3-acetylamino-7-aceto-coumann was refluxed in 250 ml of 3M hydrochloric 
acid for 30 min until all the solid present was seen to have reacted (l e until the 
solution went an orange colour) The pH of the solution was neutralised with solid 
NaHCO} The resultant yellow compound was filtered under vacuum The compound 
was dissolved in minimal boiling water then an equivalent amount of methanol was 
added and the solution was put on ice The resultant recrystallised orange-yellow 
compound was filtered and its punty and identity was determined by thin layer 
chromatography (TLC), infra-red analysis (IR) and nuclear magnetic resonance 
(NMR)
Stage III Synthesis o f a 7-hydroxycoumann diazonium-ion and its subsequent
conjugation to a protein
To 1 g of 3-amino-7-hydroxycoumann, 2 5 ml of concentrated HC1 was added giving a 
light brown ‘putty’ like substance After mixing for 5 min, 2 0 ml of distilled water 
was added To this 5 ml of 10 % (w/v) NaN02, at 0 °C, was added dropwise to 
produce the 3-diazonium ion-7-hydroxycoumann, yielding an orange compound with a 
brown crust This was allowed to mix for 20 min at 0 °C To this a 5 % (w/v) protein 
solution was added dropwise and stirred gently for 5 hr at 0 °C
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Stage I Stage II
° V
OH
OH
Glycine ^  
Acetic anhydride 
Sodium acetate
^  (Stage Ila) (Stage lib) 
HC1 (3M) NaHCO3 ►  ►
reflux neutralise
NHI 2
2,4-dihydroxy-benzaidehyde 3-acetylamino-7-aceto-coumann
Stage III
3-amino-7-hydroxy coumann
water HC1
10% NaNO Protein ^
0
Diazo coupled-protein-7-hydroxycoumann conjugate
Figure 2 5 1 1  The reactions involved in the production of 7-
hydroxycoumann protein drug conjugates The diagram shows the various stages 
involved in the preparation of diazocoupled-BSA-or-thyroglobuhn-7-
hydroxycoumann protein-drug conjugate
The pH of the reaction was monitored continuously and adjusted when necessary to 
pH 7 9 with 1 M  NaOH The protein-drug conjugates prepared were a bovine serum 
albumin (BSA) conjugate and a thyroglobuhn conjugate The unconjugated 7- 
hydroxycoumann was removed by exhaustive dialysis against several changes of 
distilled water at 4 °C for 48 hr or until the dialysis water remained clear The
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coloured solution in the dialysis tubing was reduced by reverse osmosis on a bed of 
sucrose The remaining solution was removed and freeze dned Conjugation with 
BSA yielded a rust coloured compound and conjugation with thyroglobulin yielded a 
brown compound The identity of the conjugate was determined by UV detection, and 
HPLC with photodiode array detection (see section 5 2 13)
Preparation of control protein-conjugate
The above reaction (Stage III) was repeated except for the addition of 3-amino-7- 
hydroxycoumann The conjugates produced were compared to the controls produced 
It was not possible to determine the amount of 7-hydroxycoumann diazo-coupled to 
the protein
The thyroglobuhn-7-hydroxycoumann conjugate was used for immunisation and the 
BSA-7-hydroxycoumann was used in the screening of the serum for antibodies against 
7-hydroxycoumann
2 5.2. Immunisation protocol:
Licensing
The immunisation procedures were earned out under the supervision, and performed 
with the appropnate license, of the Department of Health, Dublin, Ireland All 
appropnate efforts were made to minimise distress and discomfort to the animals used
Initial immunisation
1 ml of a 2 mg/ml solution of thyroglobulin-7-hydroxycoumann conjugate (prepared in 
water) was added to 1 ml of Freund’s complete adjuvant This was vortexed mixed for 
20 sec 1 ml was administered subcutaneously (SC) to each of two New Zealand white 
rabbits Blood samples were taken pre-injection as control The blood was allowed to 
clot, and the serum was removed after centnfugaüon (3,000 rpm for 20 min) The 
serum was stored at -20 °C until required
Subsequent immunisation (SC)
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The procedure was exacdy as above except Freund’s complete adjuvant (0 02 % w/v) 
was replaced with Freund’s incomplete adjuvant (0 02 % w/v) Booster injections 
were given every 28 days and blood was obtained 14 days later
2.5 3 Purification of antibody
Ammonium sulphate precipitation
To 30 ml of serum, 30 ml of saturated ammonium sulphate was added drop wise and 
stirred gently for 60 min on ice at 0 °C The solution was then centnfuged at 4,000 
rpm for 30 min The supernatant was discarded and the pellet was reconstituted in 4 
ml of ultra-pure water 4 ml of saturated ammonium sulphate was added and stirred as 
above for 60 min and centnfuged at 4,000 rpm for 30 min The resulting pellet was 
reconstituted into 0 75 M  ammonium sulphate before column punfication
Affi-T column preparation
The Affi-T was stored at 4 °C in 0 02 % sodium azide until required It is a thiophilic 
agent that binds the thiol- groups present in IgG The Affi-T was filtered through a 
sintered glass filter and washed with ultra-pure water, allowed to dry and then it was 
added to mobile phase (0 75 M  (NH^SC^ - ammonium sulphate) and poured to form 
a 9 cm X 1 cm column This was then washed with xlO volumes of mobile phase 
before the application of the reconstituted pellet The column was connected to a 
penstaltic pump and the flow rate was adjusted to 1 ml/min The eluent was collected 
in a fraction collector and high protein content was determined at 280 nm by 
ultraviolet spectrophotometry
The reconstituted pellet, after the ammonium sulphate precipitation, was applied to the 
top of the column and allowed to dissipate into the column before the replacement of 
the mobile phase The IgG present in the solution will interact with the thiophilic agent 
and will be retained on the column and all other non-specific proteins present will elute 
in the mobile phase The absorbance was monitored until it decreased below 0 05 
O D In order to elute off the antibody it was necessary to switch buffers from the 
washing buffer to the elution buffer The eluuon buffer was 50 m M  Tns-HCl, pH 7 4
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Fractions were analysed as above and those displaying high absorbances were pooled 
The column was reconditioned by washing through xlO volumes of mobile phase 
Reverse osmosis of the pooled fractions from several column purifications were earned 
out on a bed of sucrose solution The resultant solution was dialysed against 0 1 M  
PBS, pH 7 4, at 4 °C, and stored at -20 °C until required or in 0 02 % sodium azide 
(w/v) at 4 °C Protein concentration was determined by the bicinchonimc acid assay 
(see section 2 4 3) and antibody punty was determined by HPLC
2 5 4 Enzyme-linked immunosorbent assay (ELISA).
Screening for antibody production and the determination of 7-hydroxycoumann by 
ELISA The ELISA method is based on that of Egan, (1993) and Reinartz et a l, 
(1996) Figure 5 14 2 1 shows a diagrammatic representation of the ELISA detailed 
below
L Coating
A 1 mg/ml solution of bovine serum albumin (BSA) BSA-7-hydroxycoumann (7- 
OHC) was prepared in 0 14 M  phosphate buffered saline (PBS), pH 7 4 A 40 jig/ml 
solution was the prepared by diluting the stock solution in 0 14 M  PBS, pH 7 4 To 
each well of a 96 well NUNC maxisorb microtitre plate 100 |il was added and allowed 
to incubate at 4 °C overnight or for 1 5 hr at 37 °C
U_ Blocking
The plate was then washed 3 times with 0 14 M  PBS, pH 7 4 The plate was inverted, 
shaken and blotted dry A 1 % solution of BSA was prepared in 0 14 M  PBS, pH 7 4, 
and 200 |il was added to each well and incubated at 37 °C for 60 mm The plate was 
then washed 5 times with 0 14 M  PBS, pH 7 4, containing 0 05 % (v/v) Tween-20, ph 
7 4 and once with O H M  PBS, pH 7 4, or the plate was stored in 200 jil of 0 14 M  
PBS, pH 7 4, containing 0 05 % (v/v) Tween-20, pH 7 4, at 4 °C
ÏJL Sample preparation and antibody litre determination
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Preparation o f 7-hydroxycoumarin standards and samples in urine and their analysis 
by an enzyme-linked immunosorbent assay (ELISA)
A range of concentrations of 7-hydroxycoumann (0 - 500 jig/ml) were prepared in 
0 14 M  PBS, pH 7 4, from a 1 mg/ml stock solution prepared in ethanol 0 14 M  PBS, 
pH 7 4 (20 80 v/v) Into a 10 ml glass tube 0 9 ml of control unne and 0 1 ml of 
standard was added and vortex mixed Into a 10 ml glass tube, 1 ml of urine sample 
from a volunteer who had been treated with 250 mg of coumann, was also added 
Where necessary the unne sample was diluted with control unne to ensure that the 
drug level would be within the linear range of the ELISA For the determination of 
total 7-hydroxycoumann 1 ml of P-glucuromdase (5000 umts/ml, prepared in 0 5 M  
acetate buffer, pH 5 0) was added to standards and unknown unne samples and 
incubated for 30 min at 37 °C The samples were then extracted by the addition of 3 5 
ml of diethyl ether into the glass tube The tubes were mixed by inversion for 10 min, 
and centnfuged at 3,000 rpm for 10 min 1 8 ml of the diethyl ether layer was then 
removed into a 12 mm X 75 mm borosihcate tube and evaporated to dryness The 
sample was reconstituted into 200 [i\ of 50 m M  phosphate buffer, pH 7 4, immediately 
before it was required The samples were then diluted 1/10 in 0 07 M  PBS, 0 05 % 
(v/v) Tween-20, pH 7 4, before their analysis The remaining reconstituted sample was 
used for analysis by CE (see section 2 3 3 1 ) or HPLC (see section 2 2 3 2)
To each of three wells of a washed plate, 50 |il of the diluted reconstituted samples or 
standards was added Having determined the optimum dilution (the optimum dilution 
of the punfied antibody prepared for the ELISA was found to be 1/500) of purified 
antibody (anti-7-hydroxycoumann antibody) from titre, 50 (xl of this dilution [prepared 
in 1 % (w/v) BSA in 0 14 M  PBS, pH 7 4, containing 0 05 % (v/v) Tween-20] was 
added into each well, mixed gently, and incubated at 37 °C for 2 hr
Determining antibody titre
A range of dilutions of serum, or punfied anti-7-hydroxy coumann antibody solution 
was prepared in 1 % (w/v) BSA in 0 14 M  PBS, pH 7 4, containing 0 05 % (v/v)
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Tween-20 The dilutions prepared were from 1/500 - 1/128,000 100 jal of antibody 
was added to a washed plate and incubated at 37 °C for 1 hr
IV Addition of the 2° Antibody 
Horseradish-peroxidase-labelled antibody addition
After incubation the plate was washed 5 times with 0 14 M  PBS, pH 7 4, containing 
0 05 % (v/v) Tween-20 and then once with 0 14 M  PBS, pH 7 4 A working dilution 
of 1/10000 dilution of the goat anti-rabbit horseradish-peroxidase-labelled antibody 
was prepared in 1 % (w/v) BSA in 0 14 M  PBS, pH 7 4, containing 0 05 % (v/v) 
Tween-20 100 (il of the goat anti-rabbit HRP-labelled antibody was added to each 
well and incubated at 37 °C for 1 hr
V_ Addition o f  enzyme substrate and colour development
The plate was washed 5 times with 0 14 M  PBS, pH 7 4, containing 0 05 % (v/v) 
Tween-20 and then once with 0 14 M  PBS, pH 7 4 The enzyme substrate consisted 
of 50 mg o-phenylene diamine (OPDA) prepared in 25 ml of 0 15 M  citrate-phosphate 
buffer containing 0 05 % (v/v) Tween-20, pH 5 0 [it was kept in the dark at all times] 
5 \i\ of hydrogen peroxide was added to the substrate just before its addition to each 
well 100 |al of substrate was added into each well and the plate was incubated for 1 hr 
at 37 °C The yellow colour was allowed to develop and the absorbance was 
monitored at 405 nm on a Titretek plate reader
VI Processing of data
The mean absorbances (A) were calculated and divided by the maximal absorbance 
(A0) [l e A/A0] and plotted against the log of the concentration giving a standard
curve From this standard curve the concentrations of 7-hydroxycoumann (total and
free) were calculated The antibody titre was calculated from a plot of the log of the 
reciprocal dilution versus the mean absorbance
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3.0. INTRODUCTION
Electrophoresis is a technique where, under the influence of an electric field, the 
migration of a charged particle is monitored. Electrophoresis, in general, is carried out 
on some form of solid support to facilitate electromigration of those charged particles. 
Anti-convective media, such as polyacrylamide or agarose gels, are used as the solid 
support in normal electrophoresis. The classical electrophoresis technique has long 
analysis times, low efficiency and there are difficulties in detection and automation.
Capillary electrophoresis (CE) is a family of related techniques that employ narrow-bore 
capillaries, a voltage supply, and selective buffers to perform separations of drugs, 
proteins, DNA etc. This powerful analytical technique is used for the determination of 
many species in a multitude of areas and has been reviewed (Wainright, 1990; Li, 1992; 
Carchon and Eggermont, 1992; Landers, 1993, Landers et ai, 1993; Weinberger, 1993; 
Campos and Simpson, 1993; Marina and Torre, 1994; and Beckman Instruments CE 
booklets). All major scientific instrumentation companies are now developing separation 
kits as well as the instrumentation for CE separations. These kits allow the separation of 
a myriad of compounds including chirals, proteins, and DNA, and facilitate isoelectric 
point (pi) determination.
The use of capillaries as an electromigration channel presents a unique approach to 
separation. Capillaries present several advantages over the classical electrophoretic 
technology. The physical characteristics of narrow-bore capillaries make them ideal for 
electrophoresis. The large internal surface area make it ideal for efficient heat 
dissipation. Fused silica capillaries employed in CE typically have internal diameters of 
20-100 Jim i.d., lengths from 20 cm to 100 cm, and are externally coated with 
polyimide. This polymeric substance gives excellent flexibility to the capillary and it is 
easily removed with acid or with a flame to prepare an on-line detection window. The 
majority of CE is carried out in free solution rather than using an anti-convective 
medium, although, gels have been used as a sieving media to facilitate some separations.
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CE has several advantages over the classical electrophoretic techniques ‘Joule heat’, 
caused by the voltages applied for separation, is efficiently removed due to the high 
surf ace-to-volume ratio of capillaries Due to this efficient heat dissipation it is possible 
to increase the voltage supplied and considerably decrease the analysis nme, allowing 
greater resolution Very high electric field strengths (> 500 V/cm) are often used for the 
separation of many analytes On-column detection and computer controlled systems 
decreases analysis time Electropherograms often resemble chromatograms thanks to 
the use of modem detection technology and some form of data output e g computers or 
an integrator Typical capillaries have total column volumes in the microhter range 
Minute quantities of electrolyte buffer are thus required to run a CE separation as 
compared to other liquid chromatographic methods Sample volumes are generally 
restricted between 1 % and 5 % of total buffer volume le nanoliter volumes are 
required for analysis The small volumes will reduce waste as compared to HPLC The 
majority of buffers used are based on water rather than organic solvents which results in 
a reduction in organic solvent waste Sensitivities of CE with UV detection are in the 
order of picomoles (10l2) Interfacing of detection systems with laser-induced 
fluorescence detectors has extended the sensitivity into the attomole (1018) range
The basic instrumental configuration for CE is relatively simple (Figure 3 0 1) All that 
is required is an untreated fused-silica capillaiy, a detector viewing window, a 
controllable high voltage power supply, two electrode assembly, two buffer reservoirs, 
and an ultraviolet detector The ends of the capillary are placed in the buffer reservoirs 
and the optical viewing window is aligned with the detector After filling the capillary 
with electrolyte buffer, the sample can be introduced into the capillary under pressure or 
electrokine&cally
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Buffer/Sample Buffer
Figure 3 0 1  General schematic o f  a CE instrument (Diagram taken from  Landers 
et a l , 1993) The basic CE instrum ent consists o f  a controllable high voltage power 
supplyy two buffer troughs, a cooling system fo r  the capillary, a capillary with on-line 
UV detector and a means o f  data acquisition PI ACE System 5500 utilised in the 
studies described below was a single unit with com puter control o f  all the variables 
including voltage> detection wavelength, and data acquisition
3 0.1 Capillary Zone Electrophoresis (CZE)
With capillary zone electrophoresis (CZE) the ‘normal’ polanty is considered to be 
Inlet (+) —> Detector —> Outlet (-) as shown in Figure 3 0 1
As electrophoresis ensues under these conditions, the analytes separate according to 
their individual mobility’s and pass the detector as analyte “zones” With ‘normal’ CE 
the species migrate as ‘positives’ —» ‘neutrals’ —> ‘negatives’ and are displayed as an 
electropherogram The electrophoretic mobility is the principle force in electrophoresis
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that carries the analyte zones past the detector window Electrophoretic mobility is the 
electric force that enables the migration of charged species under the influence of an 
electrical field This force works in tandem with electroosmotic flow (EOF) 
Electroosmotic flow is the liquid flow which occurs in the presence of an electric field 
Without the EOF only positively charged ions would migrate past the detector window 
However, when the forces work in tandem positive, neutral and negatively charged 
species can migrate pass the detector window The interaction of an aqueous electrolyte 
solution with the silica surface in the capillary will cause an excess of negative charge 
due to the ionisation of the surface’s silanol groups The degree of ionisation is 
controlled mainly by the pH of the electrolyte buffer Electroosmotic flow must be 
controlled or even suppressed to run certain modes of CE However, the separation of 
charged species is only made possible by the electroosmotic flow At neutral to alkaline 
pH, the electroosmotic flow is sufficiendy stronger than the electrophoretic migration to 
allow the migration of all charged species in the CZE separation
Resolution in CE is determined by the following
1 Electroosmotic flow, (dependent on pH or capillary internal surface coating)
2 Electrophoretic mobility
3 Voltage
4 Capillary modifications
5 Electrolyte buffer (dependent on pH, buffer concentrations and constituents)
6 Temperature (determines viscosity)
The pH, ionic strength, organic solvent content, surfactant content, and the presence of 
chiral selectors will all alter the electroosmotic flow in the capillary A wide variety of 
buffers can be employed in CE A buffer (Table 3 0 1) is most effective within one or 
two pH units of its pKa e g phosphate is used at pH 7 0, and borate at pH 9 0 The 
choice of concentration is dependent on the separation required, and the dimensions of 
the capillary used, both of which will in turn determine the voltage applied Buffer 
additives can be added to alter the separation selectivity The addition of surfactants, 
cyclodextnns (chiral selectors), organic solvents, cellulose derivatives, urea, and amines
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will alter the interactions of analyte with the silanol groups thus improving separation 
efficiencies Separation of compounds normally unseparable by free solution CE 
without buffer additives maybe achieved, e g the separation of chiral compounds where 
under ‘normal’ CE the isomenc forms would co-migrate
Buffer Useful pH range
Phosphate 1 14 - 3 14
Acetate 3 76 - 5 76Phosphate 6 20 - 8 20Borate 8 14 - 10 14
Zwittenom c Buffers
MES 5 15-7 15PIPES 5 80 - 7 80HEPES 6 55 - 8 55Tncine 7 15-9 15Tns 7 30 - 9 30
Table 3 01 Buffers and their buffering regions used in capillary electrophoresis 
(Table taken from Beckman Instruments, In c, Introduction to Capillary 
Electrophoresis)
3 0.2 Capillary Isoelectric Focusing (CIEF)
Carrier ampholytes transport peptides and proteins to their isoelectric points (pi’s) A 
pH gradient is generated when a voltage is passed across the earner ampholytes present 
in the capillary The ampholyte mixture separates in the capillary giving a pH gradient 
under the applied electnc field as in typical isoelectnc focusing on a solid gel based 
surface The buffer pH is low at the anode and high at the cathode The positively 
charged ampholytes will migrate to the negative electrode while the negatively charged 
migrate to the anode After sample loading the components present will ‘focus’ at the 
pH of their respective pi value By changing the anolyte or catholyte solutions, the 
focused proteins or peptides can be mobilised past the detector to generate an 
electropherogram If the concentration of protein is too high, it is possible that it will 
precipitate in the capillary at its pi value as it would on a gel based solid support CIEF
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has been applied to peptide mapping, pi determination of proteins and it has been 
particularly useful for the separation of immunoglobulins, and post-translational 
modifications of recombinant proteins
3 0.3 Capillary Gel Electrophoresis (CGE)
In capillary gel electrophoresis (CGE) the capillary tubes are filled with a gel which acts 
as a molecular sieve to produce a size based separation CGE has been useful in the 
separation of macromolecules such as proteins, DNA polynucleotides, and DNA 
restriction fragments, because they contain mass-to-charge ratios that do not vary with 
size Polyacrylamide gel-filled capillaries are usually employed in CGE Agarose gels 
are unable to withstand the heating produced by the high voltages used in CGE In the 
separation of proteins the focus has been on the SDS-gels for size based separations 
The two fundamental classes of gels used are physical and chemical gels The 
entanglement of polymers in physical gels gives them their porous structure Chemical 
gels use covalent attachment to form their porous structure
Proteins are generally separated by CGE as follows Proteins are denatured by boiling 
the sample in 2-mercaptoethanol prior to SDS binding The binding to SDS gives an 
equal charge-to-mass ratio for all proteins present Separation is then based on size 
difference Samples are introduced by electrokinetic injection The sample is 
electrophoresed into the capillary Thus, only charged species are introduced into the 
system This prevents the extrusion of the gel from the capillary, which would occur if 
pressunsed injection was used Separation times and resolution can be altered by the 
use of changing the gel concentration, or changing the voltage, providing an adequate 
heat dissipation system is used
A hydroxypropyl methyl cellulose buffer system and a commercially available coated 
capillary were found to be ideal for the separation of large oligonucleotides or DNA 
fragments of 1 kB or larger, in addition to PCR fragment analysis Suppression of the 
EOF aids in the separation of both DNA samples and proteins This suppression inhibits
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interaction and binding of proteins and / or DNA to the capillary wall which may prevent 
accurate and reproducible separation
3 0 4 Micellar Electrokinetic Capillary Chromatography (MECC)
Micellar electrokinetic capillary chromatography (MECC) [also called micellar 
electrokinetic chromatography (MEKC)] is a variation on CZE where surfactants 
(micelles) are added to the electrolyte buffer Surfactants are molecules which exhibit 
both hydrophobic and hydrophilic characteristics This technique has been investigated 
in order to obtain selective separation of neutral and ionic compounds while retaining 
the advantage of CZE Surfactants have polar ‘head’ groups that can be either cationic, 
anionic, neutral or zwittenonic and they have nonpolar, hydrocarbon tails (Table 3 0 2)
Type Name Formula CMCa
Anionic Sodium dodecyl 
sulphate (SDS) C12ïfe0S03 Na+ 81Lithium 
perfluorooctane 
sulphonate (LiPFOS)
C8F17SO3 6 72
Cationic Dodecyl tnmethyl 
ammonium bromide 
(DTAB)
C12H25N+(CH3)3Br 15
Noniomc Polyoxyethylene (23) dodecanol (Bnj-35) Ci2H25(0CH2CH2)230H 01
Zwittenonic Af-dodecylsultame C12H25(CH3)2N+CH2-
ch2ch2so3 12
Bile salts Sodium cholate QÄC^COO Na+ 12 5Sodium deoxycholate C20H32O3COONa+ 64
a CMC values are taken at 25 °C
Table 3 02  Some of the surfactants utilised in capillary electrophoresis The table
includes their type, name, formulae and critical micelle concentration (CMC) (Table 
taken from Landers et a l , 1993)
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If the surfactant concentration exceeds a certain ‘crmcal micellar concentration’ (CMC) 
the surfactant molecules can self-aggregate, forming spherical or helical aggregates 
called micelles Ionic and hydrophobic sites of interaction are formed when the 
hydrocarbon tails are oriented toward the centre of the micelle, whilst the polar head 
group point outward Micellar solutions may solubilise hydrophobic compounds which 
would otherwise be insoluble in water The aggregation number is the number of 
surfactant molecules making up a micelle (typically in the range of 50-100) and it and 
the CMC are both unique to each surfactant Micelles are typically in the range of 3 nm 
to 6 nm in diameter The separation principle of MECC is based on the differential 
partition of the solute between the micelle and water whereas CZE is based on the 
differential electrophoretic mobility
Micellar solutions must be homogenous and not interfere with the detection of the 
analyte i e they must be UV transparent The use of some surfactants may cause 
viscous solutions The concentration and physical limitations of these surfactants must 
be optimised if they are to be utilised for MECC This is also the case for the solubility 
of the micelle and the ability of the surfactant to form micellar solutions in a particular 
buffer The hydrophobic and hydrophilic moieties of micelles and binding constants of 
solutes will determine the micelle mobility When choosing a surfactant (Table 3 0 2 )  
for a particular separation problem it is necessary to first assess the type, structure, size, 
hydrophobicity, and solubility of the analyte to be separated and analysed The micelle 
formed by sodium dodecyl sulphate (SDS), an ionic surfactant, migrates toward the 
positive electrode by electrophoresis However, the EOF transports the bulk solution 
toward the negative electrode due to the negative charge on the surface of fused silica. 
The EOF is usually stronger than the electrophoretic migration of the micelle under 
neutral conditions and, therefore, the micelle is forced to travel toward the negative 
electrode albeit slower than the EOF which is the basis of MECC separation
When the analyte of interest is added into the micellar solution an equilibrium is formed 
Some of the analyte is incorporated into the micelle and the remainder is free from the 
micelle Thus, some of the analyte migrates at the EOF, (that in free solution) and some
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will migrate with the micelle The migration velocity, of the analyte, thus depends on 
the distribution between the micellar and non-micellar (aqueous) phase The analyte will 
migrate (as a zone) between the migration of the bulk solution and that of the micelle
Another important type of surfactant is the bile salt e g sodium deoxycholate, sodium 
cholate (Table 3 0 2 )  They are biological surfactants with a hydrophobic steroid 
moiety and hydrophilic groups The microenvironment of the micellar bile salts yields 
different separations in comparison to the other micellar species There is a more polar 
centre to the micelle as compared to the centres of the long chain alkyl surfactants 
Another difference is that bile salts form helical micelles, rather than spherical micelles, 
and they yield selectivmes that are significantly different In particular, they are very 
useful for the separation of very hydrophobic compounds
3 0.5 Conclusion
Other methods for the determination of coumann and 7-hydroxycoumann by capillary 
electrophoresis are described in section 12  4 Several CE methods are described below 
for the separation and determination of 7-hydroxycoumann and 7-hydroxycoumann- 
glucuronide after in  v iv o  and in  v it r o  metabolism Separations are based on capillary 
zone electrophoresis (CZE) and micellar electrokinetic capillary chromatography 
(MECC) CZE was applied to the determination of free and total 7-hydroxycoumann in 
unne and serum after deconjugation and extraction of the compound It was also used 
for the determination of coumann 7-hydroxylase activity in liver microsomes from 
vanous species including man, rabbit, cynomolgous monkey and rat MECC was 
applied to the direct determination of 7-hydroxycoumann and 7-hydroxycoumann- 
glucuronide in unne It was also applied to the determination of 7-hydroxycoumann- 
glucuromde after the in  v it r o  metabolism of 7-hydroxycoumann by undine diphosphate 
glucuronyl transferase
80
3 1 CAPILLARY ELECTROPHORESIS AND THE ANALYSIS OF 7-
HYDROXYCOUMARIN AND 7-HYDRQXYCOUMARIN-GLUCURONIDE
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3 1 1  Determination of free and total 7-hydroxycoumann in urine and
serum by capillary electrophoresis
A method has been developed for the determination of 7-hydroxycoumann in unne and 
serum, based on deconjugation and extraction of the drug and separation by capillary 
electrophoresis, with UV detection at 210 nm Samples were prepared as outlined under 
section 2 3 2 2 Unne from two volunteers, who had been administered 100 mg of 
coumann, was analysed by both capillary electrophoresis and by HPLC The results from the 
two methods were compared and contrasted
3 1 1 1  D e v e lo p m e n t  o f  th e  C E  s e p a r a t io n
Vanous buffers e g  borate, tns-HCl, were investigated in an attempt to separate the
compounds Although several of the buffers showed some separation, phosphate buffer was 
chosen, as it gave rise to the best resolution between coumann and 7-hydroxycoumann The 
pH was then optimised, and the best separation achieved at pH 7 5 The ionic strength of the 
buffer was also assessed At 0 1 M, a very high running current was exhibited (> 250 
fiamps), but use of 0 025M phosphate buffer concentration was found to decrease the
working current to 100 jiamps approximately A CE separation of a mixture of coumann, 7-
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hydroxycoumarin and the internal standard is shown in Figure 3.1.11. From this it can be 
seen that the three compounds are well separated with baseline resolution within 1.2 minutes.
Tim© (min)
Figure 3.1.1.1. Capillary electrophoresis separation of (A) coumarin, (B) 7-
hydroxycoumarin, (Q contaminant of 7-hydroxycoumarin, and (D) the internal 
standard Samples were prepared in 0.025 Mphosphate buffer, pH 7.5. Separation was 
carried out in a 27 cm untreated silica capillary, using 25 mMphosphate buffer, pH  
7.5, with detection at 210 nm.(see section 2.3.3.1.). Each of the peaks shown in the 
electropherogram is assigned A, B, Cor D and this is the protocol throughout each of the 
figures below.
Coumarin has a net zero charge at pH 7.5 and it migrates with the solvent front, i.e. at the 
same migration time as a neutral marker, benzamide. This method cannot be used for the 
quantification of coumarin in biological fluids due to interferences from endogenous species 
present in the particular matrix. At the pH utilised one achieves the separation of coumarin 
from 7-hydroxycoumarin by virtue of the charge difference between the two compounds (7- 
hydroxycoumarin is more negatively charged at pH 7.5, relative to coumarin). The 
separation was then applied to the analysis of urine and serum samples after sample
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preparation (see section 2.3 .2.2 ). The separation of the compounds in the urine extract is 
shown in Figure 3 .1.1.2,, where it can be seen that there is only minimal interferences to the 
analysis of 7-hydroxycoumarin from co-extracted endogenous species in the urine.
Time (min)
Figure 3.1.1.2. Electropherograms of blank urine [red] and 50 /Jg/ml [blue] 7-
hydroxycoumarin standard and internal standard spiked in urine The samples were 
prepared as outlined under section 2.3.2.1. Separation was carried out in a 27 cm 
untreated silica capillary, using 25 mM phosphate buffer, pH  7.5, with detection at 
210 nm. (see section 2.3.3.1.). (A) is the solvent front and any neutral compounds, (B) is 
7-hydroxycoumarinf (D) is the internal standard\ and (E) is co-extracted endogenous 
species in urine.
The CE analysis of total 7-hydroxycoumarin in a urine sample taken from a volunteer 6 hours 
after administration of coumarin is shown in Figure 3 .1.1.3. It indicates that most of the 
interferents have longer migration times compared with those of the drug and its metabolite. 
This figure also shows that the internal standard cannot be used in the analysis of total 7- 
hydroxycoumarin owing to the greater number of interferents occurring at its migration time.
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There was also irreproducible extraction of the internal standard after the treatment of the 
unne sample with P-glucuromdase Efforts to find a alternative internal standard which 
would elute later in the electropherogram and extract reproducibly, proved fruitless The CE 
analysis of a serum extract is shown in Figure 3 1 1 4  From this it can be seen that there is 
good separation between the metabolite, the internal standard and the majority of the co­
extracted interfering substances There was no interferences from other glucuromdes with 7- 
hydroxycoumann after treatment of the serum with p-glucuromdase
Tim e (min)
F i g u r e  3 1 1 3  C E  a n a ly s is  o f  to ta l 7 - h y d r o x y c o u m a n n  in  a  u n n e  s a m p le  f r o m
v o lu n t e e r  2, 6  h  a fte r  a d m in is t r a t io n  o f  c o u m a n n  T h e  s a m p le s  w e re  p r e p a r e d  a s  
o u t lin e d  u n d e r  s e c t io n  2 3 2 1  S e p a r a t io n  w a s  e a r n e d  o u t  in  a  2 7  c m  u n t r e a t e d  s i l i c a  
c a p il l a r y , u s i n g  2 5  m M  p h o s p h a t e  b u f f e r , p H  7 5 , w it h  d e t e c t io n  a t  2 1 0  n m  (s e e  
s e c t io n  2 3 3 1 )  T h e  p e a k s  a r e  ( A )  s o lv e n t f r o n t  c o n t a in in g  a n y  n e u t r a l  c o m p o u n d s , ( B )  
7 - h y d r o x y c o u m a n n  a n d  ( E )  c o -e x tr a c te d  e n d o g e n o u s  s p e c ie s  in  u n n e
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The method was then compared to the previously developed HPLC method of Egan and 
O’Kennedy (1992) for the quantification of 7-hydroxycoumann in the urine of volunteers 
who had been administered coumann When, however, one compares the run times for the 
samples, one immediately realises the diminution in the tune for the determination step (at 
least eight fold) between the two techniques The method also has a fast regeneration step to 
recondition the capillary column between every analysis There are no carryover problems, 
less solvents are used, and there is minimal organic solvent waste as compared with the 
reversed-phase HPLC method However, as with the HPLC method, a clean-up procedure 
was used for the biological samples pnor to analysis
Tim e (min)
F i g u r e  3 1 1 4  E le c t r o p h e r o g r a m s  o f  b la n k  s e r u m  [ b l a c k ]  a n d  5 0  ju g /m l [ r e d ]  7-
h y d r o x y c o u m a n n  s t a n d a r d  a n d  in t e r n a l  s t a n d a r d  s p ik e d  in  s e r u m . T h e  s a m p le s  w e re  
p r e p a r e d  a s  o u t l in e d  u n d e r  s e c t io n  2 3 2 1  S e p a r a t io n  w a s  c a r r i e d  o u t  in  a  2 7  c m  
u n t r e a t e d  s i l i c a  c a p il l a r y , u s i n g  2 5  m M  p h o s p h a t e  b u f f e r , p H  7  5, w it h  d e t e c t io n  a t  
2 1 0  n m  (s e e  s e c t io n  2 3 3 1 )  ( A )  is  t h e  s o lv e n t  f r o n t  a n d  a n y  n e u t r a l  c o m p o u n d s , ( B )  is  
7 - h y d r o x y c o u m a n n , ( D )  a r e  c o -e x tra c te d  e n d o g e n o u s  s p e c ie s  in  s e ru m .
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3 1 1 2  L i m i t  o f  q u a n t if ic a t io n  a n d  lin e a r it y
In both unne and serum the limit of quantification of 7-hydroxycoumann was found to be 1 
pg/ml and the linear detection range for the analysis of the drug was from 0 to 50 pg/mL The 
mean equation of the line for total 7-hydroxycoumann is, y = [1 39E-2 ± 6 6E-4] + [1 43E-3 
± 9 3E-5]x and for free 7-hydroxycoumann is y = [2 16E-2 ± 8 9E-3] + [2 41E ± 2E-3]x, 
respectively Correlation coefficients were always better than 0 99
3 1 1 3  A c c u r a c y  a n d  p r e c is io n
Tables 3 1 1 1  and 3 1 1 2  are the results from the inter- and mtra- assays for the 
determination of 7-hydroxycoumann in unne
Concentration Mean Concentration ± Standard Percentage Relative
Added Calculated Deviation (n=6) Standard Deviation
0 0 0 0
1 109 009 89
5 5 16 0 37 73
10 10 37 0 58 56
20 19 45 0 82 42
50 50 85 3 23 63
T a b l e  3 1 1 1  P r e c i s i o n  a n d  a c c u r a c y  o f  t h e  C E  m e t h o d  f o r  th e  a n a ly s is  o f
t o t a l 7 - h y d r o x y c o u m a n n  in  u n n e  ( I n t e r - a s s a y )  T h e  r e s u lt s  w e re  c a l c u la t e d  b y  
r e la t in g  t h e  p e a k  a b s o r b a n c e  r a t io s  f r o m  e a c h  a n a ly s is  to  t h e  m e a n  s t a n d a r d  c u r v e  to  
g iv e  t h e  m e a n  c o n c e n t r a t io n  c a l c u l a t e d  ± s t a n d a r d  d e v ia t io n  a n d  t h e  %  re la t iv e  
s t a n d a r d  d e v ia t io n  ( n = 6 )
The results are given as the concentration added and the mean concentrations calculated 
± standard deviations, and relative standard deviations The inter-assay accuracy and 
precision for free 7-hydroxycoumann was determined over a five day penod (n=5) The 
intra-assay accuracy and precision for free drug was determined over five calibration 
sets on one specific day The inter-assay analysis for total drug was determined over six 
days (n=6) The use of the internal standard was not of significant benefit for the 
determination of free 7-hydroxycoumann
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Concentration
Added
Mean Concentration Calculated 
± Standard Deviation (n=5) 
(% Relative Standard deviation)
Mean Concentration Calculated 
± Standard Deviation (n=5)
( % Relative Standard deviation)
(ue/ml) (Mg/mi) (Inter-assay) (ug/ml) (Intra-assay)
0 0 0
1 095 ±007 (7 0) 102 ±013 (13 6)
5 5 12 ±0 26 (5 2) 5 08 ±0 40 (7 9)
10 9 81 ±0 21 (2 1) 10 30 + 0 35 (7 9)
20 21 20 ± 1 00 (4 7) 20 62 ± 0 79 (3 8)
50 51 06 ±3 84 (7 5) 49 20 ± 2 03 (4 1)
T a b l e  3 1 1 2  P r e c i s i o n  a n d  a c c u r a c y  o f  t h e  C E  m e t h o d  f o r  t h e  a n a ly s is  o f
f r e e  7 - h y d r o x y c o u m a n n  i n  u n n e  ( I n t e r  [ n = 5 ]  a n d  in t r a  a s s a y  [ n = 6 ] )  T h e  r e s u lt s  
w e re  c a l c u la t e d  b y  r e l a t in g  t h e  p e a k  a b s o r b a n c e  r a t io s  f r o m  e a c h  a n a ly s is  a n d  to  t h e  
m e a n  s t a n d a r d  c u r v e  to  g iv e  t h e  m e a n  c o n c e n t r a t io n  c a l c u la t e d  ±  s t a n d a r d  d e v ia t io n  
a n d  t h e  %  r e la t iv e  s t a n d a r d  d e v ia t io n  T h e  r e s u lt s  a r e  g iv e n  a s  t h e  m e a n  
c o n c e n t r a t io n  c a l c u l a t e d  ( \ i g f m l )  ±  s t a n d a r d  d e v ia t io n  a b o u t  t h e  m e a n  T h e  r e s u lt s  
i n  p a r e n t h e s is  a r e  t h e  p e r c e n t a g e  r e la t iv e  s t a n d a r d  d e v ia t io n s  ( % )
3 1 1 4  C l i n i c a l  a n d  p h a r m a c o k in e t ic  s tu d ie s
The method developed (see section 2 3 21 and 2 3 3 1) was applied to unne samples 
obtained from two volunteers who had been administered 100 mg of coumann p o Their 
unne was analysed for free and total 7-hydroxycoumann (see Figure 3 1 1 3 )  Dunng the 
analysis no coumann was observed m the volunteer's unne (this was determined from HPLC 
analysis) Coumann excretion was calculated by determining 7-hydroxycoumann in either of 
the 7-hydroxylated forms (i.e free or glucuromdated) The concentrations of free and total 
7-hydroxycoumann present were calculated from standard curves prepared on the day of 
analysis and the results obtained were related to the urinary volumes excreted The total 
amount of 7-hydroxycoumann excreted in milligrams was related to the amount of coumann 
administered The percentage of administered coumann, excreted as 7-hydroxycoumann 
was calculated from molecular weight ratios (Table 3 1 1 3 )  The results showed that up to 
70 %  of the coumann is excreted in the first two hours and that approximately 90 % is 
excreted within 24 hours These % coumann excreted correlate with the results of Rautio et 
a l (1992) and Egan and O ’Kennedy (1992) (see section 321») In the comparison of the
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results from CE and HPLC analysis of the volunteer’s unne samples there was no statistical 
difference
7-Hydroxycoumann excreted (m g)
Time
(h)
7-OHC excreted 
CE method
Volunteer 1 
(mg)
7-OHC excreted 
HPLC method
Volunteer 1 
(mg)
7-OHC excreted 
CE method
Volunteer 2 
_ (mg)
7-OHC excreted 
HPLC method
Volunteer 2 
(mg)
0 0 0 050 60
2 64 35 71 85 73 50 7590
6 2316 2199 25 62 21 36
10 3 61 3 30 209 220
14 113 093 0 0
24 0 030 0 040
Total 92 85 9837 101 71 10046
% Coumann 
excreted*
83 4% 88 7% 920% 905%
T a b le  3 1 1 3  C o m p a r is o n  o f  H P L C  a n d  C E  a n a ly s is  o f  7 - h y d r o x y c o u m a n n  e x c re te d  
o v e r  2 4  h o u r s y a n d  p e r c e n t a g e  o f  a d m in is t e r e d  c o u m a n n  e x c r e te d  a f te r  2 4  h o u r s  
R e s u lt s  a r e  g iv e n  a s  t h e  to ta l 7 - h y d r o x y c o u m a n n  c o n t e n t  i n  th e  u n n e  a t e a c h  t im e  a n d  
th e  to ta l a f te r  2 4  h  T h e  re s u lt s  w e re  re la te d  to 1 0 0  m g  o f  c o u m a n n  a d m in is t e r e d  a n d  
e x p re s s e d  a s  th e  %  c o u m a n n  a d m in is t e r e d  th a t w a s e x c r e t e d  a s  7 - h y d r o x y c o u m a n n  (f r e e  
o r  c o n ju g a t e d )  V o lu n t e e r  1 a n d  V o lu n t e e r  2  w e re  tre a te d  w ith  1 0 0  m g  o f  c o u m a n n  * %  
C o u m a n n  e x c r e te d  w a s c a lc u la t e d  f r o m  m o le c u la r  w e ig h t  r a t io s  ( 0 9 0 )  u e  ( m o l  wt 
c o u m a n n )  I  ( m o l  w t 7 - O H C )
3 1.2 The direct determination of 7-hydroxycoumarin-glucuromde and
7-hydroxycoumarin in urine by capillary electrophoresis
A method has been developed for the direct determination of 7-hydroxycoumann and 7- 
hydroxycoumann-glucuromde in unne without sample clean-up Separation was earned 
out in 90 % 100 mM phosphate buffer, 11 mM deoxycholic acid (sodium salt) 10 % 
acetomtnle, on a 47 cm uncoated silica capillary, at 20 kV, with detection at 320 nm. 
The linear detection range, for concentration versus peak area, for the assay, was from 0
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to 100 (ag/ml for both analytes with a limit of quantitation of 2 jig/ml for 7- 
hydroxycoumann and 5 |Xg/ml for 7-hydroxycoumann-glucuronide The method was 
applied to the direct determination of 7-hydroxycoumann and the glucuromde conjugate 
in unne from two volunteers administered with 250 mg of coumann The samples were 
analysed by the above CE method (section 2 3 2 2 )  and by high-performance liquid 
chromatography (see section 2 2 2 2 )  There was no statistical difference between the 
results determined by each of the methods Up to 83% of the coumann administered 
was excreted as 7-hydroxycoumann or 7-hydroxycoumann-glucuronide The majonty 
of the 7-hydroxycoumann excreted is in the glucuromde form (98 %) with 2 %  
occumng as free 7-hydroxycoumann
3 1 2 1  D e v e l o p m e n t  o f  th e  C E  s e p a r a t io n
The best electrolyte solution was found to be a phosphate buffer, deoxycholic acid 
(sodium salt), acetomtnle mixture Separation of 7-hydroxycoumann and 7- 
hydroxycoumann-glucuromde prepared in water is shown in Figure 3 12 1 It is shown 
that the 7-hydroxycoumann and the glucuromde are very well resolved with migration 
times of approximately 5 min and 7 mm, respectively Initially, excellent separation was 
achieved in borate buffer at pH 9 0, but the 7-hydroxycoumann-glucuromde was found 
to be unstable at this pH as it decomposed to 7-hydroxycoumann dunng the run time 
No separation was observed in buffers below pH 6 0 Separation of the analytes 
prepared in phosphate buffer was earned out in 25 mM phosphate buffer but when 
assessed in the biological fluids of interest it was found not to be applicable It was not 
possible to get good resolution of the peaks of interest from the endogenous species 
present with the 25 mM phosphate buffer, pH 7 5 Separation was achieved at pH 7 0 
due to the respective charge difference between 7-hydroxycoumann and 7- 
hydroxycoumann-glucuromde The presence of several more -OH groups on the 
glucuromde would cause it to be more negative than the 7-hydroxycoumann which has 
only one -OH group and, thus, enabled separation (see Figure 12 2 1) The acetomtnle 
served, pnmanly, in decreasing the viscosity of the buffer The phosphate 
buffer deoxycholic acid mixture is very viscous and the addition of the acetomtnle
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reduces this viscosity The optimum level of acetomtnle was found to be 10% as lower 
or higher amounts altered peak shape and separation efficiency
Time (mln)
F i g u r e  3 1 2 1  E l e c t r o p h e r o g r a m  o f  t h e  s e p a r a t io n  o f  ( A )  w a te r  ( s o lv e n t  f r o n t )  
( B )  7 - h y d r o x y c o u m a n n  a n d  ( C )  7 - h y d r o x y  c o u m a n n - g l u c u r o m d e  T h e  s a m p le  w a s  
p r e p a r e d  a s  o u t l in e d  u n d e r  s e c t io n  2  3 2 2  S e p a r a t io n  w a s  e a r n e d  o u t  in  9 0  %  1 0 0  
m M  p h o s p h a t e  b u f f e r , 1 1  m M  d e o x y c h o h c  a c i d  ( s o d iu m  s a lt)  1 0  %  a c e t o m t n le , o n  
a  4 7  c m  u n c o a t e d  s i l i c a  c a p i l l a r y , a t 2 0  k V ,  w ith  d e t e c t io n  o f  t h e  a n a ly t e s  a t  3 2 0  n m  
(s e e  s e c t io n 2  3  3 2  )
Acetomtnle is also believed to aid in sample stacking (Shihabi, 1995), and to counteract 
the deletenous effects of high concentrations of inorganic salts, and to remove proteins 
present in the sample The removal of proteins and the unwanted ions also prolongs the 
life of the capillary column
Several micellar systems were tned and it was found that separation was achieved with 
the use of a bile salt (see section 3 0 4 ) , deoxychohc acid (sodium salt) No separation
90
was achieved with the anionic surfactant, sodium dodecyl sulphate Deoxycholic acid is 
also known to complex fatty acids and this may function in a form of on-line sample 
clean-up The relatively high concentration of phosphate buffer was used to improve 
peak shape and separation efficiency
It was not possible to monitor for either analytes at 210 nm, as in the above method (see 
section 3 1 1 )  as endogenous species in unne were found to co-migrate with the 
analytes of interest 7-hydroxycoumann and 7-hydroxycoumann-glucuronide were also 
found to have an absorbance maxima at 320 nm and in order to increase selectivity, with 
some loss in sensitivity, this wavelength was chosen as it was found that the interfering 
species did not absorb at this wavelength Therefore 7-hydroxycoumann and the 
glucuromde form could be selectively isolated, resolved, and quantified in unne (Figure 
3 12 2 )  It was found that serum had a deletenous effect on the performance of the 
capillary, and hence it was not possible to analyse for 7-hydroxycoumann and 7- 
hydroxycoumann-glucuronide in this matrix After trying to analyse one serum sample 
the capillary would block up and it was then impossible to cany out further analysis with 
that particular capillary
The analysis of 7-hydroxycoumann and 7-hydroxycoumann-glucurorude in plasma 
samples was also studied but the protein binding of the metabolites, and coumann, 
interfered with their accurate determination Plasma samples, obtained from the 
volunteers who had been administered the 250 mg of coumann, were analysed Peaks 
were observed but at longer migration times as compared with spiked samples (results 
not shown) It was not possible to definitely assign those peaks to 7-hydroxycoumann 
or the glucuromde However, there was a significant difference observed on CE between 
the 0 h, 1 h and 4 h samples, which was also observed with HPLC analysis Different 
preparation methods of the plasma samples were assessed, with analysis by CE 
employing the same electrolyte buffer However, treatment of the plasma samples 
including protein precipitation, addition of organic buffers, somcation and/or heat did 
not allow the successful determination of the metabolites by CE
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The direct determination of any compound without sample clean-up is a very beneficial 
technique Separations are achieved in less than 7 5 mm and the capillary is regenerated 
in 4 5 min The previous extraction method of Egan and O’Kennedy (1992) involved an 
incubation step with P-glucuromdase as well as an extraction, evaporation step, 
reconstitution and, finally, analysis This process involved much labour and was time 
consuming
Time (min)
F i g u r e  3 1 2  2  A n  o v e r la y  o f  t h e  e le c t r o p h e r o g r a m s ,  o f  t im e  ( m i n )  v e r s u s
a b s o r b a n c e  ( A  U )  a t  3 2 0  n m ,  o f  t h e  0  ju g /m l [ b l u e ]  a n d  1 0 0  ju g /m l [ g r e e n ]  s t a n d a r d s  
p r e p a r e d  in  u n n e  a n d  a n a ly s e d  a s  o u t l in e d  i n  s e c t io n  2  3  2 2  a n d  2  3  3  2  S e p a r a t io n  
w a s  e a r n e d  o u t  in  9 0 %  1 0 0  m M p h o s p h a t e  b u f f e r , 1 1  m M  d e o x y c h o h c  a c i d  ( s o d iu m  
s a lt )  1 0  %  a c e t o m t n le ,  o n  a  4 7  c m  u n c o a t e d  s i l i c a  c a p il la r y ,  a t  2 0  k V ,  w ith  
d e t e c t io n  o f  t h e  a n a ly t e s  a t  3 2 0  n m . T h e  c o m p o n e n t s  a r e  ( A )  s o lv e n t  f r o n t
c o n t a i n in g  a n y  n e u t r a l  c o m p o u n d s ,  ( B )  7 - h y d r o x y c o u m a r in , a n d  ( C )  7- 
h y d r o x y c o u m a r in - g l u c u r o n id e
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No deterioration in capillary performance for the duration of the study was found 
Several hundred unne samples were passed down the capillary, dunng the optimisation 
of the method, and dunng the inter and the intra assay determinations It is possible to 
analyse unne and plasma samples directly on HPLC columns but it is not recommended 
The washing of the capillary, with 0 1 M NaOH, between each run removes any 
residual components from the unne, thus leaving a new homogenous surface each time
The use of capillary electrophoresis appears, from this study, to be very applicable to the 
direct determination of 7-hydroxycoumann and 7-hydroxycoumann-glucuronide in 
unne However, the method does not allow the determination of coumann Coumann 
acts as a neutral compound at this pH and it migrates with the solvent front and with any 
other neutral compounds present
3 1 2  2  L i m i t  o f  q u a n t it a t io n  a n d  l in e a r it y
7-hydroxycoumann and 7-hydroxycoumann-glucuronide, each have two absorbance 
maxima, at 210 nm and 320 nm The maxima at 320 nm has a lower extinction 
coefficient than that at 210 nm The limit of quantitation for 7-hydroxycoumann in 
unne was found to be 2 jig/ml For 7-hydroxycoumann-glucuronide it was found to be 
5 Lig/ml for unne The linear detection range for both analytes was 0-100 (ig/ml The 
mean equation of the line (inter assay) from a plot of the concentration versus the mean 
peak area are (1) 7-hydroxycoumann in unne was Y =4 5  E-3 + 4 97 E-3 X, R2 = 0 99 
and for (2) 7-hydroxycoumann-glucuromde the mean equation in unne was Y = -6 6 E- 
4 + 2  36 E-3 X, R2 = 0 99
3 1 2  3  A c c u r a c y  a n d  p r e c i s i o n
Tables 3 12  1 and 3 12  2 show the mean concentrations calculated from the intra and 
inter assays, for the determination of 7-hydroxycoumann and 7-hydroxycoumann- 
glucuromde in unne, respectively Percentage relative standard deviations were found 
to be between 0 5 % and 13 0 % The values were higher at the limit of quantitation of 
the method The accuracy and precision for the inter-assay was determined over 6 days 
(n=6) and the intra-assay over 5 (n=5) replicates on one specific day
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Concentration
Added
Mean Concentration Calculated 
± Standard Deviation (n=6) 
(% Relative Standard deviation)
Mean Concentration Calculated 
± Standard Deviation (n=5) 
(% Relative Standard deviation)
(Ug/ml) (Ug/ml) Intra-assay (^ g/ml) Inter-assay
0 0 0
2 2 86 ±0 19 (6 8) 195 ±0 25 (13 0)
5 5 56 ±0 21 (3 7) 4 97 ±0 39 (7 9)
10 9 74 ±019 (19) 10 00 ±0 53 (5 3)
20 20 16 ±0 45 (2 2) 20 50 ±0 70 (3 2)
50 52 40 ±4 82 (8 2) 5049 ±2 70(5 3)
80 78 40 ± 3 40 (4 3) 79 75 ±0 36 (0 5)
100 105 25 ±3 30 (3 2) 97 63 ±4 48 (4 5)
T a b l e  3 1 2 1  P r e c i s io n  a n d  a c c u r a c y  o f  t h e  C E  m e t h o d  f o r  th e  d ir e c t
a n a l y s is  o f  7 - h y d r o x y c o u m a n n  i n  u n n e  ( I n t e r  [ n = 5 ]  a n d  in t r a - a s s a y  [ n = 6 ] )  T h e  
r e s u lt s  w e re  c a l c u l a t e d  b y  r e l a t in g  t h e  p e a k  a b s o r b a n c e  r a t io s  f r o m  e a c h  a n a ly s is  a n d  
to  t h e  m e a n  s t a n d a r d  c u r v e  to  g iv e  t h e  m e a n  c o n c e n t r a t io n  c a l c u la t e d  ± s t a n d a r d  
d e v ia t io n  a n d  t h e  %  r e la t iv e  s t a n d a r d  d e v ia t io n  T h e  r e s u lt s  a r e  g iv e n  a s  t h e  m e a n  
c o n c e n t r a t io n  c a l c u l a t e d  ( \ i g f m l )  ±  s t a n d a r d  d e v ia t io n  a b o u t  t h e  m e a n  T h e  r e s u lt s  
i n  p a r e n t h e s is  a r e  t h e  p e r c e n t a g e  r e la t iv e  s t a n d a r d  d e v ia t io n s  ( % )
Concentration Mean Concentration Calculated Mean Concentration Calculated
Added ± Standard Deviation (n=6) 
(% Relative Standard deviation)
± Standard Deviation (n=5) 
(% Relative Standard deviation)
(Ug/ml) (us/ml) Intra-assay (Ug/ml) Inter-assay
0 0 0
5 453 ±021 (46) 4 98 ±0 62 (12 6)
10 8 80 ±0 64(7 3) 9 80 ± 1 00 (10 2)
20 20 60 ±0 56 (2 7) 20 80 ± 1 75 (8 4)
25 27 70 ±0 60 (2 1) 25 30 ±0 96(3 8)
50 49 23 ±3 16(3 2) 52 90 ±2 50 (4 8)
80 77 00 ± 3 23 (4 2) 80 40 ±4 20 (5 2)
100 102 25 ±2 57 (2 5) 100 90 ± 1 70 (1 7)
T a b l e 3  1 2 2  P r e c i s i o n  a n d  a c c u r a c y  o f  t h e  C E  m e t h o d  f o r  t h e  d ir e c t
a n a ly s is  o f  7 - h y d r o x y c o u m a n n - g l u c u r o m d e  i n  u n n e  ( I n t e r  [ n = 5 ]  a n d  in t r a  a s s a y  
[ n = 6 ] )  T h e  r e s u lt s  w e r e  c a l c u la t e d  b y  r e l a t in g  t h e  p e a k  a b s o r b a n c e  r a t io s  f r o m  e a c h  
a n a l y s is  a n d  to  t h e  m e a n  s t a n d a r d  c u r v e  to  g iv e  t h e  m e a n  c o n c e n t r a t io n  c a l c u l a t e d  ± 
s t a n d a r d  d e v ia t io n  a n d  t h e  %  r e la t iv e  s t a n d a r d  d e v ia t io n  T h e  r e s u lt s  a r e  g iv e n  a s  th e  
m e a n  c o n c e n t r a t io n  c a l c u la t e d  (|l g / m l )  ±  s t a n d a r d  d e v ia t io n  a b o u t  t h e  m e a n  T h e  
r e s u lt s  i n  p a r e n t h e s is  a r e  t h e  p e r c e n t a g e  r e la t iv e  s t a n d a r d  d e v ia t io n s  ( % )
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3 1 2  4  C l i n i c a l  a n d  p h a r m a c o k in e t ic  s t u d ie s
Two healthy volunteers were treated with an oral dose of a ‘fast release’ 250 mg 
coumann tablet Unne samples were taken pre-administration and at specific time 
intervals after administration of the drug The samples were analysed for the presence of 
7-hydroxycoumann and 7-hydroxycoumann-glucuromde by the CE method descnbed in 
section 2 3 2 2 and analysed as descnbed in section 2 3 3 2 Coumann content was not 
determined Figure 3 12  3 shows an electropherogram of a volunteers unne sample 10 
hours after coumann administration
Time (min)
F i g u r e  3 1 2  3  A n  e l e c t r o p h e r o g r a m , o f  t im e  ( m i n )  v e r s u s  a b s o r b a n c e  ( A  U  )  
a t  3 2 0  n m , o f  v o lu n t e e r  A ’ s  u n n e  s a m p le  1 0  h  a f t e r  t h e y  h a d  b e e n  a d m in is t e r e d  
c o u m a n n  T h e  u n n e  s a m p l e  w a s  a n a ly s e d  a s  o u t l in e d  i n  s e c t io n  2  3  2 2  a n d  2  3 3 2  
S e p a r a t io n  w a s e a r n e d  o u t  i n  9 0  %  1 0 0  m M  p h o s p h a t e  b u f f e r , 1 1  m M  d e o x y c h o h c  
a c i d  ( s o d iu m  s a lt)  1 0  %  a c e t o m t n l e , o n  a  4 7  c m  u n c o a t e d  s i l i c a  c a p il l a r y , a t  2 0  k V ,  
w ith  d e t e c t io n  o f  t h e  a n a ly t e s  a t  3 2 0  n m  T h e  p e a k s  a r e  ( A )  a n y  n e u t r a l  c o m p o u n d  
a n d  t h e  s o lv e n t  f r o n t ,  a n d  ( C )  7 - h y d r o x y c o u m a n n - g l u c u r o m d e
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Slight differences in peak migration times were due to individual differences between 
samples and standards (i e pH of unne, salts content) Peak identity confirmation was 
determined by spiking a sample of each standard, 7-hydroxycoumann or 7- 
hydoxycoumann-glucuromde, into the unknown sample and observing the peak 
increase No other coumann metabolites were determined The assay developed 
concentrated on the two major metabolites of coumann in man Figure 3 12 4 shows a 
plot o f the levels of 7-hydroxycoumann and 7-hydroxycoumann-glucuromde excreted 
by each of the volunteers
o>3
00 5 0 10 0 
Time
15 0
(h)
20 0 25 0
F i g u r e  3 1 2  4  P l o t  o f  t im e  ( h )  v e r s u s  7 - h y d r o x y c o u m a n n  ( 7 - O H C )  a n d  7-  
h y d r o x y c o u m a n n - g l u c u r o n i d e  ( 7 - O H C G )  c o n c e n t r a t io n s  ( f ig / m l )  f o r  e a c h  o f  t h e  
v o lu n t e e r s  ( v o l )  A  a n d  B ,  d e t e r m in e d  b y  C E  ( m e t h o d  a s  d e s c n b e d  in  s e c t io n  2  3 2  2  
a n d  2  3  3  2 ) ,  a f t e r  t h e  a d m in is t r a t io n  o f  2 5 0  m g  o f  c o u m a r in  V o lu n t e e r  A ' s  7 -  
h y d r o x y c o u m a n n  a n d  7 - h y d r o x y c o u m a n n - g l u c u r o m d e  c o n c e n t r a t io n s  a r e  s h o w n  in  
b l u e  a n d  re d , r e s p e c t iv e ly  V o lu n t e e r  B ’s  7 - h y d r o x y c o u m a n n  a n d  7 -  
h y d r o x y c o u m a r in - g l u c u r o m d e  c o n c e n t r a t io n s  a r e  s h o w n  m  b l a c k  a n d  g r e e n , 
r e s p e c t iv e ly
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The majority of the 7-hydroxycoumarin excreted is in the glucuronide form (98 %) with 
2 % occurring as free 7-hydroxycoumarin in the urine. The urine samples were also 
analysed by another CE method (see section 2.3.3.1.) and by HPLC (see section
2.2.3 .1.). Figure 3 .1.2.5. shows an overlay of the results obtained from each of the three 
methods. The results were compared for the total amount of 7-hydroxycoumarin 
excreted at the specific timed intervals. Total 7-hydroxycoumarin content was directly 
determined or calculated from the addition of free and glucuronidated 7- 
hydroxycoumarin present in the urine samples. The total conjugated 7-hydroxycoumarin 
was determined from the 7-hydroxycoumarin-glucuronide content multiplied by the 
molecular mass ratio between 7-hydroxycoumarin and 7-hydroxycoumarin-glucuronide 
(i.e. 162.1/338 1 x 100/1 =47.9%).
Time (h)
Figure 3.1.2,5. Plot o f time (h) versus total 7-hydroxycoumarin excreted (mg) 
for each o f the volunteers A and B, determined by two CE methods, CE (1) method 
[Volunteer A ’s and B ’s profile is shown as the yellow and black, respectively (see 
section 2.3.3.1.)]; CE (2) method [Volunteer A ’s and B ’s profile is shown as the 
green and red, respectively (see section 2.3.3.2.)]; and by HPLC [Volunteer A ’s and 
B ’s profile is shown as the purple and blue, respectively - see section 2.2.3. l.J.
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This result was then related to the unnary volume to determine the total amount of 7- 
hydroxycoumann excreted 54% of the coumann administered was excreted in the first 
two hours as 7-hydroxycoumann or 7-hydroxycoumann-glucuromde with up to 83 % 
being excreted within 24 hours In the comparison of the results from the three methods 
there were no significant statistical differences (3 0 % )  The CE method allowed the 
direct determination of each of the compounds without the addition of p-glucuromdase 
and with minimal sample preparation Results were obtained in shorter time than either 
the CE method (see section 2 3 3 1 ) or by the HPLC method (see section 2 2 3 1 )
Capillary electrophoresis was applied to the determination of 7-hydroxycoumann and 7- 
hydroxycoumann-glucuronide in biological fluids (1 e unne and serum) Each of the 
two methods developed were found to be both accurate and precise Both methods 
were applied to the determination of the metabolites in unne samples from two 
volunteers who had been treated with coumann The first CE method descnbed was 
based on a deconjugation, extraction procedure with separation on CE Detection was 
earned out at 210 nm The availability of pure 7-hydroxycoumann-glucuromde standard 
allowed for the development of a method for the determination of 7-hydroxycoumann- 
glucuromde after coumann metabolism
In the second method there was minimal sample preparation, and results from analysis 
were obtained within 7 5 minutes for each sample The long preparative steps involved 
in the first method were overcome by the use of the different buffer system and by 
detecting the analytes at 320 nm rather than 210 nm Although there is a loss in 
sensitivity, the benefits of quicker preparation times make the second method a more 
favourable method for the determination of both 7-hydroxycoumann and 7- 
hydroxycoumann-glucuromde simultaneously However, the use of CE with UV 
detection does not allow the determination of very low levels of metabolites
CE is an ideal method for the determination of many of the coumanns especially for 
metabolite analysis The potential for coumann analysis is enormous The next section
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deals with an in  v it r o  procedure for determining the metabolism of coumann and 7- 
hydroxycoumann Thus, CE has been shown to be very effective for determining 
several coumann in  v iv o  metabolites and in section 3 2 it is shown that CE may be used 
for determining Phase I and Phase II coumann metabolism in  v it r o
3 2. CAPILLARY ELECTROPHORESIS AND METABOLISM
STUDIES
3 2 1 The metabolism of coumann (a review)
Coumann and its denvatives are metabolised in a number of ways, which vary with the 
substrate, the species, and the presence of other drugs Coumann has been the basis for 
intense interest in metabolism studies as it is ideal for determining the activity of a drug 
metabolising enzyme called Cytochrome P4502A6 (Pelkonen et a l , 1996) As a 
relatively simple organic structure it is metabolised to a large vanety of products (Figure 
3 2 1 1 )  The clinically observed effects of coumann, the toxicity or lack of either are 
generally attnbuted to coumanns’ metabolites However, there has been some 
suggestions that the highly aromatic nature of coumann may cause some of the observed 
side effects in patient tnals (Marshall e t  a l , 1994-personal communication) Figure 
3 2 11 shows some of the possible metabolic pathways that coumann undergoes after 
administration The possible pathways include hydroxylation in the 3-,4-,5-,6-,7- and 8- 
positions and metabolites formed by the opening of the ring structure The metabolism 
of coumann via 7-hydroxycoumann to the glucuronide metabolite is given in Figure 
12 2 1 The metabolism of coumann via 3-hydroxycoumann to ring opened products is 
also shown
In man, the major Phase I metabolite of coumann is 7-hydroxycoumann and the main 
Phase II metabolism of 7-hydroxycoumann is 7-hydroxycoumann-glucuronide 7- 
hydroxylation of coumann is catalysed by a specific cytochrome P450 In man this is 
Cytochrome P450 2A6 (CYP2A6)
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F i g u r e  3  2 1 1  P o s s ib l e  m e t a b o l ic  p a t h w a y s  o f  c o u m a r in  i n  m a m m a ls  [ T a k e n
f r o m  W a lt e r s  e t a l  ( 1 9 8 0 )  y F e n t e m  e t  a l  ( 1 9 9 1 ) ,  a n d  P e l k o n e n  e t a l  ( 1 9 9 6 ) ]
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The analagous isoform of the enzyme in other species are refered to as CYP2A5 in 
mouse and CYP2A3 in rat In some species, e g rat, 7-hydroxylation is only a minor 
pathway by which coumann is metabolised The rat reportedly metabolises coumann via 
the 3-hydroxycoumann pathway The species difference in coumann hepatotoxicity is 
believed to be due to the metabolic pathway used and the metabolites formed (Fentem 
and Fry, 1993)
The majonty of work in the area of coumann metabolism has focused of coumann 7- 
hydroxylase activity both in  v iv o  and in  v it r o  Table 3 2 11 is a list of the species and 
their respective levels of coumann 7-hydroxylase activity The data in the table relates 
to the in  v it r o  study of coumann metabolism It is clearly seen that there is a great 
difference in coumann 7-hydroxylase activity between species and also within species 
The species with the highest reported coumann 7-hydroxy lation are human and monkey 
The Mongolian gerbil also has a high level of enzyme activity Within man there has 
been a focus on intenndividual vanability The production of the other metabolites will 
not be covered in this chapter The emphasis in the section below is on the in  v it r o  
metabolism of coumann to 7-hydroxycoumann and the in  v it r o  metabolism of 7- 
hydroxycoumann to 7-hydroxycoumann-glucuronide
Table 3 2 12  contains a list of the intenndividual differences in coumann 7- 
hydroxylation in population studies in man It is clearly seen that there is widescale 
vanability in the coumann 7-hydroxylase activities in man The data presented in the 
table is given as a mean ± standard deviation for the patients analysed However, the 
vanation in total 7-hydroxycoumann excretion was from 17 % - 100 % and 20% - 100 
% (Rautio e t  a l , 1992, and Iscan et a l , 1994) The mean, thus, does not give an 
accurate indication of the ranges of 7-hydroxycoumann excretion covered However, 
within the populations there is a similar profile to coumann 7-hydroxylation The mean 
is approximately 69 3% ± 10 6 % from the data in the table The methods of 7- 
hydroxycoumann determination after coumann metabolism are outlined in section 
1 2 1 3 , 1 2 2 1 , and 1 3 1
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Species
Coumann 
7-hydroxylase activity
Coumann 
7-hydroxylase activity 
± Standard Deviation
(nmol/g liver/m in) (pmol/mg protein/min)
Man 14-47 999 ±49 (100-5000)
Mouse DBA/2 cntr 6 2 38 ±13
PB-treated 19 8
Mouse C57BI/6 cntr 09
PB-treated 4 3
Rat (Wistar) < 0 5
Rat (Sprague-Dawley) < 0 5 nd
Guinea Pig 58 95 ±10
Rabbit (New Zealand) 3 1 357 ±36 (480)
Syrian Hamster 320 ±60
Chick Embryo 1200
Cynomolgus Monkey 3470 ±374 (1780)
Calf liver slices 869 ± 133
Crayfish 25 ±4
Pig 315 ±31
Cat 10
Dog 200
Rat control 3 ± 1
Phenobarbitone treated 9 ± 1
P-naphthoflavone treated 7 ± 1
Isomazid 4 ± 2
Pregnenolone 16a-carbonitnle n ± i
Mongolian Gerbil control 682 ± 85
Phenobarbitone treated 1504 ±92
P-naphthoflavone treated 844 ±22
Isomazid 378 ± 10
Pregnenolone
16a-carbomtrile
361 ±8
T a b l e  3  2 1 1  T a b l e  o f  c o u m a n n  7 - h y d r o x y la s e  a c t iv it ie s  i n  l i v e r  m ic r o s o m e s
a n d  l i v e r  h o m o g e n a t e s  [ T h e  d a t a  w a s  c o m p i l e d  f r o m -  K a i p a i n e n  et a l , (1 9 8 5 ),  
F e n t e m  a n d  F r y , ( 1 9 9 1 ) ,  G o e g e r  a n d  A n d e r s o n ,  ( 1 9 9 2 ) ,  P e l k o n e n  et a l , ( 1 9 9 3 ) ,  
(1 9 9 6 ) ,  a n d  L a k e  e t  a l , ( 1 9 9 5 ) ]  R e s u l t s  i n  p a r e n t h e s is  a r e  f r o m  a  d if f e r e n t  s o u r c e  
b u t  f o r  a  s i m i l a r  m i c r o s o m a l  m e t a b o l is m  s t u d y
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Coumann administered Total 7-OHC excreted as 
% of coumarin admin.
Reference
5 mg 59 8 % ± 21 5 % (n=100) Iscan et al 1994
5 mg 64 0 % ± 1 5  0%(n=110) Rautio et al 1992
200 mg 63 4 % ± 16 6 % (n=7) Egan et al, 1990
2 mg 86 0 % ± 3 0 %  (n=64) Cholerton et al, 1992
79 0 ± 4 0 % (n=64)
10 mg 63 7 ± 12 0 % (n=13) Merkel et al, 1994
1 Cholerton etal's results were from the comparison of two analytical methods
T a b l e  3  2 1 2  L i s t  o f  t h e  i n t e n n d m d u a l  d if f e r e n c e s  i n  c o u m a n n  7-
h y d r o x y l a t io n  i n  p o p u l a t io n  s t u d ie s  i n  m a n  T h e  r e s u lt s  a r e  g iv e n  a s  t h e  m e a n  to ta l  
%  o f  c o u m a n n  e x c r e t e d  a s  7 - h y d r o x y c o u m a n n  ±  t h e  s t a n d a r d  d e v ia t io n  a n d  in y is  
t h e  n u m b e r  o f  v o lu n t e e r s  in v o l v e d  i n  t h e  t n a l
The primary metabolic fate of coumann is hydroxylauon at all six of the possible nng 
positions (3-, 4-, 5-, 6-, 7-, and 8- hydroxycoumanns) or by opening of the heterocyclic 
nng Ring opening eventually leads to the production of o-hydroxyphenylpropiomc 
acid, o-hydroxyphenylacetaldehyde, o-hydroxyphenylethanol, and o- 
hydroxyphenylacedc acid (Figure 3 2 1 1 )  The production of some of these 
compounds has been attnbuted to the production of a reactive intermediate, coumann 
3,4-epoxide (Fentem e t  a l , 1991) They reported on the identification of o- 
hydroxyphenylacetaldehyde as a major novel metabolite of coumann formed by rat, 
gerbil and human liver microsomes It was postulated that hepatotoxicity may be due to 
the conjugation of the coumann 3,4-epoxide to glutathione or the covalent binding to 
cellular microsomes Another coumann metabolite is 6,7-dihydroxycoumann
3 2 1 1  T h e  in  v it r o  s t u d y  o f  c o u m a n n  m e t a b o lis m
Reaction (1) is a representation of a typical reaction scheme where the substrate (SH) 
may represent a steroid fatty acid, drug or other chemical that has an alkane, alkene, 
aromatic nng or heterocyclic nng substituent that can serve as a site for oxygenation
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Reactions of interest in the incubation solution
P450
(1) N A D P H  + H +  +  O 2 +  S H .................. > N A D P + + H 20  + S O H
NADPH (nicotinamide adenine dinucleoade phosphate) is needed to donate 2 electrons 
to the heme iron of the cytochrome P450 enzyme In the absence of this co-factor, no 
reaction will occur SOH in the above reaction represents the oxidised product 
Reaction (2) is the cofactor reaction (part of the pentose-phosphate pathway) which 
allows reaction (1) to occur
G-6-P-dehydrogenase
(2) N A D P * +  G lu c o s e - 6 - p h o s p h a t e  ........—> N A D P H  +  6 - p h o s p h o g l u c o n o l a c t o n e
NADP+ is initially converted to NADPH by the use of glucose-6-phosphate- 
dehydrogenase and this reduced form of the cofactor enters the second reaction where 
coumann is hydroxylated to 7-hydroxycoumann The NADP+ produced in this reaction 
can now re-enter the first enzyme reaction and can be recycled in this way Reaction 1 
is a representation of coumann metabolism where SH is coumann (Figure 12) ,  and 
SOH is the hydroxylated form 1 e 7-hydroxycoumann (Figure 1 3 )  These reactions 
were used in the preparation and study of coumann 7-hydroxylase activity in 
microsomes from humans and from vanous species
Sections 3 2 2 1 and 3 2 2 2 following give the results from two studies earned out on 
CE for the determination of 7-hydroxycoumann after coumann metabolism
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3 2.2. Interspecies Differences in Coumarm Metabolism in Liver
Microsomes examined by Capillary Electrophoresis
3  2  2  1 T h e  s t u d y  o f  c o u m a n n  m e t a b o l is m  b y  h u m a n  l i v e r  m ic r o s o m e s
3 2 2 1 1  D e v e l o p m e n t  o f  t h e  C E  s e p a r a t io n
The CE separation method developed for the determination of 7-hydroxycoumann (see 
section 2 3 3 1 ) after the in  v iv o  metabolism of coumann was adapted for the rapid 
analysis of the in  v it r o  metabolism of coumann Liver microsomes were prepared or 
obtained from vanous sources and used m determining coumann 7-hydroxylase 
activities Capillary electrophoresis was shown to be an excellent technique for the 
study of coumann metabolism to 7-hydroxycoumann in  v it r o  The method was applied 
to the determinauon of 7-hydroxycoumann production by human liver microsomes and 
in a follow-up study by microsomes from vanous different species The species studied 
included rabbit (New Zealand white), mouse (CD1, Schofield), rat (wistar), bovine, 
porcine, cynomolgus monkey, gerbil, and dog
Both studies used the same incubation solution and sample preparation (see section 
2 3 2 3 )  However, there was some vanations between the CE methods used for either 
study (see sections 2 3 3 3 and 2 3 3 4 )  The preparation of microsomal solutions from 
a liver sample is descnbed in section 2 41  above The CE method developed allowed 
the investigation of coumann metabolism to 7-hydroxycoumann without sample clean­
up and results were available within 2 mm Coumann is prepared in a minimal volume 
of methanol (0 09 % of total volume), which is known to inhibit cytochrome P450 
activity Separation was achieved in 0 025 M phosphate buffer, pH 7 0 with detection at 
210 nm Figure 3 2 12  shows the separation of the incubation mixture at 0 min and 45 
min after the reaction commenced When analysed on the CE using 25 mM phosphate 
buffer, pH 7 0, both NADP+ and NADPH exhibited very poor peak shapes (results not 
shown) It was not possible to determine peak absorbances or areas due to the poor 
peak shape exhibited However, when NADP+ and NADPH are analysed on the CE 
using 25 mM phosphate buffer, at pH 7 5 (Figure 3 2 1 2 ), it was possible to determine
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peak areas and absorbances (see section 3 2 2 1 3 ) The absorbance of coumann and 7- 
hydroxycoumann could both be monitored with good sensitivity at 210 nm
Time (min)
F i g u r e  3  2 1 2  O v e r la y  o f  e le c t r o p h e r o g r a m s  s h o w in g  s e p a r a t io n  o f  ( A )  a l l
n e u t r a l  c o m p o u n d s  i n c l u d i n g  c o u m a n n , ( B )  7 - h y d r o x y c o u m a r in ,  ( C )  m ic r o s o m e s ,  
( D )  N A D F *  a n d  ( E )  N A D P H  T h e  s a m p le s  w e r e  a n a ly s e d  a t  0  m i n  ( g r e e n )  a n d  a t  
4 5  m in  (r e d )  S e p a r a t io n  w a s  e a r n e d  o u t  in  a  2 7  c m  u n t r e a t e d  s i l i c a  c a p il l a r y , u s i n g  
2 5  m M  p h o s p h a t e  b u f f e r , p H  7 5 , w ith  d e t e c t io n  a t 2 1 0  n m . T h e  s a m p le s  w e r e  
s e p a r a t e d  a s  d e s e n b e d  in  s e c t io n  2  3  2  3  a n d  2  3  3  3
Figure 3 2 13 shows an overlay of the typical electropherograms at 0 min and after 45 
min for the metabolism incubation for the P I8 microsomal preparation The metabolite, 
7-hydroxycoumann, migrates at 0 9 minutes and its increase can be followed However, 
it is not well separated from the broad peak of the microsomal preparations at pH 7 5 
and, thus, it must be monitored at pH 7 0 (Figure 3 2 1 3 ) to resolve the compounds It 
can be seen from Figure 3 2 12 that NADP and NADPH are well separated and 
quantifiable at this pH
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F i g u r e  3  2 1 3  O v e r la y  o f  e le c t r o p h e r o g r a m s  s h o w in g  C E  s e p a r a t io n  o f  ( A )
a l l  n e u t r a l  c o m p o u n d s  i n c l u d i n g  c o u m a n n , ( B )  7 - h y d r o x y c o u m a r in ,  a n d  ( C )  
m ic r o s o m e s  T h e  s a m p le s  w e r e  a n a ly s e d  a t  0  m m  ( b l a c k )  a n d  a t  4 5  m in  (r e d )  
S e p a r a t io n  w a s  c a r r ie d  o u t  i n  a  2 7  c m  u n t r e a t e d  s i l i c a  c a p il la r y ,  u s i n g  2 5  m M  
p h o s p h a t e  b u f f e r ,  p H  7  5, w it h  d e t e c t io n  a t  2 1 0  n m  T h e  s a m p le s  w e r e  s e p a r a t e d  a s  
d e s c r ib e d  m  s e c t io n  2  3  2  3  a n d  2  3  3  3
A neutral marker (benzamide) was run under the separation conditions above (see 
section 2 3 3 1 ), and it was found to co-migrate with coumann, thus suggesting that 
coumann is behaving as a neutral molecule at this pH By knowing the migration time 
of the neutral marker it is possible to say that all the compounds that have longer 
migration times than coumann are negatively charged and hence migrate more slowly 
than coumann 7-hydroxycoumarin is more negatively charged than coumann due to 
the hydroxyl group at the 7-position This hydroxyl group is partially ionised in the 
phosphate buffer at pH 7 0 The microsomes migrate more slowly than the 7- 
hydroxycoumann and are seen as a broad peak due to the different types of proteins m 
the microsomal suspensions NADP+ has a structure with four negative charges and a
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positively charged nitrogen associated with it This suggests an overall charge of 3 
negative charges This high overall negative charge explains the slow migration of 
NADP+ The NADPH molecule has a similar structure to NADP+ but the positive 
charge on the nitrogen is no longer present (Figure 3 2 14)
NADP
o — P—o —
NH
NADPH
\\
NH +2 + H  + R
o  p — 0
IIo
<4 Adenosine
F i g u r e  3  2 1 4  C h e m i c a l  s t r u c t u r e s  o f  N A D P + a n d  N A D P H
As a result, this more negatively charged compound has the slowest migration rate of all 
the compounds Control incubations included an absence of (A) coumann, (B) 
microsomes, and (C) NADPH-regeneration system Coumann was not quantifiable 
under these conditions as other unknown reactions were occurring producing neutral 
compounds which co-migrate with coumann The neutral compound produced was 
dependent on the NADPH reaction as observed with control (A).
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3 2  2 1 2  C o u m a n n  m e t a b o l is m  p r o f i l e s
Microsome preparations from 5 different patients were used in metabolism studies 
(Table 3 2 1 3 )  Table 3 2 1 3  gives some clinical details on the sources of liver 
samples from which the microsomes were prepared Incubations were earned out in 
triplicate
Liver Donor sex Donor age Smoking status
P13 F 64 N/S
P14 F 48 N/S
P17 F 54 S
P18 F 44 N/S
R1 M 54 N/S
T a b l e  3  2 1 3  D e t a i ls  o f  l i v e r  d o n o r s  i n c l u d i n g  t h e i r  a g e , s e x ,  a n d  s m o k in g  s ta tu s
Figure 3 2 15 shows a plot of concentration of 7-hydroxycoumann [(nmol / mg 
protein) ± Std Deviation], versus time for each of the five metabolic studies There was 
no significant difference observed between the coumann 7-hydroxylase activity for the 
smoker as compared to the non-smokers It shows that each of the microsomal 
preparations displays diffenng coumann metabolism profiles Although the standard 
deviations about the mean concentrations calculated are relatively high, this corresponds 
to microsomal drug metabolism results from other researchers (Fuhr et a l , 1990)
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Figure 3.2.1.5. Plot of concentration of 7-hydroxycoumarin produced 
(nmol/mg protein) ±  Standard Deviation (n=3) versus time (min) for the five 
microsome preparations. The profiles are as follows: PI 4-blue, P17-greenf P13-redy 
Rl-purple, P18-cyan. The samples were analysed by CE (see section 2.3.2.3. and 
2.3.3.3.) and the concentrations determined from a plot o f 7-hydroxycoumarin, 
prepared in the incubation solution, versus peak absorbance.
Figure 3.2.1.6. is a comparison of HPLC and CE for the determination of 7- 
hydroxycoumarin formation. It can be seen that there is no significant difference 
between the results obtained by either method for the quantification of 7- 
hydroxycoumarin. The HPLC methods involve stopping the enzyme reactions by 
precipitating out the protein to minimise degradation of the HPLC system.
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F i g u r e  3  2 1 6  A  c o m p a r is o n  o f  H P L C  a n d  C E  f o r  t h e  d e t e r m in a t io n  o f  7 -  
h y d r o x y c o u m a n n  a f t e r  t h e  in  v it r o  m e t a b o lis m  o f  c o u m a n n  in  t h e  p r e s e n c e  o f  
h u m a n  l iv e r  m i c r o s o m a l  p r e p a r a t io n  P l o t  o f  7 - h y d r o x y  c o u m a n n  ( n m o l / m g  p r o t e in )  
±  S t a n d a r d  d e v ia t io n  ( n = 3 )  v e r s u s  t im e  f o r  m ic r o s o m e  p r e p a r a t io n  P I  7  m e t a b o lis m  
s t u d y  b y  H P L C  ( b l a c k )  a n d  C E  ( r e d )
However, it was not necessary to precipitate out the protein in the CE method used as it 
involved injecting the incubation mixture directly onto the capillary The reaction is 
stopped by the separation of the individual components m the capillary After
instantaneous separation they are thus, no longer able to interact further 7-
hydroxycoumarin is separated after 0 9 min (Figure 3 2 1 3 )  using the CE method but it 
takes up to 12 mm using the HPLC method of Egan and O’Kennedy (1992) to analyse
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for 7-hydroxycoumann Up to 500 injections were made onto the CE capillary during 
these studies without any visible degradation of capillary performance
3 2 2  1 3  N A D P + / N A D P H R a t i o  S t u d y
As part of the study we discovered that it was possible to monitor an integral part of the 
monooxygenase reaction 1 e the NADPH-dependent coumann metabolism reaction To 
slow down the production of the NADPH from NADP* (structures of both NADPH and 
NADP+ is given in Figure 3 2 14 , and the migration times after CE separation is shown 
in Figure 3 2 1 2 )  the concentration of the glucose-6-phosphate-dehydrogenase was 
reduced to 0 1 units/ml as compared to 4 units/ml for the study of coumann metabolism 
Figure 3 2 17  shows a plot of NADP+ / NADPH absorbance ratio versus time for the 
incubation mixture and also for incubations in the absence of coumann, or rmcrosomes 
The NADP+ / NADPH ratio was calculated from their respective absorbances at 210 
nm Comparing the controls to the mcubation complete incubation mixture, the NADP+ 
/ NADPH absorbance ratio changes as the cytochrome P450 utilises the NADPH for the 
metabolism of the coumann However, other biological processes in the microsomes 
also utilise the NADPH in the controls Therefore, it was possible to analyse coumann 
metabolism and the cofactor reaction which was shown to be necessary for the 
metabolism of coumann Thus, CE can be used to monitor if drugs are metabolised 
using an NADPH system or not
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Time (minutes)
F i g u r e  3  2 J  7  P l o t  o f  N A D P + / N A D P H  a b s o r b a n c e  r a t io  v e r s u s  t im e ,  f o r  
e a c h  o f  th e  c o n t r o ls  a n d  th e  in c u b a t io n  m ix t u r e  T h e  c o n t r o ls  in c l u d e d  t h e  
i n c u b a t i o n  m ix t u r e  w it h o u t  c o u m a n n  o r  w it h o u t  m ic r o s o m e s  T h e  s a m p le s  w e re  
a n a ly s e d  b y  c a p il l a r y  e l e c t r o p h o r e s is  S e p a r a t io n  w a s  e a r n e d  o u t  o n  a  2 7  c m  
u n t r e a t e d  s i l i c a  c a p il l a r y  u s i n g  2 5  m M  p h o s p h a t e  b u f f e r  ( p H  7  0 )  a n d  d e t e c t io n  at  
2 1 0  n m
3  2  2  2  I n t e r s p e c ie s  d if f e r e n c e s  in  c o u m a n n  m e t a b o lis m  i n  l i v e r  m ic r o s o m e s
3  2  2  2 1  D e v e l o p m e n t  o f  t h e  C E  s e p a r a t io n
The choice of pH and electrolyte concentration was optimised to separate the 
components of the reaction mixture 50 mM phosphate buffer (pH 6 8) was found to be 
optimal, with a working current of 80 [lamps The CE method used for the
determination of coumann 7-hydroxylase activity in the different species was only
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slightly different from that used in the study using human microsomes The ionic 
strength and pH of the buffer as well as the applied voltage were altered
3  2 2  2 2  C o u m a n n  M e t a b o l is m
To assess whether or not the microsomal preparation was still active it was necessary to 
carry out a series of controls Other side reactions occurring during the metabolism of 
coumann to 7-hydroxy coumann produced other species which migrated with coumann 
and the peak at this time was seen to increase over time Coumann acts as a neutral 
species at this pH and is seen to migrate with a neutral marker species, benzamide (see 
section 3 2 3 1 ) This was observed in the presence and absence of coumann and was 
used as an indicator of metabolism It was not possible to initiate any coumann 
metabolism without the presence of the NADPH regeneration system or the 
microsomes The senes of controls prepared included the omission of the NADPH 
regeneration system, the absence of the liver microsomes, and the absence of coumann 
It was not necessary to stop the reaction pnor to the analysis as the application of the 
high voltage separates the individual components of the reaction mixture, thus, 
preventing further reaction
A 10 [ i\  aliquot was removed at the specified time and added into a microvial, from 
which it was analysed by the capillary electrophoresis system The separation observed 
was similar to that shown in Figure 3 2 13 The analysis of such a sample by HPLC 
system would, in time, cause degradation of the injection system, column and fouling of 
the detector No detenoration in capillary performance was observed over the penod of 
the study The regeneration of the surface between every run also aided in maintaining 
the reliability of the method There was some inter-day vanability in the migration times 
for the different components This was however, attributed to the slight vanations in 
prepanng the electrolyte buffer but was always less than ±10%
Coumann 7-hydroxylation activity disappears if the microsomes are not stored correctly 
or mishandled dunng the in  v it r o  assay Table 3 2 13 shows the coumann 7- 
hydroxylase activities (pmol /  mg protein /  min) of the different species ± standard
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deviations (n=3) (This data is also represented graphically in Figure 3 2 1 8 )  The 
activity of the microsomes from the cynomolgus monkey are similar to the human 
microsomal preparations studied The other species, however, are substantially less 
active as compared with the human samples
Species
Coumann 7-hydroxylase Activity1 
± Standard Deviation (n=3)
(pmoi/mg protein/min)
Rabbit 180 0 ±16
Monkey 616 0 ± 8
Bovine 110 + 8
Porcine nq2
Rat nq
Mouse (CD1) nq
Mouse (Sch) nq
Gerbil 152 0 ± 29
Dog
Human microsomal preparation
nq
P13 867 0 ± 107
P14 415 0 ±45
P17 653 0 + 85
P18 905 0 ±54
R1 909 0 ± 84
1 The coumann 7-hydroxylase activity was determined at 45 minutes
2 nq Not quantifiable It was not possible to determine the coumann-7-hydroxylase activity in these liver 
samples as the limit of quantification of 7-hydoxycoumann was 6 2 nmol/ml
T a b l e  3  2  1 3  C o u m a n n  7 - h y d r o x y la s e  a c t iv it y  i n  m i c r o s o m a l  p r e p a r a t io n s
a s  d e t e r m in e d  b y  C E  (s e e  s e c t io n  2  3  2  3  a n d  2 3  3  4  T h e  d a ta  is  g iv e n  a s  th e  
s p e c ie s  w ith  t h e  r e s p e c t iv e  c o u m a n n  7 - h y d r o x y la s e  a c t iv it y  ( p m o l  p r o d u c e d  p e r  m g  o f  
p r o t e in  p e r  m i n ) ± t h e  m e a n  a c t iv it y  ( n = 3 )  T h e  r e s u lt s  w e re  c a l c u la t e d  f r o m  a  p l o t  
o f  7 - h y d r o x y c o u m a n n ,  p r e p a r e d  i n  t h e  in c u b a t io n  m ix t u r e , v e r s u s  p e a k  a b s o r b a n c e
Steensma et a l  (1994) found that coumann 7-hydroxylase activity in cynomolgus 
monkey liver was greater than that observed in their human liver However, they 
studied activity in precision-cut liver slices and not in microsomal preparations 
Pelkonen et a l  (1993) found coumann 7-hydroxylase activity in human, and rabbit liver, 
and very low levels in rat liver However, their activity was based on crude 
homogenates It is not possible to compare the activity, determined by the method
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above and to that determined by other methods, as liver preparations, substrate 
concentrations, incubation mixtures, etc vary from assay to assay in different 
laboratories However, some of the results for activities observed in other studies 
(Table 3 2 1 1 )  for microsomal metabolism studies were similar to the results 
determined by CE
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F i g u r e  3  2 1 8  G r a p h i c a l  r e p r e s e n t a t io n  o f  c o u m a n n - 7 - h y d r o x y l a s e  a c t iv it y  in
m ic r o s o m e s  f r o m  v a r io u s  s p e c ie s  a s  d e t e r m in e d  b y  c a p il l a r y  e le c t r o p h o r e s is  T h e  
d a t a  i s  r e p r e s e n t e d  a s  t h e  s p e c ie s  w ith  it s  m e a n  r e s p e c t iv e  a c t iv it y  ( p m o l l m g  
p r o t e in / m i n )  ±  s t a n d a r d  d e v ia t io n  ( e r r o r  b a r s )
The human microsomal preparations had a variability between 415 0 and 909 0 pmol/ 
mg protein / min as compared to the range observed by Pelkonen e t  a l (1996) of 
between 100 and 5000 pmol/mg protein/min The activity of the microsomes, 
determined by CE, were in this region Lake e t  a l ’ s  (1995) study yielded an activity of 
999 ± 49 pmol /  mg protein / min The results obtained by CE give a clear indication of
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intenndividual variability as do Pelkonen e t a l ’ s  (1996) The other activities determined 
were generally lower than those observed by other groups However, comparison of the 
results from different groups in different laboratories indicated a large variability within 
species in coumann 7-hydroxylation activities e g cynomolgus monkey microsomes had 
activities between 1780 and 3470 pmol/mg protein/min whereas the activity determined 
by our CE method was 616 0 pmol/mg protein/min Thus, it is not possible to determine 
any absolute value for coumann 7-hydroxylation activity in any species but only to 
assess intenndividual and interspecies mean vanations
The observed differences in metabolic rates between species can be due to differences in 
the cytochrome P450 substrate affinity (Kra) or its maximal rate of product formation 
(Vmax) These both depend on the evolution of the particular species The CE method 
developed will allow kinetic analysis of the P450 enzyme activity involved in the 
hydroxylation of coumann, i e to ascertain Km and Vmax values It was not determined if 
the metabolic reaction monitored followed Michaehs-Menten kinetics
It has clearly been shown that different species do not predominantly metabolise 
coumann to 7-hydroxycoumann Therefore, to assess the effect on humans an 
appropnate model for coumann metabolic studies must be chosen and from our study, 
cynomolgus monkey would be an appropnate and relevant model species for studying 
coumann metabolism and toxicity
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3 2 3. Glucuronidation (a short review)
The undine diphosphate (UDP) glucuronyl transferases (also called 
glucuronosyltransferases) (UDPGT’s) are a collection of enzymes that are membrane- 
bound and responsible for the ‘glucuronidation’ of millions of biological compounds and 
drugs The UDPGT’s act by transfemng the glucuronic acid moiety of UDP-glucuromc 
acid to compounds that have functional groups containing oxygen, nitrogen, sulphur and 
carbon (Figure 3 2 3 1 ) Figure 3 2 3 1 shows a schematic representation of the 
biological reaction to form a glucuronide conjugate of many compounds, endogenous 
and exogenous By the action of the glucuronyl transferase a hydrogen ion is displaced, 
from the substrate, and replaced with the glucuronic acid moiety forming the (3-D- 
glucuronide conjugate A molecule of UDP is also formed Kaspersen and van Boeckel 
(1987) give a review on the chemical synthesis of glucuronide conjugates
UDPGA UDP
COOH
U D P
beta-D-glucuromde
F i g u r e  3  2  3 1  G l u c u r o n i d a t i o n  o f  a  s u b s t r a t e  ( H - S )  b y  u n d i n e  d ip h o s p h a t e
( U D P )  g l u c u r o n y l  t r a n s f e r a s e s  ( *  = t h e  a n o m e n c  c a r b o n  a t o m , U D P G A  = U D P -  
g l u c u r o n i c  a c id )  T h e  s u b s t r a t e  a d d s  i n  to  t h e  g l u c u r o n i c  a c i d  a t  th e  * * \  d is p la c in g  
a  lH y w h ic h  r e a c t s  f o r m i n g  U D P  a n d  t h e  g l u c u r o n i d e  c o n ju g a t e  ( R e a c t io n  s c h e m e  
t a k e n  f r o m  K r o e m e r  a n d  K lo t z ,  1 9 9 2 )
Elimination is facilitated by increasing the polanty of molecules, in essence making them 
less active and more readily soluble in bile and unne ‘Detoxification’ is generally 
accepted as occumng in two steps - step 1 is reacting the molecule to give it a
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functional side group i e an -OH, -NH2, or -COOH, that can react further - step 2 is 
conjugation to a highly polar molecule such as glucuromde, sulphate, or acetate 
Detoxification is the general acceptance of the function of glucuromdation and as a 
product of this it facilitates elimination In general, glucuronides have high water 
solubility, low protein binding and small volumes of distribution, and, thus, are rapidly 
eliminated from the body in the unne They are thus, disregarded by many in 
pharmacokinetic and pharmacodynamic studies and are assumed to be inactive 
pharmacologically However, this may be applicable to a large array of drug- 
glucuronides, but there are some notable exceptions There is now more interest in the 
glucuromde conjugates of many xenobiotics (Dutton, 1980, Kroemer and Klotz, 1992, 
Olson e t  a l , 1992, Kauffman, 1994) in clinical observed effects and in therapy (see 
below)
The effect of some drugs is determined direcdy by its glucuromde form Indirect effects 
may also be due to glucuronides (eg  at a particular site the parent drug may be released 
from its glucuromde form and allowed to have some effect - this is usually assisted by 
enzymatic cleavage by (J-glucuromdase or covalent protein binding)
The best documented glucuromde with direct clinical effects are those of morphine 
(Kroemer and Klotz, 1992) N - 0 -glucuronides of iV-hydroxypentacetin, estnol-17-P-((J- 
D-glucuromde), estnol- 16-a-(P-D-glucuromde) and testosterone- 17-f3-(P-D- 
glucuromde) have all been shown to have a direct clinical effect (Kroemer and Klotz, 
1992) Indirect effects may also be attributed to glucuronides One way that the 
glucuromde may play a clinical role is in a systemic cycle where the parent drug and 
glucuromde conjugate may continuously conjugate and deconjugate This may occur at 
various locations in a particular environment (Figure 3 2 3 2 )
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Renai
Dysfunction
Urine/Excretion
F i g u r e  3  2  3  2  T h e  p r o p o s e d  s y s t e m ic  c y c l in g  s h o w in g  t h e  r e a c t iv it y  o f  
g l u c u r o n id e s  T h e  p a r e n t  c o m p o u n d  is  r e c r u it e d  f r o m  t h e  g l u c u r o n id e  b y  e n z y m a t ic  
c le a v a g e  E x c r e t i o n  o f  t h e  g l u c u r o n i d e  m a y  b e  h a m p e r e d  b y  k id n e y  d y s f u n c t io n  t h u s  
a l l o w i n g  it  to  r e m a in  i n  c i r c u l a t i o n  C a s l e y - S m it h  a n d  C a s le y - S m it h  (1 9 8 6 ),  
s u g g e s t e d  t h a t  d u e  to  t h e  a c t iv e  t r a n s p o r t  s h o w n  to e x is t  f o r  g l u c u r o n id e s ,  t h a t  it  is  
p o s s i b l e  t h a t  7 - h y d r o x y  c o u m a n n - g l u c u r o n i d e  is  t r a n s p o r t e d  in t o  t h e  c e l l s  
G l u c u r o n i d a s e s  p r e s e n t  in  t h e  c e l l  r e c o n v e r t  t h e  g l u c u r o n id e  to t h e  7 -  
h y d r o x y c o u m a n n  A f t e r  it  h a s  e x e r t e d  its  p h a r m a c o l o g i c a l  a c t io n ,  it  m ig h t  t h e n  b e  
r e g l u c u r o m d a t e d  b e f o r e  e x c r e t io n  ( T h e  f i g u r e  is  t a k e n  f r o m  K r o e m e r  a n d  K lo t z ,  
1 9 9 2 )
Intramolecular rearrangement of glucuronides may lead to glucuronide resistance It is 
known that ether glucuronides are very stable, however, ester glucuronides undergo 
structural rearrangement to form (3-glucuronidase resistant forms Another indirect 
effect may involve the covalent binding of the glucuronides to proteins or the removal of 
the glucuronic acid moiety at a site on a protein This effect was observed for 
zomepirac and oxaprozm Zomepirac is an anti-inflammatory drug with analgesic effects 
(Langendijk e t a l , 1984) Zomepirac-glucuronide is its major metabolite in man In the 
case of zomepirac it was believed that the zomepirac-glucuronide after undergoing 
isomensation allows nng-opemng The aldehyde moiety formed, forms an lmine linkage 
with a lysine or terminal ammo group of a protein which can undergo further 
rearrangement After the death of several people, who were being treated with
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zomepirac, it was withdrawn The effect was attributed to this protein binding 
Langendijk e t  a l  (1984) reported that they had observed an isomenc conjugate of 
zomepirac-glucuromde in the urine of patients and attributed it to acyl migration These 
direct and indirect effects observed may have an important role with respect to drug 
toxicity and immune response and also to the inaccuracies in glucuronide concentration 
determinations if p-glucuronidase hydrolysis is used in the analysis of the compound 
Several other examples are presented by Dutton (1980) and Kroemer and Klotz (1992)
The principle site of glucuromdation in vertebrates is the liver In liver cells it occurs in 
the endoplasmic reticulum and to a lesser extent in the cytoplasm, the mitochondria and 
the nuclear envelope (Dutton, 1980) The plasma membrane showed negligible UDPGT 
activity Mechanical disruption, the addition of surfactants, temperature effects, storage, 
solvents, chelating agents, trypsin, phospholipids, metal ions, and ATP/AMP are some 
of the different species investigated for studying the activation and inhibition of UDPGT 
(Dutton, 1980) The liver is not the only site of glucuromdation Table 3 2 3 1 show 
the activity of UDPGT’s in various extrahepatic tissue for the substrate 4- 
methylumbelliferone
Tissue UDPGT Activity UDPGT Activity
(nmol substrate glucuronidated / 
gram  wet weight)
(nmol substrate glucuronidated / 
gram  whole organ)
Liver 460 0 3200 0
Duodenal mucosa 260 0 96 0
Kidneys 150 0 120 0
Adrenal glands 170 0 63 0
Spleen 3 0 0 35 0
Lungs 28 0 34 0
Thymus 19 0 8 8
Heart 14 1 1
Brain 0 8 13
T a b le  3 2  3 1  U n d i n e  d ip h o s p h a t e  g l u c u r o n y l  t r a n s f e r a s e  ( U D P G T )  a c t iv it ie s
m  r a t  t is s u e  f o r  4 - m e t h y l u m b e l h f e r o n e  T h e  d a ta  is  p r e s e n t e d  a s  t h e  U D P G T  a c t iv it y  
in  n m o l  o f  4 - m e t h y l u m b e l h f e r o n e  g l u c u r o n id a t e d  p e r  g r a m  w e t w e ig h t  a n d  p e r  g r a m  
o f  t h e  w h o le  o r g a n  ( T a b l e  t a k e n  f r o m  D u t t o n , 1 9 8 0 )
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The liver was the principle sue for glucuromdation for 4-methylumbelliferone 
However, activity was UDPGT activity for the glucuromdation of 4- 
methylumbelliferone was observed in all other tissue types Activity was lowest in the 
heart and in the brain Duffy et a l , (1996) reported on the in  v it r o  glucuromdation of 7- 
hydroxycoumann in rabbit tissue sample homogenates Table 3 2 3 2 are the
concentrations (pmol) of 7-hydroxycoumann- glucuronide produced per minute per 
milligram of protein in the homogenates
Tissue UDPGT activity
(pmol 7-hydroxycoumann-glucuromde produced 
per min per milligram of protein)
Liver 2300
Kidney 220
Bladder 140
Large intestine 78
Lung 0
Spleen 0
Fat 0
Heart 0
T a b l e  3 2  3  2  U n d i n e  d ip h o s p h a t e  g l u c u r o n y l  t r a n s f e r a s e  ( U D P G T )  a c t iv it y
i n  r a b b it  t is s u e  h o m o g e n a t e s  a s  d e t e r m in e d  b y  H P L C  T h e  d a ta  is  p r e s e n t e d  a s  th e  
t is s u e  s o u r c e  a n d  t h e  a c t iv it y  i n  p m o l  o f  7 - h y d r o x y c o u m a n n - g l u c u r o m d e  p r o d u c e d  
p e r  m in u t e  p e r  m i l l i g r a m  o f  p r o t e in  ( T a b l e  t a k e n  f r o m  D u f f y  e t  a l , 1 9 9 6 )
A full length cDNA clone for a human hepatic UDPGT was isolated from a human liver 
cDNA library and stably expressed in human embryonic kidney 293 [HK293] cells 
(Green e t a l , 1994) The UDPGT activity for over 100 compounds was tested in the 
presence of the cells with the UDPGT expressing protein Glucuronyl transferase 
activity was observed toward several classes of xenobiotics, including simple phenolic 
compounds, 7-hydroxylated coumanns, flavanoids, anthraquinones and for some 
estrogens and androgens
Table 3 2 3 3 is a list of the coumanns with the respective enzyme activities of the 
transfected HK293 cells The structures of each of the denvatives are also given
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Activities were determined by assaying for undine diphospho-[U-14C]-glucuronic acid 
The reaction solution was treated with ethanol to cause protein precipitation After 
centnfugation the residue was dissolved into water and analysed by thin layer 
chromatography on 0 5 mm silica gel 60 T254 plates
R
2
Coumann denvative Ri Rz R3 Enzyme activity 
pmol/min/mg protein
4-hydroxycoumann H H OH nd
Umbelhferone H OH H 72
4-methylumbelliferone H OH c h 3 170
Esculeun OH OH H 110
Scopoletin OCH3 OH H 170
T a b l e  3  2  3  3  G l u c u r o m d a t io n  o f  c o u m a n n  d e r iv a t iv e s  b y  t r a n s f e c t e d  H K 2 9 3  c e lls  
s t a b ly  e x p r e s s in g  U G T 2 B 1 5  T h e  s u b s t r a t e  c o n c e n t r a t io n s  w e re  U D P - g l u c u r o n i c  
a c i d  0  5  m M y  a n d  c o u m a n n  d e n v a t iv e  0 1  m M  n d  - in d ic a t e s  th a t  n o  
g l u c u r o m d a t i o n  w a s d e t e c t e d  ( T a b l e  t a k e n  f r o m  G r e e n  e t  a l , 1 9 9 4 )
Conway et a l , 1984, investigated the rates of glucuromdation in penportal and 
pencentral regions of the liver lobule using micro-light guides placed on the regions of 
the liver surface The fluorescence of free 7-hydroxycoumann was determined and 
related to the glucuromdation rate by determining the decrease in fluorescence over time 
under vanous conditions The maximal rates of glucuromdation in penportal and 
pencentral regions of the liver lobule were 9 6 and 3 5 |imol/g/hr, respectively The 
details of the analysis is covered in section 13 12
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High performance liquid chromatography (Langendijk et a l , 1984, Musson et a l , 1985, 
Lehr e t a l , 1987, Goresky and Gordon, 1990, and Vree and Kolmer, 1992), and 
enzyme-lmked immunosorbent assay (Mitsuma e t a l , 1989, Lewis e t a l , 1990, Sailstad 
and Findlay, 1991, and Stabenfeldt e t  a l , 1991) are the general methods used for the 
determination of glucuromdes in unne and plasma samples The methods referenced 
above are for a range of different drug-glucuromdes including - penbutolol, oestrogen, 
bilirubin, zomepirac, diflunisal, probenecid, lamotngine, and pregnanediol Knight and 
Skellem, (1980), and To and Wells, (1984), both used HPLC for the determination of 
UDPGT activities Capillary electrophoresis has also been used for the determinauon of 
glucuromdes m unne (Wemly et a l , 1993)
Section 3 2 3 1 following descnbes the use of capillary electrophoresis for determining 
the glucuromdation of 7-hydroxycoumann A crude liver homogenate was prepared and 
the glucuronyl transferase activity was determined by quantitating the production of 7- 
hydroxycoumann-glucuromde in the reaction solution
3  2  3 1  G l u c u r o m d a t io n  o f  7 - h y d r o x y c o u m a n n  i n  v it r o
In man the majonty of coumann administered is excreted as 7-hydroxycoumann- 
glucuromde (Rautio e t  a l , 1992, Egan and O’Kennedy, 1993) The CE method utilised 
(see section 2 3 1 1 )  for the determination of 7-hydroxycoumann and 7- 
hydroxycoumann-glucuromde in unne was applied to the determination of 7- 
hydroxycoumann-glucuronide in an in  v it r o  metabolic assay
Separation of 7-hydroxycoumann-glucuronide from endogenous species present in the 
metabolic matnx and from 7-hydroxycoumann, is achieved in less than 7 minutes 
(Figure 3 2 3 1 1 )  A t l  min no appreciable 7-hydroxycoumann-glucuromde was 
observed, but after 12 min the UDPGT had already started to produce 7- 
hydroxycoumann-glucuromde At 47 and 82 min there was a visible increase in the 7- 
hydroxycoumann-glucuromde (peak C) content in the matnx The reaction proceeded 
in a linear manner for the first 70 mm The mean rate of reaction (Figure 3 2 3 1 2 and 
Table 3 2 3 1 1 ) for the first 70 min was found to be 3 09 ± 0 13 nmol of glucuromde
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produced per minute per mg of protein (n=4) After 70 min the enzyme efficiency slows 
down and after 180 min (results not shown) no more 7 - hydroxy coumann-gl ucuromde is 
formed The reaction rate was slowed due to substrate limitation, enzymatic 
deactivation, or P-glucuronidase deconjugation in the reaction solution or a combination 
of these factors
<
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Time (min)
F i g u r e  3  2  3 1 1  C E  e le c t r o p h e r o g r a m  o f  m e t a b o l ic  s o l u t io n  a s  o u t l in e d  i n  
s e c t io n  2  3  2  4  a n d  2  3  3  5  S e p a r a t io n  w a s c a r r i e d  o u t  i n  9 0  %  1 0 0  m M  p h o s p h a t e  
b u f f e r , 1 1  m M  d e o x y c h o h c  a c i d  ( s o d iu m  s a lt )  1 0  %  a c e t o m t n l e , o n  a  4 7  c m  
u n c o a t e d  s i l i c a  c a p il l a r y ,  a t  2 0  k V ,  w ith  d e t e c t io n  o f  t h e  a n a ly t e s  a t 3 2 0  n m  I t  
s h o w s  a n  o v e r la y  o f  e le c t r o p h e r o g r a m s  o f  s a m p le s  t a k e n  a t  1  m in ,  1 2  m i n , 4 7  m in  
a n d  8 2  m in ,  r e s p e c t iv e ly  T h e  p e a k s  a r e  ( A )  s o lv e n t  f r o n t  c o n t a in in g  a l l  n e u t r a l  
c o m p o n e n t s ,  ( B )  M a g n e s iu m  c h l o r id e  a n d  7 - h y d r o x y c o u m a n n  ( s h o u l d e r )  a n d  ( C )  7- 
h y d r o x y c o u m a n n - g l u c u r o m d e  E l e c t r o p h e r o g r a m s  f o r  1 2  m in ,  4 7  m in  a n d  8 2  m m  
a r e  s h o w n  i n  o f f s e t  to  i l lu s t r a t e  t h e  in c r e a s e  i n  p e a k  a r e a  a n d  a r e  d is p la y e d  b e t w e e n  
5  5  m in  a n d  7  5  m i n  o n l y  T h e  r e m a in d e r  o f  t h e  e l e c t r o p h e r o g r a m  w a s t y p ic a l  o f  th e  
1  m i n  p r o f i l e
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In the absence of enzyme, 7-hydroxycoumann or UDPGA no 7-hydroxycoumann- 
glucuronide was produced It was possible to monitor the breakdown of the 
glucuromde conjugate over time to 7-hydroxycoumann, when the undenatured protein 
solution was used as the matnx for the standards The limit of detection for 7- 
hydroxycoumann-glucuromde was 2 [lg/ml with a linear range of 0 - 100 Jig/ml 
Percentage relative standard deviations for each standard peak area were all below 10%
Time
7-hydroxycoumarm- 
glucuronide 
Concentration 
± Standard Deviation (n=4)
% Relative Standard 
Deviation
(min) OiM)
1 0 0
12 35 1 ± 4  3 12 3
23 72 8 ± 4  6 63
35 112 3 ± 6 0 53
47 1409 ±11 5 82
58 1894 ± 4  2 22
70 207 6 ± 2 0 10
82 222 1 ± 7 9 36
T a b l e  3  2  3 1 1  R e s u l t s  f o r  t h e  7 - h y d r o x y c o u m a n n - g l u c u r o m d e  c o n c e n t r a t io n  
f r o m  t h e  s t u d y  in t o  t h e  i n  v it r o  p r o d u c t io n  o f  7 - h y d r o x y c o u m a n n - g l u c u r o m d e  f r o m  
7 - h y d r o x y c o u m a n n  T h e  r e s u lt s  a r e  g iv e n  a s  t h e  t im e  a t  s a m p l i n g  a n d  th e  r e s p e c t iv e  
7 - h y d r o x y  c o u m a n n - g l u c u r o m d e  c o n c e n t r a t io n  ± s t a n d a r d  d e v ia t io n  ( n = 4 )  
d e t e r m in e d  b y  C E ,  a n d  t h e  %  r e la t iv e  s t a n d a r d  d e v ia t io n
The CE method developed was found to be very fast and reliable for the direct 
determination of 7-hydroxycoumann-glucuromde as the in  v it r o  metabolite of 7- 
hydroxycoumann and UDPGA by the enzymatic action of UDPGT The method was 
reproducible with excellent precision and accuracy No sample-clean up was necessary 
and injection of the neat mixture onto the capillary allows results to be obtained virtually 
in ‘real-time’ without any interference from errors due to sample preparation (extraction 
steps, precipitation steps e tc ) The method would be ideal for the investigation of 
UDPGT inhibitors or activators and for the assessment of glucuromdation in other tissue
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types besides the liver Thus, CE has been demonstrated to be applicable to the in  v it r o  
and in  v i v o  determination of both Phase I and Phase II metabolic studies of coumann
Time (min)
F i g u r e 3 2  3 1 2  A  p l o t  o f  T i m e  ( m i n )  v e r s u s  m e a n  7 - h y d r o x y  c o u m a n n -  
g l u c u r o m d e  c o n c e n t r a t io n  ( n = 4 )  ( [ im o l / m g  p r o t e in )  f r o m  in c u b a t io n  a s s a y  s t u d y  ± 
s t a n d a r d  d e v ia t io n  ( e r r o r  b a r s )  T h e  e q u a t io n  o f  th e  l i n e  is  y  = -3 2 E - 4  + 3  I E - 3  x  
w ith  a n  r 2 = 0  9 9  T h e  s a m p le s  w e re  a n a ly s e d  b y  C E  a s  d e s c n b e d  i n  s e c t io n  2  3 2  4  
a n d  2  3  3  5  T h e  c o n c e n t r a t io n s  w e re  c a l c u la t e d  f r o m  a  p l o t  o f  7 - h y d r o x y  c o u m a n n  -  
g l u c u r o m d e  c o n c e n t r a t io n , p r e p a r e d  i n  d e n a t u r e d  e n z y m e  s o lu t io n ,  v e r s u s  p e a k  
a b s o r b a n c e
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Summary
Capillary Electrophoresis was shown to be an excellent tool for the determination of 7- 
hydroxycoumann and 7-hydroxycoumann-glucurorude in urine and serum, either by 
direct injection or after extraction, evaporation and reconstitution CE was also shown 
to be very applicable for studying the in  v it r o  metabolism of coumann and 7- 
hydroxycoumann Each of the methods developed were compared to HPLC and some 
unne samples were also analysed by ELISA (see section 5 4 1 )  There was no 
statistical difference between the results as determined by CE and any of the other 
methods to which it was compared
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HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY 
AND THE ANALYSIS OF COUMARINS
CHAPTER 4
4 0 AN INTRODUCTION TO HIGH-PERFORMANCE 
LIQUID CHROMATOGRAPHY (HPLC)
4 0.1. Normal-phase HPLC 
4 0 2  Partition-chromatography
4.0 3. Gel-permeation chromatography 
4 0.4 Reverse-phase HPLC 
4 0.5 Instrumentation
4.1 THE SIMULTANEOUS DETERMINATION OF COUMARIN, 7- 
HYDROXYCOUMARIN, AND 7-HYDROXYCOUMARIN-GLUCURONIDE IN 
HUMAN PLASMA, SERUM AND URINE BY HIGH-PERFORMANCE LIQUID 
CHROMATOGRAPHY (HPLC)
4 1.1 Development of the HPLC separation 
4 1.2 Limit of detection, linearity, precision and accuracy 
4 13  Clinical and pharmacokinetic studies
4 1 3 1  S t u d y  1  A n a l y s is  o f  p l a s m a  s a m p le s  f r o m  v o lu n t e e r s
w h o  h a d  b e e n  t re a t e d  w it h  2 5 0  m g  o f  c o u m a r t n
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h a d  b e e n  t r e a t e d  w it h  2 5 0  m g  o f  c o u m a n n  
4 1 3  3  S t u d y  2  A n a l y s is  o f  s e r u m  s a m p le s  f r o m  v o lu n t e e r s
w h o  h a d  b e e n  t r e a t e d  w ith  7 - h y d r o x y c o u m a n n  
4 2 ANALYSIS OF THE GLUCURONIDATION OF
7-HYDROXYCOUMARIN BY HIGH-PERFORMANCE LIQUID 
CHROMATOGRAPHY (HPLC)
4 2.1 HPLC separation parameters 
4 2.2 Glucuromdation of 7-hydroxycoumarin by UDPGT
4.3. A STUDY INTO THE METABOLISM OF 7-HYDROXYCOUMARIN IN 
PATIENTS WITH ADVANCED MALIGNANCIES
4.3 1. Objectives of the study
4 3.2 Phase I trial of 7-hydroxycoumarin
4.3 3. Patient selection criteria
4 3.4 The determination of total 7-hydroxycoumarin in serum 
samples
4 3  4 1  T o t a l  7 - h y d r o x y c o u m a n n  c o n c e n t r a t io n s
4 3  4 2  T h e  a n a l y s is  o f  t h e  d a ta
Summary
4 1 3  2 Study 1 Analysis o f urine samples from volunteers who
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4.0 AN INTRODUCTION TO HIGH-PERFORMANCE LIQUID
CHROMATOGRAPHY (HPLC)
4 0 1  Normal-phase HPLC
Normal-phase chromatography, also known as adsorption chromatography, allows the 
separation of components based on differences both in their degree of adsorption by the 
adsorbent and solubility in the solvent used for separation The molecular structure of 
the compound to be separated governs these features The eluents in normal-phase 
chromatography are usually relatively non-polar organic solvents e g hexane There is 
usually a polar stationary phase Thus, the analytes are eluted off the HPLC system in 
order of increasing polanty, while retention decreases with increasing solvent polanty 
Compounds that are highly soluble in organic solvents, such as lipids and fat-soluble 
vitamins, are usually separated by normal-phase HPLC
4 0.2 Partition-chromatography
Partmon-chromatography is used for the separation of a very wide range of biological 
compounds It is based on the partition of the solute between the liquid stationary phase
and the mobile phase In normal phase partition-chromatography, the stationary phase is
water supported by a matrix In reverse-phase partition chromatography, the stationary 
phase is a non-polar compound such as liquid paraffin supported by a matnx similar to 
those employed in normal phase systems (i e cellulose, starch or silicic acid)
4 0 3. Gel-permeation chromatography
Gel-permeation chromatography or size-exclusion chromatography, separates 
compounds on the basis of their molecular size Large molecules, outside the molecular 
weight ‘cut-off’ range of the gel, are excluded from the gel, as they cannot enter the 
pores of the stationary phase Elution occurs in order of decreasing size, the smallest 
molecules being eluted last
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4 0 4 Reverse-phase HPLC
Reverse-phase chromatography is the opposite to normal-phase chromatography Thus, 
the mobile phase is more polar than the stationary phase The solute is retained mainly 
as a result of hydrophobic interactions between the solutes and the hydrophobic 
stationary phase surface Solutes are normally eluted in order of decreasing polanty 
(increasing hydrophobicity) and increasing the content of the non-polar component in 
the mobile phase, results in the decrease of the retention of the solutes Various 
additives can be incorporated into the mobile phase to give special selectivities to the 
separation Hence, reverse-phase chromatography may be extended to include ion- 
pairing, ionisation and lon-suppression forms of HPLC The typical stationary phase in 
reverse-phase HPLC is a silica surface with 18 carbon hydrophobic chains chemical 
coupled to it and mobile phases are typically based on methanol, water, acetomtnle, or 
tetrahydrofuran
4 0.5. Instrumentation
The basic equipment required for HPLC separation is a pump, sample introduction 
system, column, detector, waste collector and data analyst (computer or integrator) 
Figure 4 0 1 is a schematic representation of the system used for the development of the 
methods described in section 4 1 and 4 2 The separation and determination of 
coumann and some of its derivatives by HPLC was described in section 12 2
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F i g u r e  4 0 1  S c h e m a t ic  r e p r e s e n t a t io n  o f  H P L C  s y s t e m  T h e  s y s te m  c o n s is t e d  o f  a  
d u a l  p u m p f s o lv e n t  d e l iv e r y  s y s te m  a n d  s o lv e n t  m i x e r  [ m o d u l e  1 2 6 ],  a n  a u t o s a m p le r  
in je c t io n  s y s te m  [ m o d u l e  5 0 7 ] ,  a  r e v e r s e - p h a s e  s i l i c a  b a s e d  C 1 8  c o l u m n ,  a  U V  
d e t e c t o r  [ m o d u l e  1 6 6 ] ,  a  s o lv e n t  w a ste  b o tt le  a n d  d a t a  p r o c e s s i n g  u n it  ( c o m p u t e r - 
D e l l  D im e n s i o n  4 8 6 )  T h e  s y s te m  w a s  c o n t r o l l e d  b y  S y s t e m  G o l d ? 14 s o f t w a re  ( v e r s io n  
8 0)
The sections following are the applications of HPLC for the determination of coumann 
and some of its metabolites in a variety of matrices A HPLC method was developed 
and utilised for the direct determination of 7-hydroxycoumann, coumann, and 7- 
hydroxycoumann-glucuromde in human plasma, serum and unne The method was also 
used for the determination of the in  v it r o  production of 7-hydroxycoumann-glucuromde, 
by undine diphosphate glucuronyl transferase (UDPGT) in liver homogenate The 
method of Egan and O ’Kennedy (1992) was utilised in the study of the metabolism of 7- 
hydroxycoumann in patients with advanced malignancies
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4.1. THE SIMULTANEOUS DETERMINATION OF COUMARIN, 7-
HYDROXYCOUMARIN, AND 7-HYDROXYCOUMARIN-GLUCURONIDE IN 
HUMAN PLASMA, SERUM AND URINE BY HIGH-PERFORMANCE LIQUID 
CHROM ATOGRAPHY (HPLC)
A HPLC method was developed for the determination of the in  v iv o  metabolites of 
coumarin and 7-hydroxycoumarin, i.e. coumarin, 7-hydroxycoumarin and 7- 
hydroxycoumarin-glucuronide, in urine, plasma and serum (see section 2 . 2 3 . 2 . ) .  The 
HPLC method was applied to the determination of coumarin, 7-hydroxycoumarin and 7- 
hydroxycoumarin-glucuronide in volunteers who had been treated orally with coumarin 
(urine and plasma samples) or 7-hydroxycoumarin (serum samples).
4.1.1. Development of the HPLC separation
The separation of coumarin, 7-hydroxycoumarin, 7-hydroxycoumarin-glucuronide and 
the internal standard, 4-hydroxycoumarin (see Choice of internal standard in this section 
below) was optimised to give baseline resolution (Figure 4.1.1.) of the four compounds. 
This HPLC separation method (see section 2.2.3.2.) was found to be applicable to the 
analysis of each of the compounds in urine, plasma and serum. The method was initially 
developed with the standards spiked into water. Standards of coumarin, 7- 
hydroxycoumarin, 7-hydroxycoumarin-glucuronide and 4-hydroxycoumarin were then 
spiked into each of the relevant biological fluids and the method was adjusted until the 
analytes were successfully resolved from any endogenous species present in the matrix 
of interest. However, interference from endogenous species present in urine, did not 
allow complete baseline separation of the analytes of interest from the interfering 
species.
The solvents used for the separation were selected because they had been successfully 
used previously by Egan and O’Kennedy (1992). However, when 7-hydroxycoumarin- 
glucuronide was analysed by the method of Egan and O’Kennedy (1992) it eluted in the 
void volume and thus, a method that would retard it on the column was sought. The
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method of Egan and O’Kennedy (1992) was based on separation under isocratic 
conditions (see section 2 2 3 1) A separation based on gradient elution was developed 
and the method for separation is descnbed in section 2 2 3 2 The gradient profile found 
to be most ideally suited for the separation of coumann, 7-hydroxycoumann, 7- 
hydroxycoumann-glucuromde and 4-hydroxycoumann is shown in Figure 4 11
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F i g u r e  4 1 1  T h e  c h r o m a t o g r a p h ic  s e p a r a t io n  o f  7 - h y d r o x y c o u m a n n -
g l u c u r o m d e  ( 1 3  3  m in ) ,  7 - h y d r o x y c o u m a n n  ( 1 6  0  m i n ) ,  c o u m a n n  ( 1 7  3  m in ) ,  a n d  
t h e  i n t e r n a l  s t a n d a r d  4 - h y d r o x y c o u m a n n  ( 1 9  6  m i n )  p r e p a r e d  i n  w a t e r  A  
c h r o m a t o g r a m  o f  t im e  ( m i n )  v e r s u s  a b s o r b a n c e  a t  3 2 0  n m  ( a b s o r b a n c e  u n it s )  T h e  
g r a d ie n t  p r o f i l e ,  r e p r e s e n t e d  a s  a  p e r c e n t a g e  o f  s o lv e n t  B  ( 1 0 0  %  m e t h a n o l)  v e r s u s
t im e  ( m i n )  is  s h o w n  a s  a  d a s h e d  l i n e  ( ------  ) T h e  s a m p le  w a s s e p a r a t e d  b y  r e v e r s e -
p h a s e  H P L C  o n  a  C 1 8  c o l u m n  w ith  g r a d ie n t  e l u t io n  (s e e  s e c t io n  2 2  3 2 )  a n d  
d e t e c t io n  a t  3 2 0  n m
3
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Starting with 100 % solvent A (95 5 0 2 water methanol acetic acid, (v/v/v) and 
ramping up to 50 50 solvent A solvent B (100 %  methanol) over 14 minutes gives 
excellent separation of the analytes and the internal standard However, if the 
percentage solvent of each changed more rapidly to a 50 50 solvent A solvent B, the 
samples were not fully resolved and if the rate was slowed the time factor for separation 
became too long After the gradient profile returned to 100 %  solvent A (l e at 23 min) 
the absorbance was monitored until it returned to baseline zero At this point (about 9 
min later) the system was then set to inject the next sample (this was assessed initially 
when the samples were prepared in water and subsequently in plasma, serum and unne)
C h o ic e  o f  in t e r n a l  s t a n d a r d
A range of compounds, mainly coumanns (o-coumanc acid, 7-amino-4-methyl 
coumann, warfann, coumann-3-carboxylic acid and o-hydroxyphenylacetic acid), were 
investigated for their applicability as internal standards An internal standard is used to 
allow for differences in the physical properties of a senes of sample solutions that 
contain the same analyte A fixed quantity of a pure substance is added to samples and 
standards alike The responses (e g absorbance) of the analyte and internal standard are 
determined, and the ratio of the two responses is calculated (i e absorbance analyte /  
absorbance internal standard) The response for the internal standard should be constant 
since the concentration of the internal standard is fixed If, however, one or more of the 
parameters that effect the measured responses vary, the responses of the analyte and the 
internal standard should be equally affected Thus, the response ratio should only be 
dependent on the analyte concentration A plot of the response ratio as a function of the 
analyte concentration yields a calibration curve from which unknown analyte 
concentrations may be calculated from their respective response ratio The internal 
standard must be added before measurement is made to allow for dissolution, mixing 
and any other reactions to occur The internal standard should be a substance, similar to 
the analyte, with an equally measurable signal that does not interfere with the response 
of the analyte The retention time of the internal standard must be within a range that 
makes it practical for its use 4-hydroxycoumann proved to be the best candidate for 
internal standard It does not coelute with any other species, there is no interference
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from other endogenous species in urine, plasma or serum, and it has a similar absorbance 
at 320 nm to the other analytes.
Figure 4.1.2. shows an overlay of the separation of the three analytes and the internal 
standard in serum and in blank serum. It is clearly seen that there is no interference from 
endogenous species present in the serum. This is also seen for the analysis of blank 
plasma and standards in plasma (result not shown).
Time (min)
F i g u r e  4 .1 .2 . C h r o m a t o g r a m  s h o w in g  t h e  o v e r la y  o f  t h e  s e p a r a t io n  o f  ( A )  7- 
h y d r o x y c o u m a r in - g l u c u r o n id e f ( B )  7- h y d r o x y c o u m a r in , ( C )  c o u m a r in  a n d  ( D )  4 -  
h y d r o x y c o u m a r in  s t a n d a r d s  p r e p a r e d  in  s e r u m  [ p u r p l e /, a n d  b l a n k  s e r u m  [ b la c k ] .  
T h e  s a m p le s  w e r e  s e p a r a t e d  b y  r e v e r s e - p h a s e  H P L C  o n  a  C 1 8  c o l u m n  w ith  g r a d ie n t  
e lu t io n  (s e e  s e c t io n  2 .2 .2 .2 . )  a n d  d e t e c t io n  a t  3 2 0  n m . N o t e :  f o r  a l l  s u b s e q u e n t  
c h r o m a t o g r a m s  e a c h  o f  t h e  a n a ly t e s  a n d  t h e  in t e r n a l  s t a n d a r d  is  r e f e r r e d  to  a s  
( A ) , ( B ) , ( C ) ,  a n d  ( D ) ,  r e s p e c t iv e ly  a s  in  t h is  F i g u r e .
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Figure 4.1.3. shows the separation of coumarin, 7-hydroxycoumarin, 7- 
hydroxycoumarin-glucuronide and 4-hydroxycoumarin prepared in control urine and 
analysed by HPLC with gradient elution (see section 2.2.3.2.). The standards samples 
were prepared and analysed as outlined in section 2 2 . 2 . 2 .  and 2.2.3.2. The urine 
samples were analysed directly, except for the addition of the internal standard, or, if 
dilution in control urine was required to facilitate analyte concentration calculation. 
Protein precipitation was not utilised in sample preparation. The control urine was 
donated from a volunteer who had not been treated directly with coumarin or 7- 
hydroxycoumarin.
Time (min)
F i g u r e  4 .1 .3 . O v e r la y  o f  t h e  H P L C  s e p a r a t io n  ( 8  m i n - 2 2  m i n )  o f  ( A )  7 -  
h y d r o x y c o u m a r in - g l u c u r o n id e , ( B )  7 - h y d r o x y c o u m a r in , ( C )  c o u m a r in  a n d  ( D )  4 -  
h y d r o x y c o u m a r in  s t a n d a r d s  ( 0  n g / m l  [ b la c k ] ,  2 0  ju g /m l [ r e d ]  a n d  5 0  n g / m l  [ b l u e ] )  
p r e p a r e d  in  u r i n e  a n d  a n a ly s e d  a s  o u t l in e d  in  s e c t io n  2 . 2 . 3 2 .  T h e  s a m p le s  w e r e  
s e p a r a t e d  b y  r e v e r s e - p h a s e  H P L C  o n  a  C l 8  c o l u m n  w ith  g r a d ie n t  e lu t io n  a n d  
d e t e c t io n  a t  3 2 0  n n t
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4 1 2  Limit of Detection, linearity, precision and accuracy
Plasma and serum standards
In both plasma and serum the limit of detection was 50 ng/ml for 7-hydroxycoumann 
and 200 ng/ml for coumann and 7-hydroxycoumann-glucuromde The linear detection 
range was from 0 5 |ig/ml to 100 |ig/ml The accuracy and precision (Table 4 11) was 
determined for standards between 1 |ig/ml and 100 (ig/ml Correlation coefficients for 
any of the standard curves prepared were always better than 0 995 The absorbance 
ratio (absorbance of the analyte / absorbance of the internal standard) was plotted versus 
the concentration added to ascertain the precision of the method and the regression 
lines
The mean equation for absorbance ratio for the intra assay for each of the analytes were 
Coumann - y = -0 01 + 0 01 X r2 = 0 99, 7-hydroxycoumann - y = -0 02 + 0 03 X 
r2 = 0 99, 7-hydroxycoumann-glucuromde - y = -0 01 + 0 02 X r2 = 0 99 
For the inter assay the mean standard curves were Coumann- y = -2E-3 + 0 01 X, r2 = 
0 99, 7-hydroxycoumann- y = 0 01 + 0 03 X, r2 = 0 99, 7-hydroxycoumann- 
glucuromde- y = 2E-4 + 0 02 X, r2 = 0 99
The accuracy and precision and the results in Table 4 12  1 and Table 4 12 2 were 
calculated from these regression lines Table 4 12  1 and Table 4 12  2 give the mean 
concentration calculated ± standard deviation and the percentage relative standard 
deviations for both mtra and inter assays The companson of the calculated 
concentrations to the concentrations added and %  relative standard deviations show that 
the method is both precise and accurate The percentage relative standard deviations in 
both the inter and intra assays are all below 10 % for each of the three analytes
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Concentration Mean calculated Mean calculated Mean calculated
Added concentration concentration concentration
7-Hydroxycoumann 7-Hydroxycoumann Coumann
-glucuromde
Cone ± St Dev Cone ± St Dev Cone ±St Dev
(% RSD) (% RSD) (% RSD)
0 0 0 0
1 00 169 ± 0  01 (0 5 %) 1 39 ± 0 04 (2 6 %) 1 19 ± 0 03 (28% )
5 00 5 38 ± 0 04 (0 7%) 4 97 ± 0 0 5  (09% ) 5 31 ± 0 2 4  (4 5 %)
10 00 9 60 ± 0 05 (0 5 %) 9 89 ± 0  12 (12% ) 9 7 0 ± 0  07 (0 7%)
20 00 19 42 ± 0 05 (0 3 %) 19 82 ± 0  24 (1 2%) 19 52 ± 0 11 (0 6 %)
50 00 49 30 ± 0 09 (02% ) 49 16 ± 0  11 (0 2 %) 4943 ± 006(02% )
80 00 79 27 ± 0  23 (0 3 %) 82 20 ± 3 8 (4 6 %) 80 9 8 + 0  16(0 2%)
100 00 102 5 ± 0  59 (0 6%) 101 09 ± 0 9  (0 9) 1024 ± 063  (06% )
Table 4 1 2  1 Intra-assay precision and accuracy for the determination o f coumann, 
7-hydroxycoumann and 7-hydroxy coumann-glucuromde in plasma and serum 
(n=5) The samples were analysed by HPLC and the concentrations were calculated 
from the mean respective standard curves The data is presented as the mean 
calculated concentration ±  standard deviation and the relative standard deviation 
about the mean
Concentration Mean calculated Mean calculated Mean calculated
Added concentration concentration concentration
7-Hydroxycoumann 7-Hydroxycoumann Coumann
-glucuromde
Cone ±St Dev Cone ±St Dev Cone ±St Dev
(% RSD) (% RSD) (% RSD)
0 0 0 0
100 0 89 ± 0 08 (8 8 %) 0 97 ± 0 04 (4 1 %) 129 ± 0 1 2  (9 6%)
500 4 82 ± 0  27 (5 6%) 4 82 ± 0  23 (4 7%) 4 91 ± 0  37 (7 7%)
10 00 10 16 ± 1 0 4  (10 0%) 9 92 ± 0 57 (58% ) 9 93 ± 0 67 (67% )
20 00 20 31 ± 1 60 (7 9 %) 20 00 ± 0 79 (3 9 %) 20 22 ± 1 29 (64 %)
50 00 50 70 ± 2 05 (4 0 %) 51 13 ±1 86 (3 6%) 49 10 ± 1 47 (3 0 %)
80 00 79 38 ± 3 62 (4 6 %) 78 70 ± 2  55 (3 2%) 80 40 ± 2 78 (3 4 %)
100 00 100 10 ± 6  09 (6 1 %) 100 60 ± 3 82 (3 8 %) 100 08 ± 6  45 (64%)
Table 4 1 2  2 Inter-assay precision and accuracy fo r the determination o f coumann, 
7-hydroxycoumann and 7-hydroxy coumann-glucuromde in plasma and serum 
(n-5) The samples were analysed by HPLC and the concentrations were calculated 
from the mean respective standard curves The data is presented as the mean 
calculated concentration ±  standard deviation and the percentage relative standard 
deviation about the mean is given in parenthesis
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Urine standards
The limit of detection of coumann, 7-hydroxycoumann and 7-hydroxycoumann- 
glucuronide in unne was 500 ng/ml due to the high background signal as compared to 
plasma or serum The linear detection range was from 2 |ig/ml - 100 (ig/ml Tables 
4 12 3 and 4 12 4 are the results for the mtra- and inter- assay precision and accuracy 
for the determination of coumann, 7-hydroxycoumann and 7-hydroxycoumann- 
glucuronide in unne, by HPLC The companson of the mean concentrations calculated 
to the concentrations added and % relative standard deviations show that the method is 
both precise and accurate
Concentration Mean calculated Mean calculated Mean calculated
Added concentration concentration concentration
7-Hydroxycoumann 7-Hydroxycoumann Coumann
-glucuromde
Cone ± S t  Dev Cone ± S t  Dev Cone ± S t Dev
(% RSD) (% RSD) (% RSD)
0 0 0 0
200 2 09 ± 0 04 (2 1 %) 2 01 ± 0  14 (7 0%) 2 38 ± 0 08 (32% )
5 00 5 05 ± 0  08 (1 6%) 4 83 ± 0  31 (6 5%) 5 10 ± 0  11 (2 1 %)
10 00 10 08 ± 0  26 (2 5%) 10 25 ± 041  (3 9%) 9 90 ± 0  17 (1 7 %)
20 00 19 70 ± 0  25 (0 5 %) 20 11 ± 0  26(1 3%) 19 60 ± 0  07 (0 3 %)
50 00 49 60 ± 0  17(0 8%) 50 80± 1 88 (37 %) 49 43 ± 0  30 (0 6%)
80 00 81 32 ± 1 66 (2 0 %) 80 65 ± 0  96 (1 2 %) 80 27 ± 2  64 (3 3 %)
100 00 100 90 ± 3 91 (3 8 %) 99 00 ± 0  98 (1 0%) 99 98 ±3 61 (3 6 %)
Table 4 1 2  3 Intra-assay precision and accuracy for the determination o f coumann, 
7-hydroxycoumann and 7-hydroxy coumann-glucuronide in unne (n=5) The 
samples were analysed by HPLC and the concentrations were calculated from the 
mean respective standard curves The data is presented as the mean calculated 
concentration ± standard deviation and the relative standard deviation about the 
mean
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Concentration Mean calculated Mean calculated Mean calculated
Added concentration concentration concentration
7-Hydroxy coumarin 7-Hydroxy coumarin Coumarin
-glucuronide
Cone. ± St. Dev. Cone. ± St. Dev. Cone. ± St. Dev.
(% RSD) (% RSD) (% RSD)
0 0 0 0
2.00 1.6 ±0.06 (4.1 %) 2.01 ±0.06 (2.9%) 1.97 ±0.15 (7.7%)
5.00 4.67 ±0.12 (2.5%) 4.86 ±0.15 (3.1 %) 4.90 ±0.24 (4.9%)
10.00 9.70 ±0.48 (5.0%) 9.86 ±0.23 (2.3%) 9.56 ±0.13 (1.4%)
20.00 20.70 ±0.37 (1.8%) 20.82 ±0.77 (3.7%) 19.60 ±0.94 (4.8%)
50.00 49.96 ±2.45 (4.9%) 49.50 ±0.89 (1.8%) 51.30 ±2.03 (3.9%)
80.00 81.60 ±3.29 (4.0%) 79.75 ±1.24 (1.6%) 80.60 ±6.65 (8.3%)
100.00 98.80 ±4.89 (4.9%) 99.73 ±3.73 (3.7%) 99.72 ±2.67 (2.7%)
Table 4.1.2.4. Inter-assay precision and accuracy fo r  the determination o f  coumarin , 
7-hydroxycoumarin and 7-hydroxycoumarin-glucuronide in urine (n=5). The 
samples were analysed by HPLC and the concentrations were calculated from  the 
mean respective standard curves. The data is presented as the mean calculated 
concentration ± standard deviation and the relative standard deviation about the 
mean.
4.1.3. Clinical and pharmacokinetic studies
The method developed was applied to two separate studies:
Study 1: Plasma and urine samples were taken from each of three volunteers who
had been treated with 250 mg of coumarin. The samples were analysed by HPLC.
Study 2: Serum samples were taken from patients with advanced malignancies
(see section 4.3.) who had been treated with 7-hydroxycoumarin. The samples were 
analysed by HPLC.
4.1.3.1. Study 1: Analysis o f  plasm a samples from  volunteers who had been
treated with 250 mg o f  coumarin
250 mg of coumarin was orally administered to each of three volunteers and plasma 
samples were taken at 0 h, 1 h and 4 h, respectively. The concentrations of coumarin, 7- 
hydroxycoumarin and 7-hydroxycoumarin-glucuronide, calculated from the standard
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curve of mean absorbance ratio versus mean calculated concentration, is given in Table 
4 13 1
Sample Coumann 7-Hydroxycoumarin 7-Hydroxycoumarin-
Time concentration concentration glucuromde
concentration
h UR/ml UK/ml Ufi/ml
Volunteer 1
0 NQ 0 0
1 NQ ca 0 1 218
4 NQ 0 10
Volunteer 2
0 NQ 0 0
1 NQ ca. 0 2 12 7
4 NQ 0 08
Volunteer 3
0 NQ 0 0
1 NQ ca 0 1 9 6
4 NQ 0 05
T a b le4131  Table o f HPLC results fo r  the determination o f 7-
hydroxycoumann, 7-hydroxy coumann-glucuromde and coumann in plasma after 
the oral administration o f 250 mg o f coumann The results were calculated from a 
standard curve o f the mean absorbance ratio (Absorbance o f analyte/absorbance o f 
internal standard) versus mean concentration NQ - not quantifiable ca. - 
approximately- i e levels o f drug were observed but their exact quantification was 
not possible as their absorbance values did not he within the limits o f the linear 
detection range
The samples were prepared as outlined under section 2 2 2 2 and analysed as outlined in 
section 2 2 3 2 Figure 4 13 1 shows the chromatograms from volunteer 2’s plasma 
samples in overlay There is a majority of 7-hydroxycoumann-glucuromde, as compared 
to 7-hydroxycoumann, in the plasma sample after 1 h After 4 h the level of 7- 
hydroxycoumann-glucuromde has decreased significantly After 1 h some free 7- 
hydroxycoumann was observed in the plasma samples (ca 0 1 |Ug/ml) No coumann 
was detected in the plasma after its oral administration From these results it was shown 
that coumann enters the blood circulation, predominantly as (>98 % of the coumann
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observed) 7-hydroxycoumann-glucuronide with some free unconjugated 7- 
hydroxycoumann (ca 1 %)
Time (min)
Figure 4 1 3 1  Chromatogram showing the overlay o f volunteer 2 ’s plasma
samples after the administration o f coumann p o  It shows the separation o f (A) 7- 
hydroxycoumann-glucuronide, (B) 7-hydroxycoumann and (D) 4-hydroxycoumann 
at Oh [black], 1 h [red] and 4 h [blue], respectively The samples were analysed by 
reverse-phase HPLC on a C l8 column with gradient elution (see section 2 2 3 2) and 
detection at 320 nm.
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4 1 3  2 Study 1 Analysis o f  unne samples from volunteers who had been
treated with 250 mg o f coumann
Each of three volunteers were given 250 mg of coumann orally and unne samples were 
taken at 0 h, 2 h, 6 h, 10 h, 14 h, and 24 h, respectively The unne samples were diluted 
where necessary with control unne to ensure that the concentration of 7- 
hydroxycoumann or 7-hydroxycoumann-glucuromde was within the limits of the 
standard curve i e 2 p.g/ml - 100 ng/ml Figure 4 13 2 shows the an overlay of two 
chromatograms for volunteer 2’s unne samples taken at 0 h and 10 h, respectively
Time (min)
Figure 4 1 3  2 Overlay o f volunteer 2 fs unne sample analysed by HPLC It
shows the overlay o f the unne sample at 0 h [black] and at 10 h [red] after the oral 
administration o f 250 mg o f coumann The separation o f (A) 7-hydroxycoumann- 
glucuromde (B) 7-hydroxycoumann and (D) 4-hydroxycoumann The samples were 
analysed by reverse-phase HPLC on a C18 column with gradient elution (see section 
2 2 3 2) and detection at 320 nm.
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From the chromatogram, it is seen, that there is an excess of 7-hydroxycoumann- 
glucuronide as compared to 7-hydroxycoumann The concentrations of 7- 
hydroxycoumann, coumann and 7-hydroxycoumann-glucuromde are given in Table 
4 13 2 Up to 98 % of the 7-hydroxycoumann excreted was excreted as the 
glucuronide conjugate The samples were also analysed by capillary electrophoresis (see 
sections 2321,232 2, 2331,2332, and 3 11) and the results determined by CE 
and HPLC were compared (Table 4 13 3) There was up to ± 11 % difference between 
the results from either method Up to 83 % of the coumann administered was excreted 
as 7-hydroxycoumann (free and conjugated)
Sample Coumann 7-Hydroxycoumarm 7-Hydroxycoumarin-
Time concentration concentration glucuronide
concentrationh M-g/mi M-g/ml pM M-g/ml HM
Volunteer 1
0 NQ 0 0 4 5 13 3
2 NQ 18 11 1 226 7 670 5
6 NQ 0 0 105 5 312 0
10 NQ 0 0 20 9 618
14 NQ - - - -
24 NQ 0 0 4 7 13 9
Volunteer 2
0 NQ 0 0 0 0
2 NQ 603 372 2 2954 6 8738 8
6 NQ 16 6 102 5 880 5 2604 4
10 NQ 0 0 109 2 322 9
14 NQ 0 0 35 6 105 3
24 NQ 0 0 68 201
Volunteer 3
0 NQ 0 0 0 02 NQ 39 3 242 6 3002 6 8880 86 NQ 53 32 7 680 8 2013 610 NQ 0 0 617 182 514 NQ 0 0 9 2 27 224 NQ 0 0 17 50
Table 4 1 3 2  HPLC results fo r the determination o f 7-hydroxycoumann, 7-
hydroxycoumann-glucuromde and coumann concentration (\lgfml and \xM) in 
unne after the oral administration o f 250 mg o f coumann. The analyte 
concentrations (\ig/ml) were calculated from the standard curve o f the mean 
absorbance ratio versus mean calculated concentration
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There was a large variability between the three volunteers in their ability to excrete 
coumann Only the excretion of coumann as coumann, 7-hydroxycoumann or 7- 
hydroxycoumann-glucuromde was assessed
Sample Time 7-OHC excreted
(mg)
% Coum 
hydroxj 
c
(% of 0
tarin excreted as 7- 
coumarm (free or 
unjugated)
lose administered)
HPLC CE CE HPLC CE CE
h method method method method method method1 2 1 2
Volunteer 1
0 19 0 ND 0 7 0 ND
2 40 2 52 9 ND 14 5 19 1 ND
6 20 2 25 6 ND 73 9 2 ND
10 2 9 2 8 ND 1 1 10 ND
14 NS NS ND NS NS ND
24 0 9 0 ND 0 3 0 ND
Total 66 1 81 3 ND 23 8 29 3 ND
Volunteer 2
0 0 0 0 0 0 0
2 88 5 107 4 1106 319 38 7 39 9
6 30 7 36 4 40 9 11 1 13 1 14 7
10 15 6 13 3 17 7 5 6 4 8 6 4
14 1 7 16 2 6 0 6 0 6 0 9
24 17 0 17 0 6 0 0Total 138 2 158 7 173 5 49 8 57 2 62 5
Volunteer 3
0 0 0 22 0 0 0
2 133 2 153 4 149 3 48 0 55 3 53 8
6 65 7 67 7 69 8 23 7 24 4 88
10 89 65 87 32 23 0814 1 8 2 2 14 0 6 08 0524 03 0 0 0 1 0 0Total 209 9 229 8 2314 75 7 82 8 83 4
Table 4 1 3  3 7-hydroxycoumann concentrations and % coumann excreted
as 7-hydroxycoumann (free and conjugated) as determined by HPLC and CE 7- 
hydroxycoumann (mg) excreted was calculated from total 7-hydroxycoumann 
concentration [free and conjugated 7-OHC excreted (\Lg/ml)J X unnary volume 
collected (ml) 7-hydroxycoumann excreted (mg) was related to the coumann 
administered by multiplying it by their molar ratio (0 90) le  the % coumann 
excreted was calculated from the total 7-OHC excreted (mg) X  molar ratio (0 90) I 
coumann administered (250 mg) X 100/1 The samples were prepared and analysed 
by HPLC method (see section 2 2 2 2 ,  and 2 2 3 2 ) ,  by CE (Method 1, see section 
2 3 2 1  and 2 3 3 1 )  and by CE (Method 2, see section 2.3 2.2. and 2 3 3 2 )  ND 
indicates that the sample concentrations were not determined and NS indicates that 
no sample was available fo r  analysis
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Volunteer 1 excreted ca 24 % of the coumann administered as free or conjugated 7- 
hydroxycoumann Volunteer 2 excreted ca 50 % and volunteer 3 excreted ca 76 % 
The presence of other coumann metabolites in the unne samples was not determined 
Thus, the coumann may have been excreted but in a different form, eg o- 
hydroxyphenylacetaldehyde or 3-hydroxycoumann or 7-hydroxycoumann-sulphate
The relatively low levels of 7-hydroxycoumann and 7-hydroxycoumann-glucuromde 
determined in the unne of volunteer 1 may have been due to a low level of the enzyme 
necessary for metabolism of coumann to 7-hydroxycoumann (see section 3 2 1) 
However, the low levels of 7-hydroxycoumann (free and conjugated) observed in the 
unne of volunteer 1 may have been related to the fact that she was undergoing hormone 
replacement treatment (HRT) Perhaps, coumann metabolism or the excretion of its 
metabolites was being impaired by the action of the HRT Levels in the volunteers 
plasma were however, (see Table 4 13 1) almost twice as high as each of the other 
volunteers This may also have been due to the HRT The volunteer with the lowest 
plasma levels of 7-hydroxycoumann-glucuromde had the highest levels present in their 
unne i e volunteer 3 A companson of blood levels to unne levels, of 7- 
hydroxycoumann/7-hydroxycoumann-glucuromde, may give a greater insight into 
coumann metabolism and drug disposition (see section 4 3)
4 1 3  3 Study 2 Analysis o f serum samples from  volunteers who had been
«treated with 7-hydroxycoumann
Serum samples were taken from each of three volunteers who had been treated with 7- 
hydroxycoumann Two separate panents were treated orally with 40 g of 7- 
hydroxycoumann and 7 0 g was administered to another patient These patients were 
undergoing treatment with 7-hydroxycoumann as part of a study into the metabolism of 
7-hydroxycoumann in panents with advanced malignancies (see section 4 3 ) Blood 
samples were removed at specific time intervals on each of two different days [Day 1 
and Day 15] (Table 4 13 4) and allowed to clot The serum was removed and stored at 
-80 °C until required Samples were prepared as outlined in section 2 2 2 2 Table
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4 13 4 are the results for 7-hydroxyeoumann and 7-hydroxycoumann-glucuromde 
concentrations in the serum from two of the patients7 on day 1 and day 15 of the trial
Sample
Time
Patient 1
Pay L Day 15
Patient 2 
Day 1 Day 15
Concentrations of Concentrations of Concentrations of Concentrations of
70HCG 7-OHC 70HCG 7-OHC 70HCG 7-OHC 70HCG 7-OHC
mm Hg/ml Hg/ml Hg/ml Ufi/ml
0 0 0 ca 0 5 ca 0 1 0 0 ca 0 5 0
5 0 0 1 1 ca. 0 1 0 0 ca 0 5 0
15 0 0 12 C£L 0 1 0 0 ca 0 5 0
30 1 1 ca 0 1 1 1 ca. 0 1 0 6 ca 0 1 1 1 0
45 25 ca 0 1 54 ca. 0 1 36 ca.0 1 5 0 ca 0 1
60 4 9 ca 0 2 14 1 ca 0 2 67 ca 0 1 16 5 ca 0 2
120 32 1 ca 0 7 36 9 0 6 52 6 ca 0 5 48 7 ca 0 3
240 133 9 1 2 125 3 1 3 148 4 ca 0 8 162 0 ca 0 6
480 64 1 ca 0 7 66 2 10 761 ca. 0 4 72 7 ca 0 3
1440 14 ca 0 1 1 1 ca 0 1 55 ca. 0 1 18 ca 0 1
Table 4 1 3  4 HPLC results fo r the determination o f 7-hydroxyeoumann (7-
OHC), 7-hydroxycoumann-glucuromde (7-OHCG) in serum after the oral 
administration o f 4 0  g (patient 1) and 7 0 g (patient 2) o f 7-hydroxycoumann The 
concentrations were calculated from the standard curve o f the mean absorbance 
ratio versus the mean concentrations calculated fo r  each o f the analytes ca. • 
approximately- i e levels o f drug were observed but their exact quantification was 
not possible as their absorbance values did not he within the limits o f the linear 
detection range
Approximately 95% - 99 % of the 7-hydroxycoumann detected in the serum is in the 
glucuronide form with the remainder circulating as free 7-hydroxycoumann (Table 
4 13 4) Other metabolites were not determined Over time the levels of 7- 
hydroxycoumann increase as the drug is released into the circulation The maximum 
levels of 7-hydroxycoumann, in the serum of each of these patients, was observed at 4 
h At 24 h the levels of 7-hydroxycoumann and 7-hydroxycoumann-glucuromde 
returned, almost, to the levels before administration of the drug It is assumed that this 
is due to its excretion in the unne Figure 4 13 3 shows an overlay of two
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Ichromatograms for time 0 on day 15 and 2 h after administration of the drug for the 
third volunteer !
£c
oC\lCO
OccdSik.o
V)
JO<
Time (min)
Figure 4 1 3  3 Overlay o f  two chromatograms o f serum samples at Oh [black]
and 2 h [red] after the oral administration o f 4 g o f 7-hydroxycoumann to patient 3 
on Day 15 It shows the separation o f (A) 7-hydroxycoumann-glucuronide, (B) 7- 
hydroxycoumann and (D) 4-hydroxycoumann at the different times The samples 
were separated by reverse-phase HPLC on a Cl 8 column with gradient elution and 
detection at 320 nm.
The levels of 7- hydroxycoumann (free or conjugated) determined or the amount 
remaining in circulation observed at day 15 were different for each of the patients 
studied These samples were also analysed by the method of Egan and O’Kennedy 
(1992) for total 7-hydroxycoumann content m serum The total 7-hydroxycoumann 
(fig/ml) content m the serum was also determined from the results obtained after the 
analysis with the gradient elution method (see section 2 2 2 2 and 2 2 3 2) Table
150
4 13 5 gives the comparison of the results determined by both HPLC methods 1 e the 
method of Egan and O’Kennedy and the method described (see section 2 2 2 2 and 
2 2 3 2) % of the 7-hydroxycoumann present in the serum was present as the
glucuronide form The total 7-hydroxycoumann concentration (analysed by the method 
as descnbed in section 2 2 2 2 and 2 2 3 2) was determined from the 7- 
hydroxycoumann-glucuromde concentration by multiplying it by the molar ratio 
between the two compounds (i e 0 48 - see section 2 2 2 2 3) There is a difference of 
up to ± 11 % between the results
Sample HPLC results HPLC results
Time Patient 1 (Day 1) Patient 3 (1Day 15)
7-OHC 7-OHC 7-OHC 7-OHC
concentration concentration concentration concentration
Method of Egan and HPLC method * Method of Egan and HPLC method
O Kennedy t O’Kennedy
min Hg/ml ¿ig/ml Mg/ml Mg/ml
0 0 0 91 81
5 0 0 85 7 6
15 0 0 9 0 81
30 11 0 5 8 0 75
45 18 12 8 0 8 0
60 39 25 9 7 76
120 17 3 15 4 51 3 41 3
240 616 64 1 93 2 861
480 28 8 29 3 643 514
1440 12 0 7 93 9 0
Table 4 1 3  5 A comparison o f two HPLC methods fo r  the determination of
7-hydroxycoumann and 7-hydroxycoumann-glucuronide in serum after the oral 
administration o f 7-hydroxycoumann to each o f two patients The samples were 
analysed by the method of^Egan and O’Kennedy (1992) and by * HPLC method (see 
section 2 2 2  2 and 2 2 3 2 )
From the analysis of the serum it was clearly seen that two weeks after the initial dosage 
of the drug there is a constant pool of circulating 7-hydroxycoumann-glucuromde and 
7-hydroxycoumann in the serum On day 1 no 7-hydroxycoumann, free or conjugated,
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was observed in the serum. The drug concentration time profile for the third patient 
after the administration of 4.0 g of 7-hydroxycoumarin on day 15 is shown in Figure
4.1.34.
0.0 240.0 480.0 720.0 960.0 1200.0 1440.0
Time (min)
Figure 4.1.3.4. Time profile o f 7-hydroxycoumarin concentration [red] and 7- 
hydroxycoumarin-glucuronide concentration [blue] versus time for a patient who 
had been administered 4 g o f 7-hydroxycoumarin. The samples were taken on day 
15 and analysed by reverse-phase HPLC on a C l8 column with gradient elution and 
detection at 320 nm. Concentrations were calculated from a standard curve o f mean 
absorbance ratio versus mean concentrations calculated.
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4 2. ANALYSIS OF THE GLUCURONIDATION OF
7-HYDROXYCOUMARIN BY HIGH-PERFORMANCE LIQUID 
CHROMATOGRAPHY (HPLC)
The in vitro metabolism of 7-hydroxycoumann to 7-hydroxycoumann-glucuromde was 
investigated in bovine liver homogenate by HPLC A metabolic reaction mixture was 
prepared that included a crude preparation of uridine diphosphate (UDP) glucuronyl 
transferase (UDPGT), 7-hydroxycoumann and UDP-glucuronic acid (UDPGA) [see 
section 2 2 2 2] Over a time penod of 150 nun the 7-hydroxycoumann-glucuromde 
produced enzymatically was determined by HPLC
Concentrations of 7-hydroxycoumann-glucuromde produced were calculated from a 
plot of 7-hydroxycoumann-glucuromde concentration versus the mean absorbance ratio 
(n=4) The absorbance ratio is calculated from 7-hydroxycoumann-glucuromde 
absorbance/4-hydroxycoumann absorbance The method allowed both the 
determination of 7-hydroxycoumann as well as 7-hydroxycoumann-glucuromde The 
identity of the compound produced was confirmed by photo-diode array spectral 
analysis A plot of time versus 7-hydroxycoumann-glucuromde produced indicates that 
the metabolism is linear for the first 90 nun and reached a plateau at 150 mm The rate 
of reaction in the first 90 mm was 2 96 ± 0 06 (R S D 1 7%, n=3) nmol of 7- 
hydroxycoumann-glucuromde produced per minute per milligram of protein After 150 
mm 0 34 ± 0 01 m M  (R S D 1 4%) of 7-hydoxycoumann-glucurorude was produced, 
from 0 77 m M  7-hydroxycoumann introduced into the reaction mixture 58 0 % ± 5 3 
% (or 0 44 ± 0 02 mM) of the 7-hydroxycoumann remained after the 150 min
4 2.1. HPLC separation parameters
HPLC was applied to the determination of 7-hydroxycoumann-glucuromde 
concentration after the in vitro metabolism of 7-hydroxycoumann by UDPGT The 
HPLC separation method details are descnbed in section 2 2 3 2 The HPLC method 
had a limit of quantitation, for 7-hydroxycoumann-glucuronide, of 0 5 |Xg/ml (1 47 |lM) 
The linear range was from 0 -100 [ig/mi (0 - 295 7 jiM) To prevent the endogenous |3-
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glucuronidase, present in the liver homogenate causing the deconjugation of 7- 
hydroxycoumann-glucuromde, the standards were prepared in the reaction mixture 
which containing the liver homogenate denatured with trichloroacetic acid Table 
4 2 11 gives the mean peak absorbance ratios for the 7-hydroxycoumann-glucuronide 
standards and their percentage relative standard deviations (n=4)
7-hydroxycoumann- 
glucuronide concentration
(HM)
Mean peak absorbance 
ratio (n=4)
% Relative standard 
deviation
0 0 0
147 6E-3 ± 2E-4 13
2 96 0 01 ± 2E-4 30
5 92 0 02 ± 1 5E-3 83
14 79 0 05 ± 1 5E-3 32
29 58 0 09 ± 3 0E-3 32
5915 0 19 ± 6 9 E-3 37
147 89 0 46 ± 9 9E-3 22
236 62 0 73 ±40 7E-3 56
295 77 0 88 ± 59 0 E-3 67
Table 4 2  11 7-hydroxycoumann-glucuromde standard concentrations (piM) and 
their respective mean absorbance ratios ± standard deviation (n=4), and their 
percentage relative deviations 7-hydroxycoumann-glucuromde standards (n=4)
were prepared in the incubation mixture, (see section 2 2 2 2 )  The samples were 
analysed by reverse-phase HPLC on a C18 column with gradient elution and 
detection at 320 nm The absorbance ratio was calculated from (absorbance 7- 
hydroxycoumann-glucuromde / absorbance internal standard)
4 2 2 Glucuronidation of 7-hydroxycoumarin by UDPGT
7-hydroxycoumann-glucuronide was monitored over time, as it was produced 
enzymatically as the in vitro metabolite of 7-hydroxycoumann The increase of 7- 
hydroxycoumann-glucuromde content could be observed visually (Figure 4 2 2 1 ) in 
each of the chromatograms, resulting after HPLC analysis of the samples, taken at the 
different times The concentration of 7-hydroxycoumann-glucuronide produced was 
determined from the plot of mean peak absorbance ratio for 7-hydroxycoumann- 
glucuronide versus 7-hydroxycoumann-glucuronide concentration (Table 4 2 11)
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Table 4 2 2 1 are the results for the mean 7-hydroxycoumarin-glucuromde 
concentration produced (n=3) over time (min)
Time (mm)
Figure 4 2 21 Overlay o f three chromatograms, (time (min) versus
absorbance at 320 nm (absorbance units) from  12 5 min to 20 5 min, o f samples 
taken at 0 min [black], 20 min [red], and 70 min [blue], respectively, showing the 
decrease in (B) 7-hydroxycoumann absorbance, and the increase o f (A) 7- 
hydroxycoumann-glucuromde absorbance over time. (D) is the internal standard, 4- 
hydroxycoumann The samples were analysed by reverse-phase HPLC on a C l8 
column with gradient elution and detection at 320 nm as outlined in section 2 2 2 2 
and 2 2 3 2
After 90 min the metabolic rate decreased and the level of 7-hydroxycoumarin- 
glucuromde no longer increased linearly Figure 4 2 2 1 shows a plot of 7- 
hydroxycoumann-glucuromde produced (jiM) for each of the incubation solutions 
analysed versus time (mm) It was also possible to monitor the decrease in the 7- 
hydroxycoumarm content as it was consumed by the enzymatic process It was possible 
to observe the 7-hydroxycoumann content decrease over time (Figure 4 2 2 1 ) The %
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decrease in 7-hydroxycoumann content (1 e 58 %) was calculated by comparing the 
peak absorbance ratios for 7-hydroxycoumann absorbance / 4-hydroxycoumann 
absorbance at 0 min and at 150 min In the absence of 7-hydroxycoumann, liver 
homogenate containing the UDPGT, or UDPGA, no 7-hydroxycoumann-glucurorude 
was produced Using the same metabolic mixture, another similar metabolic assay study 
was earned out, with capillary electrophoresis (CE) as the mode of separation of 7- 
hydroxycoumann-glucuromde from the reaction components, with UV detection at 320 
nm (see section 2 3 2 4 and 3 2 4)
Sampling
Time
Mean 7-hydroxycoumarin- 
glucuronide concentration ±  
Standard Deviation
% Relative standard 
deviation
min |iM
0 0 0
10 47 1 ± 0 7 16
20 92 6 ± 5 5 59
30 122 4 ± 3 1 25
40 153 8 ± 3 1 2 0
50 177 8 ± 3 9 2 2
60 200 5 ± 5 5 27
70 233 1 ± 12 4 53
85 262 3 ± 4  7 17
90 280 4 ± 3 8 14
105 287 2 ± 3 0 1 1
120 302 6 ± 10 6 35
135 331 3 ± 0  6 20
150 336 7 ± 5 0 1 5
Table 42  2 I  Mean concentrations o f 7-hydroxycoumann-glucuromde (±
Standard Deviation) over time produced by bovine liver UDPGT and the % relative 
standard deviation (n=3). The samples were analysed by reverse-phase HPLC on a 
C18 column with gradient elution and detection at 320 nm Concentrations were 
calculated from a standard curve o f 7-hydroxycoumann-glucuromde, prepared in 
the incubation mixture, versus absorbance ratio as desenbed in section 2 2 22
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There was no statistical difference, for the determination of 7-hydroxycoumarin- 
glucuronide concentration and enzyme activity, between the CE method and the HPLC 
method. The rate of reaction from the CE study was 3.09 ± 0.13 jjM  (n=3) 7- 
hydroxycoumarin produced per min per mg of protein as compared to 2.96 ± 0.06 jiM  
for the HPLC method.
Time (min)
Figure 4.2.2.2. Metabolism o f 7-hydroxycoumarin by uridine diphosphate 
glucuronyl transferase (UDPGT) with the cofactor UDP-glucuronic acid A plot o f  
the 7-hydroxycoumarin-glucuronide concentration (/¿M) (produced enzymatically) 
versus time (min), fo r  each o f three incubations is shown (Incubation 1 [grey]; 
Incubation 2 [blue]; Incubation 3 [red]). The samples were analysed by reverse- 
phase HPLC on a Cl 8 column with gradient elution and detection at 320 nm. 
Concentrationswere calculated from a standard curve o f 7-hydroxycoumarin- 
glucuronide, prepared in the incubation mixture, versus absorbance ratio as 
described in section 2.2.2.2.
The difference between the two methods, with respect to sample preparation, was that, 
for CE, samples were removed from the reaction mixture and analysed immediately
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without any sample preparation 1 e without protein precipitation The application of 30 
kV to the sample from the reaction mixture stopped the reaction by separating the 
individual components of the reaction However, it was not possible to monitor the 
decrease in 7-hydroxycoumann content on CE, due to interference from magnesium 
chloride Magnesium chlonde was found to co-migrate with the 7-hydroxycoumann
High-performance liquid chromatography was found to be an excellent analytical 
technique for the determination of coumann, 7-hydroxycoumann and 7- 
hydroxycoumann-glucuromde over a range of applications The method, developed and 
descnbed above, was both accurate and precise in the determination of coumann, 7- 
hydroxycoumann and 7-hydroxycoumann-glucuromde in plasma, serum and unne It 
was also shown to be applicable to the investigation of the in vitro metabolism of 7- 
hydroxycoumann to 7-hydroxycoumann-glucuromde
The advantages of this method over other HPLC methods (e g Moran et a l, 1987, and 
Egan and O’Kennedy, 1992) for the determination of coumann and 7-hydroxycoumann 
was that there was no deconjugation step, thereby reducing sample preparation time 
There was no extraction, no evaporation and no reconstitution steps, thus, the sample 
preparation time was significantly decreased There is less organic waste and the assay 
is less costly than the method of Egan and O’Kennedy (1992) as there was no need for 
expensive HPLC grade organic solvents used in the solvent extraction step (l e diethyl 
ether) or for (3-glucuromdase The tubes used did not need to be solvent resistant 
Sample volumes were reduced which causes less inconvenience to volunteers or patients 
alike The limit of detection for the determination of coumann, 7-hydroxycoumann and 
7-hydroxycoumann-glucuromde in serum and plasma was improved by a factor of 10 
The analysis time of the method developed and descnbed above was longer, 16 min for 
the method of Egan and O ’Kennedy (1992) as compared to 30 min (see section 2 2 3 2) 
The above advantages outweigh this minor disadvantage The analysis and data 
processing was computer controlled and the samples were analysed via an autosampler 
(see Figure 4 0 1) Thus, time in this case does not cause any major disadvantages as 
analysis takes place overnight with the automated injection system and data processing
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4 3. A STUDY INTO THE METABOLISM OF 7-
HYDROXYCOUMARIN IN PATIENTS WITH ADVANCED MALIGNANCIES
Acknowledgement
This work was earned out in conjunction with M  Ernest Marshall and Katherine Kervin 
of the Comprehensive Cancer Center of Alabama University at Birmingham, 
Birmingham, Alabama. Blood samples were taken from each of 59 patients, each with 
advanced malignancies, and the serum samples were forwarded from Birmingham to 
Dublin on dry ice for analysis
Before any drug can produce its desired action, it must first pass through several 
processes, all of which will have an effect on its final pharmacological profile (Bowman 
and Rand, 1980) A general scheme for the profile of an orally administered drug, e g 
7-hydroxycoumann, is outlined in Figure 4 3 1 The vanous processes involved are 
divided into three phases In the pharmaceutical phase, the formulation of an agent is 
changed, from the stable production form, in which it is given, to the form by which it is 
absorbed The pharmacokinetic phase encompasses the subsequent steps of absorption, 
distnbution, metabolism and excretion The pharmaceutical and pharmacokinetic phases 
desenbe what happen to a drug This is also called drug disposition
The pharmacological effect, or what the drug does to the body, is evident in the 
pharmacodynamic phase, where the drug, in some form determined by the drug 
disposition, interacts with a specific system to produce the complete, therapeutic and 
toxic effects observed These effects are, therefore, a product of the interaction of all 
elements of each phase, and any variation in one may ultimately leads to a change in the 
whole pharmacological profile of the drug The profile of a pharmaceutical agent is 
stnctly unique to an individual, since it represents a product of biochemical vanation
t
The section below deals with the drug disposition of 7-hydroxycoumann after the oral 
administration of a range of doses to patients with advanced malignancies with reference 
to distnbution of the drug in free and conjugated forms into serum
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Dose of Formulated Drug
Administration
Disintegration/dissolution to suitable 
physicochemical form
Pharmaceutical 
Phase
Drug available for absorption 
(Pharmaceutical Availability)\
Effect
Figure 43 1 A flow diagram o f the processes which contribute to the 
pharmacological profile o f an orally administered drug This process is normally 
divided into three phases The pharmaceutical phase describes the processes taking 
place from the administration o f an agent to release o f the substance into the body 
fluids The pharmacokinetic phase describes what the body does to the drug and the 
resultant effect on the body is encompassed in the pharmacodynamic phase (Taken 
from Bowman and Rand, 1980, a n d 0 9Connor, 1995)
1 6 0
4.3.1. Objectives of the study
Coumann and 7-hydroxycoumann are under investigation for the treatment of certain 
malignancies or for the chemoprevennon of malignancy (Marshall et a l, 1994, Marshall 
et a l , 1994 personal communication) 7-hydroxycoumann was given to a large number 
of cancer patients over a wide range of doses with no significant toxicity While much is 
known of the basic pharmacology of coumann and 7-hydroxycoumann there is 
insufficient data on serum levels and glucuromdation at the high dose levels used in 
clinical trials Furthermore, much of the pharmacological work was performed in non­
human mammalian species where the metabolism may differ from that in humans 
(Ritschel et a l, 1977, 1981a, 1981b, 1983,1984,1988,1992a, and 1992b, Shanfi et a l, 
1993b) Therefore the purpose of the study was to monitor serum levels of total 7- 
hydroxycoumann (free and/or conjugated) levels over 24 hours following a single oral 
dose on each of two different days, 14 days apart
4.3 2 Phase I trial of 7-hydroxycoumann
On the basis that coumann may be a prodrug for 7-hydroxycoumann (Ritschel 1992a, 
Shanfi et a l , 1993b), as it is quickly metabolised to 7-hydroxycoumann in man, 7- 
hydroxycoumann was investigated for its clinical efficacy for the treatment of advanced 
malignancy It was also unknown whether 7-hydroxycoumann would have less toxic 
side effects than coumann as it lacks the strong aromatic properties of coumann 7- 
hydroxycoumann, the major human metabolite of coumann, was formulated into a 
pharmaceutical preparation (100 mg tablets) This preparation was subjected to a phase 
I tnal among patients with advanced malignancies which were refactory to “standard” 
therapies or for which no “standard” effective therapies existed Patients were treated 
with 7-hydroxycoumann as a single daily oral schedule at doses 100 mg - 7000 mg (see 
section 2 2 2 1 and Table 2 2) The study was halted at 7000 mg due to practical 
reasons The patients at the highest doses were taking 70 tablets as a single daily dose 
The timing of the blood sampling was chosen to allow the study to be earned out on an 
outpatient basis Samples were taken for the first 8 hours and at 24 hours (see Tables 
4 3 4 1 A-G) and analysed for total 7-hydroxycoumann content (free and conjugated)
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4 3.3 Patient selection criteria
Patients had to fulfil the following criteria to be eligible for the trial (taken from Marshall 
et al y personal communication, 1994)
1 Patients must have a histologically or cytologically confirmed diagnosis of cancer 
which is metastatic or unresectable
2 Patients must have bidimensionally measurable or evaluable disease which is 
refactory to standard therapies or for which no standard effective therapy exists
3 Patients may have received any prior therapy for their disease but must be at 
least 4 weeks remote from the last treatment (6 weeks if a nitrosourea) and have 
recovered from any toxicities associated with such therapy
4 Patients may not receive concomitant chemotherapy, immunotherapy, radiation 
therapy or hormonal therapy (except oral contraceptives) while on this study
5 Patients must have an ECOG performance status of 0-2
6 Patients must have adequate baseline organ functions (measured within 14 days 
of beginning treatment) defined as WBC > 3,000/ mm3, platelets > 100,000/ mm3, 
hemoglobin > 10 0, normal bilirubin, 1 5 X upper limit of normal > SGOT, 2 0 > serum 
creatinine or a creatinine clearance (measured or estimated) > 60 ml/min
7 Patients must be at least 3 months remote from myocardial infarction and with 
no residual angina or congestive heart failure Patients with angina pectons are not 
eligible Patients with poorly controlled cardiac anythmias are not eligible
8 Pregnant or lactadng women are not eligible for this study Men and women of 
reproductive age and capacity must use an effective form of contraception
9 Patients must be informed of the investigational nature of the study and must 
give wntten informed consent to participate
4.3.4 The determination of total 7-hydroxycoumann in serum samples
The method of Egan and O’Kennedy (1992), was developed for the determination of 
free and total 7-hydroxycoumann in unne and plasma The method was then adapted 
and applied to the determination of total 7-hydroxycoumann in serum samples taken 
from patients who had been treated with a single oral dose of 7-hydroxycoumann
1 6 2
Blood samples were taken at specific times and analysed as outlined in section 2 2 2 2 
and 2 3 2 1
4 3 41 Total 7-hydroxycoumann concentrations
Figure 4 3 4 1 1 shows a chromatogram of 7-hydroxycoumann standards and the 
internal standard spiked in serum, treated with P-glucuromdase, extracted, reconstituted 
and analysed by HPLC as described in section 2 2 2 2 and 2 2 3 1
Time (min)
Figure 4 3 4 1 1  Chromatogram showing the overlay o f the separation o f (A) 7-
hydroxycoumann standards [0 jjg/ml (red), 10 jug/ml (blue) and 50 fjg/ml (black)] 
and the internal standard (B) 7-amino-4-methyl-coumann prepared in serum, 
extracted and analysed by the method o f Egan and O’Kennedy, as described in 
section 2 2 2  2 The samples were separated by reverse-phase HPLC on a C18 
column under isocratic conditions (see section 42  3 1 )  with detection at 320 nnu
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A standard curve of 7 - hydroxy coumann versus peak absorbance ratio was prepared as 
outlined under section 2 2 2 2 Figure 4 3 4 12 shows a typical standard curve plot 
obtained The equation of the line was Y = 1 26 E-2 + 4 34 E-2, R2 = 0 99 The 
standard curves were prepared daily with every set of analysis of ‘unknowns’ The 
regression coefficient (R2) was typically at least 0 99 Table 4 3 4 1 (A-G) are the 
results obtained for the study The study consisted of 59 patients and the range of doses 
was between 100 mg and 7000 mg The tables give the total 7-hydroxycoumann (free 
and conjugated) concentrations, determined by HPLC, in serum from each of the 
patients at the different sampling times and the related dose administered
7-OHC concentration [ug/ml]
Figure 4 3  4 1 2  A standard curve plot o f 7-hydroxycoumann concentration 
versus peak absorbance ratio The standards were prepared in serum and treated as 
outlined in section 2 2 2 2 They were then analysed by HPLC as outlined in section 
2 3 2 1  The peak absorbance ratio was calculated from the peak absorbances o f the 
internal standard and the 7-hydroxycoumann standard. Standard curves were 
prepared daily The equation o f the line is Y = 0 01 +0 04 X R2 = 099
164
Time Day 1 Day 15 Day 1 Day 15 Day 1 Day 15
nun |Ag/ml |xg/ml |xg/ml Hg/ml |Xg/ml Hg/mi
PI 100 P2 100 P3 100M 56 RCC F 60 CAR M 50 RCC
0 0 0 0 0 0 05 0 0 0 0 0 015 0 0 0 0 030 0 0 0 0 0 045 0 05 0 0 0 060 1 8 16 1 8 0 0
120 09 1 13 0 0 0240 0 09 05 16 0 06480 0 06 0 05 0 091440 0 0 0 0 0 0
P4 300 P5 300 P6 300F 50 RCC F 60 RCC M 48 NSL0 0 05 0 05 0 05 0 015 0 0 05 0 030 0 0 05 045 0 0 05 0 060 0 0 05 12 1 1
120 1 1 0 06 20 60240 57 0 55 22 82480 26 29 08 0 561440 0 0 0 0 0
P7 500 P8 500 P9 500F 71 RCC F 82 RCC M 70 RCC0 0 0 0 0 095 0 0 0 0 0915 0 0 0 0 1030 0 0 0 3 1 1045 16 0 23 82 2760 30 0 58 12 0 3 1
120 62 33 11 7 184 92240 65 71 10 5 14 7 13 4480 14 38 43 10 1 1121440 0 0 0
Table 4 341 A-G A table of the 7-hydroxy coumann serum concentrations as determined by 
HPLC and the times at which samples of serum were taken The results are given as the patient 
number and the dose administered to the patient i e P5 300 F 60 RCC represents patient number 5 
(female, 60 years old who was diagnosed with renal cell carcinoma) and she was administered 300 
mg of 7-hydroxycoumarin Where there are spaces in the data indicates that there was no sample 
available at this time or the patient did not partake in the study i e patient 4 did not undergo the day 
15 drug trial and thus, there was no serum samples to be analysed For the abbreviations used see 
Table 4341G The patients were administered the drug on two days, Day 1 and 14 days later i e 
Day 15 Serum samples were taken on both days and analysed for total 7-hydroxycoumann.
PTO
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Tim e Day 1 Day 15 Day 1 Day 15 Day 1 Day 15
nun Mg/ml |ig/ml |xg/mì Hg/ml M'g/ml Mg/ml
PIO 700 PII 700 PI 2 700
M68 COL F62NSL F 65 COL0 0 0 0 0 0 065 0 0 0 0 0615 0 0 06 0 0 0630 0 0 10 0 0 1 145 09 05 1 1 0 0 1560 35 16 1 3 11 0 26120 92 66 36 60 1 3 42240 64 86 82 24480 20 23 24 56 5 1 221440 10 0 0 0
PI 3 900 P14 900 P15 900
M 52 BLD F 62 COL F 27 SAR0 0 0 0 0 05 0 0 0 0 015 0 0 0 0 030 0 0 0 0 045 0 06 0 0 1 360 07 14 0 07120 1 8 60 38 99 20240 11 0 70 96 69 97480 44 37 60 67 331440 0 0 0 0 0
Pi 6 1200 P17 1200 P18 1200
M  54 COL F 66 NSL F 38 COL0 0 0 07 05 05 0 0 05 05 015 0 0 06 05 030 0 07 06 09 0545 0 86 1 3 19 0760 07 10 7 24 23 10120 1 1 20 1 96 50 1 7240 19 3 95 25 7 26 9 36480 14 3 20 10 4 10 8 1161440 28 0 06 0 08
Table 4 3 4  I B
P T O
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Tim e Day 1 Day 15 Day 1 Day 15 Day 1 Day 15
min jig/ml Hg/ml |xg/ml Mg/ml Mg/ml |xg/ml
PI 9 1500 P20 1500 P21 1500M 53 RCC F76NSL F 47 ADR
0 0 0 0 1 1 295 0 0 0 1 1 2515 0 0 19 12 2530 0 09 35 1 1 3045 0 2 6 57 1 1 6960 1 1 45 79 2 1 118120 57 14 8 27 7 26 9 23 4240 6 6 440 28 0 30 8 25 9480 28 94 12 8 22 81440 58 0 2 6 2 6 26
P22 2000 P23 2000 P24 2000F 60 RCC F 68 NSR M 61 COL0 0 0 0 0 05 0 0 0 0 015 0 0 0 0 030 0 07 0 18 7845 05 1 3 0 34 18 860 39 4 6 0 89 35 0120 25 8 36 2 35 118 50 0240 17 9 17 2 33 6 33 6 24 7480 2 1 73 114 118 881440 0 0 0 0
P25 2500 P26 2500 P27 2500F 75 CAR M 67 COL F 47 COL0 0 0 0 0 05 0 0 0 0 015 0 0 0 0 030 0 0 0 0 045 0 16 35 05 060 0 6 2 50 33 0120 114 36 2 23 6 119 7 6240 32 5 39 5 15 7 500 33 0480 25 1 114 10 3 16 9 721440 0 0 20 09
Table 43  41  C
P T O
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Tim e Day 1 Day 15 Day 1 Day 15 Day 1 Day 15
nun |ig/ml Mg/ml Hg/ml lig/mi Mg/ml Mg/ml
P28 3000 P29 3000 P30 3000M 58 COL F 57 RCC F 66 RCC
0 10 08 20 0 535 1 0 08 4 6 0 5015 1 0 5 2 0 4 630 20 0 9 6 0 0 4 945 3 6 13 61 15 6560 63 30 70 74 14 8120 19 6 88 10 9 30 0 33 1
240 51 2 79 5 708 515 416480 10 3 60 3 36 6 25 71440 0 8 10 6 19 1 76
P31 3500 P32 3500 P33 3500M 65 BRC F 75 CAR F 71 CAR0 0 0 6 0 29 0 085 0 0 6 0 2 7 0 0815 0 0 6 0 25 0 0830 12 3 28 0 25 0 1045 22 0 6 1 0 4 23 0 2060 40 5 12 1 1 7 2 0 10 36120 52 1 45 6 12 0 2 0 95 13 1240 39 8 32 0 20 2 83 43 7 26 7480 6 1 55 39 1 13 3 35 6 33 91440 0 4 7 0 20
P34 4000 P35 4000 P36 4000F 69 COL M 79 CAR F 38 GBL0 0 54 0 0 0 605 0 4 8 0 0 4 815 0 4 9 0 0 0 5030 0 4 4 1 1 1 2 0 5 145 0 53 1 8 5 0 0 4960 0 12 7 39 10 3 0 48120 10 6 26 7 17 3 25 6 0 52240 39 2 33 2 616 761 0 52480 61 6 23 1 28 8 41 0 29 761440 1 1 3 2 12 18 6 6 63
Table 43  41 D
P T O
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Tim e Day 1 Day 15 Day 1 Day 15 Day 1 Day 15
m m jxg/ml M£/ml Mg/ml M'g/ml Mg/ml M-g/ml
P37 4500 P38 4500 P39 4500
M 69 COL M 61 PRS M 66 PAR
0 0 0 0 9 1 0 105 0 0 0 85 0 0915 0 0 0 90 0 0830 0 0 0 80 0 07
45 0 0 0 78 3 3 07
60 0 0 0 97 77 08120 0 0 95 513 36 0 98240 0 0 1169 93 2 66 5 59 4
480 20 6 11 3 68 0 643 29 2 45 11440 115 83 55 93 38 05
P40 5000 P41 5000 P42 5000F58RCC M 46 CAR F 54 RCC0 0 0 0 14 0 455 0 0 0 1 2 0 3715 0 0 0 1 1 0 3430 0 0 0 32 19 3545 4 4 1 3 15 13 9 77 3460 22 2 37 10 26 8 79 4 7120 54 9 6 6 17 9 41 8 12 1 53240 25 3 77 4 25 7 16 0 18 3 48 4480 52 95 6 7 14 3 50 9 62 31440 0 0 0 0 18 93
P43 5500 P44 5500
M 65 PRS M 69 PRS
0 12 12 0 185 1 2 1 5 0 1715 1 1 10 0 1 630 26 5 0 0 1 645 7 6 117 0 1860 13 3 25 8 0 22120 32 9 82 0 24 8 13 1240 100 0 78 0 504 48 0480 47 4 31 2 12 1 11 41440 14 1 5 21 30
Table 43  41 E
P T O
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Tim e Day 1 Day 15 Day 1 Day 15 Day 1 Day 15
mm fig/ml ^ig/ml Mg/ml P-g/ml Hg/ml Hg/ml
P45 6000 P46 6000 P47 6000F 72 NSL F 61 REC M 61 PRS0 0 61 0 30 0 1 15 0 58 2 6 0 1 115 2 0 53 2 6 0 1630 6 0 2 6 0 1 345 1 2 6 0 39 0 17 860 39 9 0 79 09 32 7120 18 6 56 7 415 10 6 67 0240 801 73 5 130 2 54 2 75 6 103 5480 32 5 89 8 710 75 2 40 31440 39 4 8 4 1 82 12
P48 6500 P49 6500 P50 6500M 77 RCC M 61 COL M 64 COL0 0 34 0 24 0 2 15 0 30 0 2 1 0 2715 0 32 0 2 2 0 1830 0 3 1 0 1 8 08 2045 0 3 1 0 7 19 1 1 1 960 0 3 1 10 2 2 27 1 9120 6 2 117 73 38 13 7 14 3240 28 1 210 77 5 23 3 418 40 8480 49 4 56 8 s 640 112 8 19 7 19 41440 18 6 17 6 3 1 12 4 30 4 4
P51 6500 P52 6500 P53 6500M 57 PRS M 45 COL M 75 PRS0 0 0 0 6 2 0 075 0 0 0 59 0 0 615 0 0 0 57 0 0530 0 0 0 7 9 0 0 0745 0 07 08 84 0 6 0860 11 3 32 13 7 1 1 1 14120 52 2 38 2 12 9 27 0 10 0 10 0240 50 9 74 5 73 3 70 8 264 36 5480 22 4 13 8 28 3 31 0 23 5 37 71440 09 1 9 36 89 11 7
Table 43  4 1 F
P T O
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Tim e Day 1 Day 15 Day 1 Day 15 Day 1 Day 15
min Mg/ml Mg/ml |xg/ml |Xg/ml M-g/ml M-g/ml
P54 7000 P55 7000 P56 7000F 70 HEP M 67 PRS F 37 HEP0 0 32 0 0 29 0 1 85 0 28 4 0 2 9 0 1515 0 27 2 0 2 6 0 1 330 0 22 9 0 2 6 0 1445 0 21 1 0 2 6 07 1 960 0 18 9 0 3 1 10 29120 07 16 3 95 53 7 30 83240 29 9 61 3 131 2 144 8 10 9 15 3480 105 2 142 3 87 8 69 4 16 2 14 21440 4 7 1 8 33 4 6 15 4 18 6
P57 7000 P58 7000 P59 7000M 64 PRS F 60 SCL M 65 RCC0 0 6 0 0 6 0 235 0 6 0 0 6 0 1815 05 0 05 0 1630 07 07 0 8 0 1645 08 2 0 2 2 07 1 860 1 4 39 6 9 09 22120 10 0 22 1 15 3 43 2 63 9240 36 5 640 50 3 94 8 108 6480 37 8 314 26 4 34 8 39 21440 11 7 36 24 3 1 75
Table 43  41 G
The abbreviations used, fo r  the cancer diagnosis fo r each patient in the table, are as 
follows RCC - renal cell carcinoma, NSL  - non-small cell lung, PRS - 
prostate, REC - rectal, - hepatoma, SCL - sma// a?// Zu/ig, CA/? - carcinoid,
COL - co/on, G2?L - ga// bladder, BRC - bronchial carcinoma, ATCS - neurosarcoma, 
- adrenal, SAR  - sarcoma, BLD  - bladder
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On direct observation of the results it is clearly seen that there is a large mtenndividuali
variability in the levels of total 7-hydroxycoumann circulating in the serum of patients 
after the administration of the drug The time at maximal concentration vanes from 
patient to patient A large proportion of the patients have a maximal concentration of 7- 
hydroxycoumann at 4 h but some also have peak maxima at 2 h, and at 8 h The profile 
for drug level in the blood for a ‘typical5 patient is shown in Figure 4 3 4 2 1
4 3  4 2 The analysis o f the data
.a"Ho
oaoo
O«o
o o 240 0 480 0 720 0 960 0
T im e (m m )
1200 0 1440 0
Figure 4 3  4 2 1  Plot o f time versus total 7-hydroxycoumann concentration fo r
a patient who had been treated with 4 5 g o f 7-hydroxycoumann (P39 4500 -see 
Table 4 3 41 E )  It is clearly seen that the peak maxima is at 4 h and after 24 h the 
level o f  drug in the serum has decreased significantly The samples were prepared as 
descnbed in section 2 2 2 2 and analysed by reverse-phase HPLC on a C l8 column 
under isocratic conditions with detection at 320 nm The concentrations were 
calculated from  a plot o f  absorbance ratio versus 7-hydroxycoumann concentration 
(see Figure 43  4 1 2 )
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Unfortunately serum samples for some of the patients were not available and thus, it was 
sometimes impossible to determine peak maxima times and maximum 7- 
hydroxycoumann concentrations A single oral dose of the drug was administered to 
each of the patients on each of two days On day 1 and day 15 samples of blood were 
taken before and after administration of 7-hydroxycoumann It was possible in some 
patients to observe a circulating ‘pool’ of the drug 14 days after the initial administration 
e g P38, P54 In patients P21, P57 7-hydroxycoumann was found in their serum 
samples before they were treated on Day 1 The source of the 7-hydroxycoumann was 
not determined as the clinical data and history for each patient was not included with the 
serum samples It was not possible to access the clinical data and correlate it to the 
observed serum profiles, the concentrations of 7-hydroxycoumann determined, the drug 
disposition and the peak maxima In order to correlate the results it was decided to 
determine the area under the curve from a plot of time versus total 7-hydroxycoumann 
concentration (Figure 4 3 4 2 2)
Figure 4 3  4 2 2  Plot o f time versus total 7-hydroxycoumann concentration in 
serum fo r a patient who had been orally treated with 7-hydroxycoumann The area 
under the curve (shaded area) was calculated and utilised in assessing a relationship 
between dose administered and drug disposition The serum samples were prepared 
as descnbed in section 2 2 2 2  and analysed by reverse-phase HPLC on a C18 
column under isocratic conditions with detection at 320 nm The concentrations 
were calculated from a plot o f absorbance ratio versus 7-hydroxycoumarin 
concentration (see Figure 4 3 4 L2 )
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This would allow the determination of a relationship, if any, between the dose 
administered and the level of total 7-hydroxycoumann found circulating in the serum 
When the area under the curve is plotted against the dose administered it is possible to 
see that there is a very large intenndividual variability between the patients for each of 
the doses administered (Figure 4 3 4 2 3 )
7-hydroxycoumann administered (mg)
Figure 4 3 4 2 3  A plot o f the area under the curve (see Figure 4 3 4 2 2 )  versus 
7-hydroxycoumann dose administered (mg) The plot includes the data observed for  
patients (with complete data sets) fo r  analysis on both days o f the study The plot 
shows a large vanabihty in the amount o f 7-hydroxycoumann present in the patients 
serum fo r each dose administered and between different doses
Figure 4 3 4 2 4 is a plot of the mean area under the curve ± standard deviation about 
the mean for each of the doses administered (the results from the studies on both days
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are combined for this figure) The plot of the mean area under the curve versus the dose 
of 7-hydroxycoumann administered shows a linear relationship between the amount of 
drug present over time and the dose administered (Figure 4 3 4 2 4 )  Table 4 3 4 2  1 
are the results in tabular form It is clearly seen from the results in the table that there is 
up to 80 % difference between some patients in the same dosage group The results 
were determined for complete sets of data and all incomplete data sets were ignored
7-hydroxycoumarin administered (mg)
Figure 4 3  4 2 4  A plot o f the mean area under the curve ± standard deviation 
versus the dose o f 7-hydroxycoumann administered to each patient The equation o f 
the line is Y = 733 5 + 7 03X R2 = 0 84 Serum samples were taken from patients 
treated orally with 7-hydroxycoumann, and analysed by HPLC (see section 2 2 2 2 
and 2 2 3 1 ) The area under the curve was determined from the profile o f time 
versus total 7-hydroxycoumann concentration fo r  each patient (see Figure 
4 3 4 2 2 )
The results display that there is a large intenndividual variability in 7-hydroxycoumann 
metabolism and release into the circulation This has previously been observed for 
coumann (Rautio et a l , 1992, Iscan et a l , 1994) and is now shown for 7- 
hydroxycoumann The standard deviation about the mean area under the curve vanes
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from 20 % to 76 % (Table 4 3 4 2 1 ) again illustrating the intenndividual variability in 
the 7-hydroxycoumann metabolism
7-Hydroxycoumarm
Administered
Mean Area 
Under the 
Curve
± Standard 
Deviation
% RSD n = x
(mg) (AU)
100 468 3 239 3 510 5
300 2407 2 1835 6 76 0 5
500 6688 2 3715 0 55 5 5
700 2761 5 7012 25 4 4
900 4932 0 981 6 20 0 5
1200 8712 4 3215 6 36 9 5
1500 16315 5 4674 8 28 6 5
2000 12327 0 3526 2 28 6 5
2500 16689 6 4919 9 29 5 5
3000 32489 8 17650 8 54 3 5
3500 21545 5 7988 4 37 1 6
4000 26163 3 16600 0 63 4 6
4500 38842 0 22987 0 59 2 6
5000 24724 0 15984 5 642 6
5500 32718 7 16228 0 500 4
6000 61423 5 15424 4 25 1 4
6500 37559 0 16549 8 440 12
7000 50876 8 26860 4 52 8 11
Table 43  4 2 1  Table o f the mean area under the curve ± standard deviation, 
and % relative standard deviation (% RSD) and the number o f data points (n = x) 
Serum samples were taken from patients treated orally with 7-hydroxycoumann, and 
analysed by HPLC (see section 2 2 2 2  and 2 2 3 1 )  The area under the curve was 
determined from  the profile o f time versus total 7-hydroxycoumann concentration 
for each patient (see Figure 43  4 2 2 )  The mean area under the curve was 
determined fo r  n=4 - n=12,for each o f the doses o f 7-hydroxycoumann administered 
(100 mg - 7000 mg)
Hansen and Stentoft (1995) and Herman et a l , (1994) reported on intenndividual 
vanability in the rates of glucuromdation Hansen and Stentoft (1995) reported up to a 
seven fold difference in undine diphosphate glucuronyl transferase activity in human 
livers for the glucuromdation of benzazepine They also reported an age-related
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decrease in activity There was no age related differences in the glucuromdation of 7- 
hydroxycoumann observed in this study (results not shown) Herman et a l, (1994) 
reported on the metabolism of diflumsal to diflumsal sulphate and diflumsal phenolic 
glucuromde and diflumsal acyl glucuromde in 110 volunteers They found that the 
metabolism of the drug is altered by cigarette smoking and oral contraceptives The 
medical histories of each of the patients or their smoking status was not included It 
was, thus, not possible to assign the intenndividual vananon in the glucuromdation of 7- 
hydroxycoumann to their smoking status (i e smoker or non-smoker) or if they were 
taking oral contraceptives
Coumann is metabolised in humans by cytochrome P4502A6 (see section 3 2 1) 
However, the ‘phase I’ metabolism step is by-passed and the drug progresses straight to 
glucuromdation, referred to as ‘phase II’ metabolism (see section 3 2 3 ) The majonty 
of work previously earned out has focused on the Phase I metabolism and the vanabihty 
both between species and within species vanabihty (see section 3 2 1) The results, 
shown here, also show a large scale vanabihty in the phase II metabolism and the 
enzymes involved in the further metabolism of coumann in man after the initial phase I 
metabolism Thus, the large intenndividual vanabihty in coumann metabolism is not 
dependent solely on the phase I metabolising enzymes but also phase II metabolism
It has been proven both in vivo and in vitro that there is this vanabihty in the 
cytochrome P450 enzyme activity within species and between species but in addition to 
this fact it must now be correlated with the fact that there is also a large vanabihty in the 
secondary metabolism of coumann i e the glucuromdation of 7-hydroxycoumann, the 
release of the drug into the serum and the availability of free or conjugated drug Free 
drug was not determined as part of this study for practical reasons However, the serum 
samples were also analysed by another HPLC method (see section 4 13 3) and it was 
possible to determine both free and conjugated drug circulating in the serum 98 % of 
the 7-hydroxycoumann present in the serum was present as the glucuromde form with 
up to only 2 % of it was circulating in the free form The exact pharmacological role of 
the glucuromde conjugate has not as yet been determined (a review on glucuromdes is
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given in section 3 2 3 ) Again it was not possible to access the clinical effects of the 
drug and the response of the patients to the treatment The clinical results have not been 
released However, the true maximally tolerated dose and dose-limiting toxicity were 
not determined in the study due to the low level of toxicity from the drug
Summary
HPLC was shown to be an excellent tool for the determination of 7-hydroxycoumann 
and 7-hydroxycoumann-glucuromde in serum, plasma, urine and for studying the in 
vitro metabolism of 7-hydroxycoumann HPLC was also used for the determination of 
7-hydroxycoumann after the in vitro metabolism of coumann (see section 3 2 2 1 ) The 
determination of 7-hydroxycoumann in unne was determined by an enzyme-linked 
immunosorbent assay (ELISA) and compared to HPLC (see section 5 4 1) There was 
no statistical difference between the two methods All samples analysed by capillary 
electrophoresis were also analysed by HPLC and there was no statistical difference 
between either of the methods
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PRODUCTION AND CHARACTERISATION OF AN 
ANTI-7-H YDROX Y C OUM ARIN ANTIBODY
CHAPTER 5
5.0 INTRODUCTION 
5 1 . ANTIBODIES
5.11. Antibody structure and functions
5.1.2. Antibody-Antigen interaction
5 1 2 1  Forces that bind Antibody to Antigen
5 1 2 2  Antibody Affinity
5 1 2  3 Avidity and the bonus effect o f  m ultivalent binding
5 1 2  4 Cross-Reactivity
5.1 3 Antibody production
5 1 3 1  Polyclonal antibodies
5 1 3 2  M onoclonal antibody production
5 1 3  3 Antibody engineering
5 1 3  4 Bifunctional antibodies
5.1.4 Detection systems for the measurement of antibody-antigen 
interactions
5 1 4 1  Enzym e-Linked Imm unosorbent Assay (ELISA)
5 1 4 2  Determination o f  7-hydroxycoum ann by an antigen- 
inhibition ELISA
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5 2. PRODUCTION OF 7-HYDROXYCOUMARIN-PROTEIN CONJUGATES 
USED FOR IMMUNISATION TO PRODUCE ANTI-7-HYDROXYCOUMARIN 
ANTIBODIES AND FOR THE SCREENING OF THESE ANTIBODIES.
5 2.1 Synthesis and characterisation of 7-hydroxycoumarin derivatives 
5 2 1 1  3-acetylam ino-7-acetoxycoum ann
5 2 1 2  3 -am ino-7-hydroxycoum ann
5 2 1 3  Characterisation o f  thyroglobuhn-7-hydroxycoumann  
and bovine serum album in-7-hydroxycoumann  
conjugates
5 2 1 3 1  Ultraviolet (UV) spectral analysis
5 2 1 3 2  Analysis o f  conjugates by gel filtration - 
Sephadex G25 column
5 2 1 3 3  Analysis o f  the conjugates by HPLC  
5 3. PRODUCTION AND PURIFICATION OF 
ANTI-7-HYDROXYCOUMARIN ANTIBODIES
5.3 1 Purification of anti-7-hydroxycoumarin antibodies from serum 
5 3.2 Analysis of an anti-7-hydroxycoumarm antibody by HPLC
5.3 3 Determination of antibody activity titre
5 3 4. Cross-reactivity of the anti-7-hydroxycoumarin antibody 
5 3 5. The use of the anti-7-hydroxycoumarm antibody for the
determination of free and total 7-hydroxycoumann in urine 
5 3 5 1  ELISA m ethod
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This chapter describes the production of polyclonal sera to 7-hydroxycoumann Drugs 
(with a molecular weight less than 5000 Da - Catty and Raykundalia, 1988) like 7- 
hydroxycoumann are too small to elicit an immune response and must be conjugated to 
other molecules (usually a protein) for use in antibody production Examples of proteins 
used for conjugation are thyroglobulin, bovine serum albumin (BSA), ovalbumin and 
keyhole limpet haemocyamn (KLH) These protem-drug conjugates are immunogenic 
and can be used for the raising of antibodies after immunisation of a host One of the 
protein-drug conjugates is generally used for immunisation while another conjugate is 
used for screening for antibody production The antiserum was produced in rabbits, by 
immunising with 7-hydroxycoumann, coupled to a protein (thyroglobulin), and the 
resultant antibodies were punfied and used in an enzyme-linked immunosorbent assay 
(ELISA) for the determination of free and total 7-hydroxycoumann in unne The anti-7- 
hydroxycoumann antibodies produced were also used for the development of a 
bispecific antibody (anti-7-hydroxycoumann - anti-alkaline phosphatase antibody) [see 
section 14 112], in electrochemical based sensors for the determination of 7- 
hydroxycoumann in unne (see section 14 2) and in the determination of total 7- 
hydroxycoumann in serum on a commercial biosensor system - the BIAcore™ from 
Pharmacia Biosensor (see section 14 3)
51 ANTIBODIES
The ability to stimulate the production of specific antibodies, in a particular host, is not 
an inherent property of a substance An antigen is a substance capable of stimulating the 
immune system of an animal to produce a response specific to it - this may be antibody 
production, cell-mediated immunity or tolerance (Catty and Raykundalia, 1988, Rom el 
a l, 1989, Roitt, 1994, Kuby, 1994) Antigens must be ‘foreign’ to activate the defence 
mechanisms and it must be of a certain complexity to react with the different 
components of the immune system necessary to induce the immune response (Tijssen, 
1985) Antigens may be divided into two main groups 1 Immunogens are substances
5 0 INTRODUCTION
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which are themselves capable of eliciting an antibody response Their antigenic 
determinant usually consists of a short sequence or part of the whole molecule called an 
epitope which ‘fit’ into an antigen-antibody binding site (the paratope) The epitopes of 
one antigen are usually different from those on another antigen Some antigens have 
repeated epitopes Epitopes are molecular shapes recognised by the antibodies and cells 
of the adaptive immune system Each antibody recognises one epitope rather than the 
whole antigen Even simple organisms have many different antigens 2 Another form 
of antigen is a hapten Haptens are substances which themselves are incapable of 
inducing an immune response but will do so if attached to a earner like a protein e g 
BSA, thyroglobulm or KLH
“The recognition of a foreign antigen is the hallmark of the specific adaptive immune 
response” (Roitt et a l, 1989) Two distinct molecules are involved in the process le 
the immunoglobulins (Ig) and the T-cell antigen receptors Antibodies are a group of 
glycoproteins present in the serum and tissue fluid of all mammals They are produced 
by plasma cells which have developed from precursor B lymphocytes Contact between 
these B lymphocytes and a foreign antigen is required for the induction of antibody 
formation
5 11 Antibody structure and functions
The structure of an antibody is shown in Figure 5 11 An antibody consists of heavy 
and light chains which are joined by disulphide linkages A ‘basic5 antibody consists of 
two light (ca 25 kDa) and two heavy (ca 50 kDa) chains and has a relative molecular 
mass of 150-160 kDa The (H) heavy and (L) light chains of the antibody can be further 
divided into vanable (V) and constant (C) regions ChI, Ch2 and Ch3 refer to vanous 
constant domains on the heavy chain Within the vanable regions there are certain areas 
which are highly conserved and provide a backbone for the structure There are also 
hyper-vanable areas called complementanty determining regions (CDR) which are 
involved in defining the binding specificity of the antibody (Killard et al, 1995, Cahill et 
a l, 1995) The constant regions (Fc) of the antibody are involved in binding to cell 
surface receptors The Fc region undergoes a change in conformation on antigen
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binding to the Fab region The hinge region (H) allows flexibility and some degree of 
freedom for the two arms of the antibody molecule The antibody exposes sites, using 
conformational 3-D structural changes, for antigen binding The 3-D structure of IgG 
consists of P-pleated sheets (constant region), connecting loops (hypervanable regions), 
and P-sheets connected by disulphide linkages which sandwich the hydrophobic intenor 
The carbohydrate moiety on the Ch2 region functions in stabilisation of the antibody, in 
inhibiting proteolytic digestion and secretion and may play a role in specifying antibody 
configuration There are five classes of immunoglobulins 1 e IgG, IgA, IgM, IgD and 
IgE IgG is the predominant form of antibody found in the serum
ANTIGENBINDING VARIABLE REGION
Figure 5 1 1  The basic structure o f  an immunoglobulin (IgG) An antibody 
consists o f  heavy (H) and light chain (L) which are jo in ed  by disulphide linkages 
with carbohydrate chains on the constant heavy chain (Ch2) The antibody can be 
fu rther divided into variable (V) and constant (C) regions C h1£,3,4, refer to various 
constant functional dom ains There is also the hinge (H) region that allows 
flexibility and some degree o f  freedom  fo r  the two arms o f  the antibody molecule 
The antibody can be broken down into fragm ents by treatm ent with enzymes such as 
pepsin and papain Two antigen binding fragm ents (F(ab') ) o f  the IgG , containing 
one antigen binding site each, and one crystalhsable fragm ent (Fc) are produced by 
papain digestion o f  the IgG The antigen binding fragm ent (F(aV )2 ) o f  the IgG , 
containing two antigen binding sites, is obtained by pepsin digestion o f  the IgG The 
heavy chain fragm ents rem aining after pepsin digestion are called F cr fragm ents 
The complementarity determining region (CDR) are the hyper-vanable regions 
within the variable regions and  are prim arily responsible fo r  antigen binding The 
structure is adapted from  the structure in Killard et a l , (1995)
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5 12 Antibody-Antigen interaction
5 1 2 1  Forces that bind Antibody to Antigen
The folding of the variable chains of the light and heavy chains (see Figure 5 11) forms 
a 3-D binding spaces which are complementary, with respect to its shape and its charge 
distribution, to the antigenic determinant allowing it to ‘fit’ into the binding site The 
forces that hold an antigen and an antibody together may be classified under four 
headings (Roitt, 1980, Roitt 1994)
(a) Electrostatic forces are due to the attraction between two oppositely charged ionic 
groups on a protein side chains e g the binding of and ionised ammo group (NH3O and 
an ionised carboxyl group (COO) The force of attraction (F) is inversely proportional 
to the square of the distance between the charges (Equation 5 12 11)
Equation 5 1 2 1 1  F lief
(b) Hydrogen bonding These are relatively weak and reversible hydrogen bridges 
formed between hydrophilic groups such as -OH, -NH2, and -COOH and the forces are 
dependent on the close approach of the two molecules carrying these groups
(c) Hydrophobic attraction is the interaction between hydrophobic groups to exclude 
water If the net surface, of the hydrophobic region, in contact with water is reduced 
(e g after the exclusion of water by the binding of antibody-antigen) there is a lower 
energy state formed between the two species, relative to no binding, forming a stable 
bond with a high force of attraction It has been estimated that the hydrophobic forced 
may contribute up to 50 % of the total strength of the antigen-antibody bond
(d) Van der Waals Forces This is the attraction between the external cloud electrons 
on the two species The force of attraction is inversely proportional to the seventh 
power of the distance (Equation 5 12 12)
Equation 5 1 2 1 2  F lid7
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5 1 2 2  Antibody Affinity
The antibody affinity is the strength of a single antibody/antigen bond, 1 e it is the sum 
of the attractive and repulsive forces between the antigen and the antibody Figure 
5 12 2 1 shows three of the possible affinities of an antibody/antigen interaction 
Antibody 1 Tits’ with nearly the whole of the hapten and is of high affinity Antibody 2 
fits with less of the molecule and not so tightly, and has a moderate binding affinity 
while the low affinity antibody 3 is complementary in shape to so litde of the hapten 
surface that its binding energy is very litde above that occurring between completely 
unrelated proteins or other macromolecules
Aaufody. 1. Antibody 2 Antibody 2
High binding affinity 
“good fit*
Moderate binding affinity Low binding affinity 
‘poor fit
Figure 5 1 2 2 1  Schematic representation o f  binding o f  antibodies present in 
the sam e antiserum with different ‘affinities’ to the same antigen Antibody 1 fits  
with nearly the whole o f  the hapten and is thus o f  high affinity Antibody 2 f its  with 
less o f  the molecule and not so tightlyy and has a moderate binding affinity while the 
low affinity Antibody 3 is complementary in shape to so little o f  the hapten surface 
that its binding energy is very little above that occurring between completely 
unrelated proteins Only a portion o f  the antibody binding site is shown Diagram  
adapted from  Roitt (1980)
The better the ‘fit’, both structurally and in charge distribution allowing the interactions 
detailed in section 5 12 1, the stronger the binding The combination of the antibody 
with the antigen is reversible and the complex may dissociate, depending on this binding
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strength (Equation 5 12 2 1) Equation 5 12 2 1 is the equilibrium formed between 
antibody (Ab) and antigen (Ag) and immune complex (Ab-Ag) where K* and Kd 
represent the association and dissociation constants (Tijssen, 1985)
KaEquation 5 1 2 2  1 [Ab] + [Ag] - [Ab-Ag]Kd
The equilibnum constant (average affinity constant - K, units are 11 mol) for the reaction 
(see Equation 5 12 2 1) between the antibody [Ab] and the hapten [Ag] is given in 
Equation 5 1 2 2 2 When the antibody and the antigen fit well together (high affinity 
binding - Figure 5 12 2 1) one gets an equilibnum that lies to the nght and vice versa 
for low affinity binding
Equation 5 1 2  2 2 K = iL = fAb-AglKd [Ab][Ag]
The affinity is dependent on the area of contact, on the approach of the two substances 
together and on the positioning of charged and hydrophobic groups in their respective 3- 
dimensional structures Antisera of multiple specificity (see section 5 13 2) cannot be 
assessed for affinity but the general charactenstics of the binding reaction, e g the 
strength of binding, can be utilised for companson of one antibody with another 
antibody This is the avidity of antibody interaction
5 1 2  3 Avidity and the bonus effect o f multivalent binding
The strength of the interaction of antibody with a monovalent hapten or a single antigen 
determinant is called antibody affinity In most situations the avidity, i e the binding due 
to the interaction of the antiserum with a multivalent antigen molecule, is of greater 
concern (Equation 5 12 3 1 - Roitt, 1980) Avidity is ‘how well’ the antigen binds to 
the antibody and it is dependent on the number of binding sites on the antigen (see 
Figure 5 12 3 1) It is the performance of the antiserum (antibodies) in a particular 
assay (Catty and Raykundalia, 1988)
Equation 5 1 2.3 1 nAb + mAg Ab„Agm
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Figure 5.1.2.3.1. illustrates the ‘bonus’ effect of antibody-antigen bonds. The binding of 
an antibody to two antigen molecules is greater than the sum the individual antibody 
links. The bond increases with increasing numbers of bridges formed between different 
antibodies to other epitopes.
(a) M oderate binding (b) M oderate binding (c) Very strong binding
Figure 5.1.2.3.1. Schematic representation o f the ‘bonus’ effect o f multivalent
attachment on binding strength. The force binding the two antigen molecules in (c) 
with two antibody bridges is often at least ten times greater then (a) + (b) where only 
single antibody bridges are formed. The effect varies with the average affinity 
constant (K) [see equation 5.12.2.2.]. Diagram taken from Roitt (1980).
The antibody-antigen reaction is reversible. If there is only one antibody binding two 
antigens i.e. one at each arm of the antibody, there is the possibility of separation of 
antibody and antigen with loss of the antigen. However, the formation of two antibody- 
antigen bridges will reduce the opportunity for dissociation of the antibody-antigen 
complex. This is illustrated in Figure 5.1.2.3.2.
(a) Single antibody 
bridge (b) Separation (c) No separation
Antigen Antib°dy X .
n  Antibody
Figure 5.12.3.2. Schematic representation o f the mechanism o f the bonus 
effect. Each antigen-antibody complex bond is reversible and with a single antibody 
bridge between the two antigens (a), dissociation o f either bond could result in the 
1loss’ o f one antigen as in (b). Two antibody bridges7 even when one is dissociated, 
prevents the ‘loss’ o f the second antigen, holding it in place fo r  the reform o f the 
other antigen-antibody bond. Diagram taken from Roitt (1980).
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5 1 2  4 Cross-Reactivity
An antiserum raised against a particular epitope or hapten may ‘cross-react’ with a 
partially related antigen which may have identical or similar determinants on its surface 
Figure 5 12 4 1 illustrates this effect
(a) Original (b) One identical (c) Similar (d) No structural
antigen determinant determinant similarity
Antigen Antibodies
Figure 5 1 2  4 1  Schematic representation o f  the cross-reactivity and specificity 
o f the antigen-antibody bond The avidity o f  the serum is greatest in (a) > (b) > (c) > 
(d) so that the antiserum shows specificity Two antibodies in (a) bind to the antigen 
In (b) only on o f  the antibodies has a strong binding affinity whereas the second 
antibody does not have any affinity fo r  the antigenic site In (c) the antigenic site is 
similar to the site in (b) and the antibody can recognise this and bind (with a lower 
affinity) - this antibody will show ‘cross-reactivity’ with the actual antibody to this 
site In (d) there is no structural similarities between the antigenic sites and the 
antibodies and no binding will occur or it will be very low Diagram taken from  
Roitt (1980)
The antiserum raised against the ‘original antigen’ will react more strongly than that of 
the antigen with an identical determinant which in turn reacts more strongly than the 
antigen with a similar determinant The weakest interaction will be for the antigen that 
has no structural similarity, 1 e there will be no significant reaction observed The 
specificity of the antiserum is thus determined by the cross-reactivity of the antibody- 
antigen (Section 5 3 4 describes the cross-reactivity of the anti-7-hydroxycoumann 
antibody produced)
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5 13 Antibody production
There is no single procedure for immunisation that guarantees an ideal antibody for a 
specific requirement Certain principles may be adopted which give a procedure which 
may be suited to a particular problem as immunogens and animals differ The essential 
properties of the antisera produced must be a high titre, good affinity and specificity 
(Catty and Raykundalia, 1988) The degree of stimulation of antigen-sensitive cells of 
the animals immune system will determine the affinity of the antibody There must be a 
high enough quantity of the immunogen present to allow an immune response Two 
criteria for antibody production are
1 Does the antigen need to be conjugated to a earner molecule or is it large 
enough to elicit an immune response by itself 9
2 How foreign is the antigen to the host (does the antigen require assistance to 
elicit an immune response by the addition of adjuvant and T-Helper cells to stimulate 
antibody production) 9
As soon as these questions are answered it is then possible to stimulate the immune 
system of a host species for the production of antibodies directed against the 
immunogen
The steps for antibody production are as follows
A host is chosen depending on the particular application Many different animals are 
used as host species e g mouse, rabbit, goat, donkey, horse and human The antigen 
can be soluble e g a protein, or insoluble e g protem-hapten The antigen is generally 
prepared in adjuvant, e g Freunds adjuvant (the adjuvant increases level of antibody 
response by causing inflammation and attracting macrophages to the site of injection) 
Having chosen the host, it is immunised, generally intradermally, subcutaneously or 
intrapentoneally with the immunogen or protein-hapten The host will respond to the 
invading species and produce antibodies In order to increase the quantity of antibody 
response the host is ‘boosted* by re-immunising Blood is taken from the host and the 
antibody titre (what dilution of antibody still gives reactivity against the antigen in vitro), 
specificity, affinity, stability, punty, class and isotype can be determined
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Some of the advantages of rabbit and mouse anti sera are now compared The 
applicability of rabbit antisera in precipitation reactions, and the relative ease of handling 
and breeding of rabbits make them ideal hosts - the immunoglobulin is easy to punfy and 
the antibodies produced are generally of high avidity/affinity for a particular 
immunoassay Mice only produce a few millilitres of blood and usually require sacrifice 
whereas rabbits can provide up to 100 ml or more without sacrificing the animal Rabbit 
antisera is used for the preparation of polyclonal antibodies (see section 5 13 1) Mouse 
spleen is usually used for the preparation of monoclonal antibodies (see section 5 13 2)
5 1 3 1  Polyclonal antibodies
Polyclonal antiserum is the serum product of an immunised animal, usually a rabbit, 
sheep or goat The major advantage of polyclonal sera is its capacity to form large 
insoluble immune complexes with antigen, or in agglutinating cells readily so that the 
reactions can be seen and measured visually or photometrically The disadvantages, 
which may limit their exploitation in immunoassays, is the heterogeneity in specificity 
between batches and between animals The polyclonal sera produced is heterogenous in 
the classes and subclasses, in the specificity, in the titre and in the affinity of the 
antibodies produced In one antiserum the antibodies present will be to many different 
antigens, or to only a few but the antibodies produced will never be homogenous 
Different antibodies may compete for the same epitope with varying degrees of affinity 
(see section 5 12 2) The polyclonal antiserum produced, after immunisation, will be 
unique in specific antibody composition, in optimal binding conditions and in its 
performance in an immunoassay Affinity purification may be necessary for individual 
applications, e g preparation of bispecific antibodies (see section 5 13 4) The 
determination of fine structural and antigenic differences at the individual epitope level is 
not feasible with polyclonal antisera due to the heterogeneity and variations between 
batches and animals
Polyclonal antibodies can be developed quickly and relatively cheaply and do not require 
the amount of time or expertise required for the production of monoclonal antibodies
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(see section 5 13 2) Antiserum levels can be determined by ELISA and qualitatively 
by Immunoelectrophoresis When a high titre of antibody is found the polyclonal 
antibodies can be purified by ammonium sulphate precipitation and affinity 
chromatography Milligram quantities of punfied antibody may be obtained from a few 
millilitres of serum Table 5 13 1 is a comparison of some of the properties of 
monoclonal and polyclonal antibodies (Tijssen, 1985)
Property Monoclonal Polyclonal
Punty of immunogen not of pnme importance important
Time and expense miually high little
Useful antibody content 0 5-5 mg/ml (ascites) < 1 mg/ml-few mg/ml
5-40 jAg/ml (medium)
Irrelevant Ig 0 5-1 mg/ml about 10 mg/ml
Physicochemical properties individual spectrum which changes
Cross-reactivity to copunfying negauve (-) posiUve (+)
immunogens
Cross-reacuvity removable 9 no mostly
Number of epitopes recognised 1 many
Affinity homogenous heterogenous
Table 5 1 3 1  Comparison o f  some the properties o f  monoclonal and
polyclonal antibodies Table taken from  Tijssen (1985)
5 1 3  2 M onoclonal antibody production
In 1975, Kohler and Milstein fused antibody-producing mouse spleen cells with mouse 
myeloma cells (Hurrell, 1988, and Rom, 1994) The hybrid formed le the fusion 
product, secretes antibodies of the specificity dictated by the spleen cells, of the 
immunised animal, but in the quanuty characteristic of a myeloma An outline of the 
procedure for the production of monoclonal antibodies is shown in Figure 5 13 2 1 
The plasma cells of the spleen, taken from an immunised animal, are fused with a 
myeloma cell line The characteristics for the ideal myeloma cell are 
1 The myeloma cell does not secrete an antibody of its own
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2 They are usually deficient in the enzyme hypoxanthme-guanine phosphonbosyl 
transferase (HGPRT) HGPRT deficient cells when grown in media containing 
hypoxanthine, ammoptenn and thymidine (HAT) cannot synthesis DNA
3 The cell has the necessary machinery needed for high level of protein synthesis 
and secretion
4 The cells are well characterised in terms of growth characteristics and genetics
The fusion products formed are isolated by selective growth on HAT medium In the 
HAT medium the myeloma cells die because they cannot synthesise DNA for their 
survival The spleen cells die naturally in culture In the HAT media the hybndoma can 
synthesise DNA and it will survive The hybndoma cells are not HGPRT deficient 
thanks to the spleen cell, and it will survive due to the robust nature of the myeloma 
One then has an immortalised hybndoma cell that produces antibodies Many 
hybndomas will be formed by the fusion of myeloma and the splenocytes and each in 
turn will produce an antibody One hybnd secretes one specific antibody The vanous 
antibodies secreted are screened by the use of enzyme-linked immuno-sorbent assay 
(ELISA), or radio immunoassays (RIA) The hybnd selectively secreting the antibody 
of interest is then cloned The cells are then produced in batch culture, or as ascitic 
tumours, and the antibody is punfied from solution and charactensed
Monoclonal antibodies are used in cancer diagnosis and therapy (Borrebaeck and 
Lamck, 1990, Epenetos, 1991, Roitt, 1994, and Kuby, 1994) including tumour imaging, 
in blood group analysis (Roitt 1994, and Kuby, 1994), m virology (McMichael and 
Fabre, 1982) They can be radiolabelled and used for the detection of tumours and 
metastases (Epenetos, 1991) They are used in affinity columns for isolation of 
interferons, growth factors, and tumour antigens (Kuby, 1994) Monoclonal antibodies 
can also be used for the removal of drugs from the circulation e g digoxin and addictive 
drugs (Hurrell, 1988) They can be used for targeting of drugs (e g ncin) or radioactive 
matenal to tumour sites for treatment of cancer (Roitt 1994, and Kuby 1994) These 
are only some of the numerous applications of monoclonal antibodies Table 5 1 3 1 is 
a companson of some of the properties of monoclonal and polyclonal antibodies
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Figure 5 1 3 2 1  Scheme fo r  the production o f  monoclonal antibodies 
(procedure described in text) The diagram is adapted from  Cahill et al (1995)
5 1 3  3 Antibody engineering
One form of antibody production used involves the isolation of the genes that code for 
the production of heavy and/or light chains from cells of the immune system from the 
animal of interest (Killard et a l, 1995) These cells can be from the spleen, blood, 
lymph node or bone marrow These genes can be combined and expressed as antibody 
proteins on the surface of a phage particle (a virus that infects bacterial cells) The 
phage producing the best antibody affinities are transfected into bactena and the bacteria 
are grown in media. Antibodies produced by the transfected bactena can be isolated 
from the media, or from cell lysate The antibodies are then punfied and charactensed 
Typically only ponions of the antibodies e g VH, VL, and CH or a combination of them
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i e the Fab fragment (see Figure 5 1 1 ) are produced by antibody engineering The 
antibody fragments prepared can be used in sensor applications (Killard et a l, 1995) or 
the system can be adapted to produce humanised antibodies Antibodies from a non­
human foreign species will illicit an immune response in humans The humanised 
antibodies produced by antibody engineering will overcome this major disadvantage of 
antibodies for use in therapy or imaging in humans
5 1 3  4 Bifunctional antibodies
An antibody has two arms that bind to the same antigen (Figure 5 11) which function 
in triggering effector cells and in forming immune complexes Antibodies, that have 
binding specificities for two unique species, can be produced by several methods 
Bispecific/bifunctional antibodies have specificity for two distinct antigens (Nolan and 
O’Kennedy, 1992, Fanger, 1995, and Cahill et a l, 1995) Figure 5 13 4 1 illustrates 
two of the methods available for the production of these antibodies
Hybndoma producing 
antibody A
Hybndoma producing 
antibody B
Quadroma secreting 
antibodies with affinities for 
A and B
^  A y■s\,\ V / Fuston
-■i .V * + n — ** TII , 1
BIOLOGICAL
Antibody A
\K >
CHEMICAL
Antibody B Bifimctional Antibody
(=),
Cross linking retgeni
/\ u ou u
f f f
Cross linking reagent
Figure 5 1 3  41 Strategies for the biological and chemical production of bispecific 
antibodies The biological production of bifunctional antibodies requires the fusion of two 
hybndomaSj that produce two different antibodies A and B, to form a quadroma which 
secretes a bifunctional antibody with the same specificities as antibodies A and B Most 
chemical methods start with pepsin digestion to produce Ffab'h fragments (see Figure 
5 11 ) of two unique antibodies The disulphide bonds are reduced to the F(ab') fragments, 
using mercaptoethylamine, in the presence of sodium arsemte and Ellmanys agent The 
F(ab') fragments from each antibody are mixed in equimolar quantities and recombined 
under appropriate conditions to produce the hybrid F(ab')2 bifunctional anttbody
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The bispecific nature of the bifunctional antibody lends them to uses in novel 
applications e g non-enzyme-based immuno assays, and in drug targeting to tumour 
sites The biological production of bifunctional antibodies involves the fusion of two 
hybndomas, producing two specific antibodies, to form a quadroma that secretes 
antibodies with a bispecific nature determined by the two specific antibodies Chemical 
techniques for the production of bifunctional antibodies typically start with pepsin 
digesnon to produce F(ab'>2 fragments (see Figure 5 1 1 ) of two unique antibodies 
The disulphide bonds are reduced to produce the F(ab') fragments, using 
mercaptoethylamine, in the presence of sodium arsenite and Ellman’s agent The F(ab') 
fragments from each antibody are mixed in equimolar quantities and recombined under 
appropriate (e g they can be recombined using o-phenylene dimaleimide as a cross- 
linking agent), conditions to produce the hybnd F(ab') 2 bifunctional antibody
Bifunctional antibodies can be used in non-enzyme-based immunoassays (see section 
1 4 1 1 2) or in drug tumour therapy (Fanger, 1995) They have been used for the 
determination of 7-hydroxycoumann in urine (see section 14 112) In drug tumour 
therapy one arm of a bifunctional antibody can be directed at tumour specific antigens 
and the other arm at a drug or toxin The antibody will bind to the drug or toxin while 
the other arm is free to find the tumour antigen and bind to it giving association site 
directed drug targeting
5 1.4. Detection systems for the measurement of antibody-antigen
interactions
The techniques of radioimmunoassay (RIA) and enzyme-linked immunosorbent assay 
(ELISA) are sensitive for detecting antigens and antibodies, and are extremely 
economical in the use of reagents (Roitt et a l, 1989) RIA and ELISA are the most 
widely used immunological assays Multiple assays may be earned out in a relatively 
short time In RIA, detection is based on the measurement of the radioactivity emission 
from a radioactive label on an antibody or antigen The units of measurement are counts 
per minute (cpm) and it is related to the amount of radioactive species labelled to the
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antigen or antibody present The assay system used in RIA is similar to that employed 
for ELISA (see section 5 14 1) In an ELISA assay system, detection is, typically, 
based on a colounmetnc change after the reaction of an enzyme with its substrate to 
produce a coloured product The absorbance of the coloured product formed is 
dependent on the amount of antibody-antigen interaction in the assay The antibodies 
and antigens used in ELISA should be relatively pure to prevent non-specific reactions 
which may give high background readings Section 1 4 outlines the antibody-based 
immunoanalytical techniques for the determination of coumann and 7-hydroxycoumann 
Section 5 14 1 outlines the theory, advantages and disadvantages of an ELISA and it 
describes an ELISA for the determination of 7-hydroxycoumann in unne
5 1 4 1  Enzym e-Linked Im m unosorbent Assay (ELISA)
One of the most popular methods for measuring the antibody-antigen interaction is the 
ELISA Figure 5 14 11 shows the principle of the use of enzyme labels in a basic 
immunoassay Firstly, the antigen is immobilised to the surface of a plastic well of an 
ELISA plate (typically in a ‘96-weir format) An antibody (labelled with an enzyme) 
raised against the antigen is then added and allowed to interact with the immobilised 
antigen
Immobilise, 
antigen A
> — ©
Add antibody ' 
with enzyme 
label
© Colourless
substrate
< S >
Labelled antibody Add enzyme Enzyme surrounded by 
bound to antigen substrate coloured product
Figure 5 1 4 1 1  Schem atic representation showing the basic principle in the 
use o f  enzyme labels in a basic immunoassay The presence o f  the antigen is 
detected using the enzym e-labelled antibody The am ount o f  coloured product is 
proportional to the concentration o f  the enzyme and thus to the concentration o f  the 
antigen
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A colourless substrate, for that particular enzyme, is then added and the amount of 
coloured product formed is determined spectrophotometncally The amount of 
coloured product is proportional to the amount of enzyme present and thus, to the 
concentration of the antigen All ELISA are adaptations of the one described in Figure 
5 14 11 ELISA’s can be adapted for each particular application Heterogenous (see 
section 1 4) ELISA’s can be divided into competitive and non-competitive systems An 
example of a competitive ELISA, is where antibody is immobilised on a solid surface of 
a 96 well ELISA plate Enzyme-labelled and unlabelled antigen are then added into the 
assay well after washing A competition between the labelled and unlabelled antigen for 
antibody-antigen interaction occurs After the removal of unbound antigen, the 
substrate for the enzyme is added and the amount of coloured product, le the 
absorbance, formed by the reaction of the enzyme and substrate is determined The 
enzyme activity (e g determined by the absorbance of the enzyme-substrate reaction) is 
inversely proportional to the concentration of unlabelled antigen
In non-competitive ELISA e g antibody is immobilised at the solid surface After 
washing away any antibody excess, antigen is added and allowed to bind to the antibody 
A secondary enzyme-labelled antibody (which reacts with a different epitope on the 
antigen) is then added and the enzyme activity is determined after the addition of the 
substrate The enzymes used in an ELISA must fill the following criteria They must be 
cheap, easy to conjugate chemically without loosing their activity, be stable, have high 
purity, be easily prepared, there should be no endogenous enzyme activity in the 
samples, no interfering species should be present that would inhibit enzyme activity or 
cause pH extremes, and the product formed should be easily detectable The most 
common enzymes and their respective substrates are given in Table 5 14 11
Enzyme Substrate
Horseradish peroxidase 
Alkaline phosphatase 
ß-galactosidase 
Glucose oxidase 
Urease
o-phenylenediamme
p-nitrophenylphosphate
o-mtrophenylphosphate
p-D-glucose
urea
Table 5 1 4 1 1  The enzymes and substrates m ost commonly used in ELISA 
(Table taken from  Tijssen , 1985)
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There are many advantages of enzyme immunoassays These include 
(I) The assay is highly sensitivity and requires very small reagent volumes, (11) The 
antigen-antibody interaction can be of a high specificity avoiding any interferences from 
cross-reactivity and interference from other endogenous species present, (111) The assays 
are relatively cheap and relatively rapid, ( iv )  Both reproducible qualitative and 
quantitative results can be obtained, (v) The product formed between the enzyme and 
the substrate is, generally, easy to detect colounmetncally, (vi) Automation of the assay 
is straight forward, (vn) Enzyme immunoassays are very versatile and can be adapted for 
a variety of applications, (vm) The use of enzymes removes the need for radioactive 
labels and thus, removes problems associated with radiation, ( ix )  Enzyme immunoassays 
are applicable for use with monoclonal and polyclonal antibodies (see section 5 13)
The disadvantages and problems with enzyme immunoassays include 
(I) The antigen-antibody interaction is dependent on the specificity of the antibody for 
the antigen For polyclonal antibodies, there can be batch to batch variations in 
specificities, (11) Extraneous reactions may interfere and cause non-specific binding of 
antibodies to solid surfaces, cells etc This can be overcome by improving blocking 
procedures, (111) It is important to ensure that the antibodies and enzymes used are still 
active and that they are stable in the reaction system, (iv) In order to detect some 
antigen-antibody interactions it is sometimes necessary to add further steps to amplify 
enzyme-substrate activity signal and increase sensitivity, (v) The antibody-enzyme 
labelling may interfere with enzyme activity and antibody-antigen binding The antigen- 
antibody binding and enzyme activities must be tested to ensure that no major 
alterations have occurred in binding charactensties, (vi) If the enzyme label used is on 
the antigen, it is necessary to ensure that there is successful binding of the label to the 
antigen This must be both in quantity and quality le the enzyme activity and the 
antigenic site must be maintained
Enzyme immunoassays are widely used for a variety of applications (Braithwaite, 1995, 
Marks and Kwasowski, 1995, Fukal, 1995, Miyaishi, 1995) These include the 
detection and monitoring of drug levels e g amphetamines, benzodiazepines, and
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morphine (Braithwaite, 1995, Marks and Kwasowski, 1995) They are used for 
measurement of protein levels associated with disease e g Factor VIII in haemophilia 
and for detection of hormone levels e g (3-HCG in pregnancy (Marks and Kwasowski, 
1995) They are used for the detection of food additives, food contaminants and food 
constituents, e g proteins, mycotoxins, and pesticides (Fukal, 1995) They are also 
applied to the area of forensic science e g bloodstain analysis, saliva, semen and drug 
level analysis (Miyaishi, 1995)
5 1  4 2  Determination o f  7-hydroxycoum ann by an antigen-inhibition ELISA
The ELISA developed for the determination of 7-hydroxycoumann was a competitive 
‘antigen-inhibition’ ELISA (Reinartz et a l , 1995) Figure 5 14 2 1 is a diagrammatic 
representation of the antigen-inhibition ELISA developed for the determination of 7- 
hydroxycoumann (see section 2 5 4) It shows what occurs in one single well of a 96 
well plate The assay uses an enzyme-labelled antibody raised against rabbit IgG (the 
source of the anti-7-hydroxycoumann antibody) The following steps are the steps in 
the antigen-inhibition ELISA for the determination of 7-hydroxycoumann (Figure 
51421)
Step 1 Immobilisation of bovine serum albumin (BSA)-7-hydroxycoumann (BSA-7- 
OHC) protein-drug conjugate to the activated plate surface Non-covalent interactions, 
of the hydrophobic type, are the main interactions responsible for this adherence 
Unbound protein-drug is washed away with phosphate buffered saline (PBS)
Step 2 To prevent non-specific binding by other proteins e g anti-7- hydroxycoumann 
antibody, or anti-rabbit-HRP-labelled, any remaining available sites on the plate surface 
are ‘blocked’ with BSA Unbound protein is removed with detergent (Tween-20) in 
PBS
Step 3 7-hydroxycoumann standards or dilutions of the anu-7-hydroxycoumann 
antibody are prepared m PBS A competition for the antibody occurs, between the 7- 
hydroxycoumann coated, via the protein, on the plate and that of the free 7-
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hydroxycoumann in solution The amount of free 7- hydroxycoumann will determine 
the amount of antibody available to bind to the coated 7- hydroxycoumann
determination o f  7-hydroxycoum ann (7-OHC) by the use o f  anti-7-hydroxycoumann  
antibodies The steps involved in the assay are detailed in the text
Thus, a relationship between the 7-hydroxycoumann concentration and the amount of 
antibody at the plate surface is formed Unwanted antibody, free 7-hydroxycoumann 
and antibody-7-hydroxycoumann complexes are removed with washing
1 Coat plate with 
BSA-7 hydroxycoumann
2 Remaining sites are
blocked with BSA
3 Add free 7 OHC A  and the 
antibody raised against 7 OHC
A competition occurs 
between coaled conjugated 7 OHCand 
free 7 OHC for the antibody
4 Add the goat anti rabbit 
HRP labelled antibody
5 Add substrate (OPD) for the en2yme 
and develop coloured product
Colour (read absorbance)
Figure 5 1 4 2 1  The principle steps in an antigen-inhibition ELISA fo r  the
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Step 4 Addition of a secondary antibody with an enzyme label It is antibody raised in a 
goat against rabbit IgG and labelled with horse-radish peroxidase (HRP) Following 
binding of the secondary antibody to the anti-7-hydroxycoumann antibody and washing 
any excess away, the enzyme substrate is added (step 5)
Step 5 o-Phenylene diamine (OPD) reacts with horse-radish peroxidase (HRP) to give 
a yellow product (see Table 5 14 11) The absorbance of the resultant colour is 
related to the amount of free 7- hydroxycoumann added in step 3 To calculate the 
antibody titre, at step 3 no 7- hydroxycoumann is added However, dilutions of the 
antibody are prepared and added Using a 96 well plate it is possible to carry out 
multiple analysis Each well is an individual assay In theory it is possible to carry out 
96 assays concurrently However, the wells are usually used for analysis in duplicate 
and the mean absorbance values are calculated for each standard or unknown
Step 6 The absorbance reading is proportional to the free 7-hydroxycoumann 
concentration added The absorbance of the standards (A) were divided by the 
maximum absorbance value Ao (A/A0) and plotted versus the log 7-hydroxycoumann 
concentration From this standard curve the concentrations of unknown 7- 
hydroxycoumann concentrations may be calculated
5 2. PRODUCTION OF 7-HYDROXYCOUMARIN-PROTEIN
CONJUGATES USED FOR IMMUNISATION TO PRODUCE 
ANTI-7-HYDROXYCOUMARIN ANTIBODIES AND FOR THE 
SCREENING OF THESE ANTIBODIES.
The conjugation o f 7-hydroxycoumarin utilising haptemc aromatic amino group 
conversion to a diazonium group
It is necessary to conjugate 7-hydroxycoumann to a earner protein in order to stimulate 
the immune response of a host animal to produce antibodies against it Conjugation of 
7-hydroxycoumann to proteins is achieved by prepanng the 3-amino-7- 
hydroxycoumann denvative (see Figure 2 5 11 in section 2 5 1) The conjugation 
reaction occurs in two stages The reaction requires the diazotisation of the amino 
group on the hapten to diazonium chlonde with HC1 and NaN02, which then 
spontaneously couples with the histidine, tyrosine and tryptophan residues on the earner 
protein molecule (see Figure 2 5 11 and section 2 5 1) [Catty and Raykundaha, 1988] 
The highly reactive diazonium ion (in alkaline solution) reacts with the aromatic nng of 
the amino acid residues on the protein The 7-hydroxycoumann was conjugated to 
thyroglobuhn and bovine serum albumin
The thyroglobulm-7-hydroxycoumann produced was used in an immunisation protocol 
for the production of polyclonal sera in New Zealand White rabbits (see section 2 5 2) 
In order to monitor for the production of antibodies to 7-hydroxycoumann (see sections 
2 5 4 and 2 5 5 ) it was necessary to prepare another conjugate of 7-hydroxycoumann 
It is not possible to directly immobilise 7-hydroxycoumann to a plastic surface In order 
to monitor for a specific anti-7-hydroxycoumann antibody from the general population 
of antibodies in the polyclonal antisera, a bovine serum albumin (BSA)-7- 
hydroxycoumann conjugate was produced This was used for screening the antisera for 
the presence of anti-7-hydroxycoumann antibodies in an ELISA (see section 5 14 2) 
The use of the thyroglobulm-7-hydroxycoumann conjugate would give a very high 
background signal due to the presence of many antibodies in the antisera to many 
epitopes on the thyroglobuhn surface There is enough of a difference between the
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surfaces of thyroglobulin and bovine serum albumin to reduce interferences due to any 
background signals from antibodies to epitopes on the bovine serum albumin surface
5 2.1. Synthesis and characterisation of 7-hydroxycoumarm derivatives
The reaction and procedure for the production of 7-hydroxycoumann derivatives is 
descnbed in section 2 5 1 (see also Figure 2 5 11) The method was that described by 
Egan (1993)
5 2  1 1  3-acetylamino-7-aceto-coumann
The compound produced from the refluxing of 2,4-dihydroxybenzaldehyde, glycine, 
sodium acetate and acetic anhydride gave a single spot on TLC after washing and 
recrystallisation from glacial acetic acid The yield was 30 %, and the compound had a 
melting point of 238 °C (literature value - 234 °C) The infra red (IR) analysis (profile 
not shown) showed C=0 stretch (1770 cm l, 1720 cm \ 1670 cml), N-H stretch (3380 
cm1) and C-H stretch (3100 cm1) It is difficult to assign all the other bands due to 
interference from carbonyl groups etc that may cause a shift m the stretching frequency
5 2 1 2  3-amino-7-hydroxy coumartn
The 3-acetylamino-7-aceto-coumann was refluxed in hydrochloric acid to produce 3- 
amino-7-hydroxycoumann After neutralisation, filtration and recrystallisation from 
water methanol the product was analysed by IR, nuclear magnetic resonance (NMR), 
and TLC Analysis of the compound produced by TLC gave two spots which 
corresponded to the TLC of a standard prepared by Egan (1993) which also had two 
spots under TLC The IR analysis (Figure 5 2 12 1) showed asymmetric and 
symmetric stretches of N-H bond (in NH2 moiety) at 3450 cm \ and 3350 cm *), O-H 
stretch (3200 cm l) and C=0 (1700 cm l) Speculative identification of other peaks is 
difficult due to shifts in frequencies caused by other groups present on the molecule e g 
carbonyl groups cause band shifts (James, personal communication, 1996)
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Figure 5 2 1 2 1  Infra red analysis o f 3 -amino-7-hydroxycoumann The IR 
analysis (Figure 5 2  1 2  1 ) showed asymmetric and symmetric stretches of N-H  
bond (in NH2) at 3450 cm \  and 3350 c m 2), O-H stretch (3200 c m }) and C =0 (1700 
c m 2) The infra red spectrometer used was a Nicolet I R  Spectrometer The infra 
red spectra was scanned between 4000 cm 1 and 600 c m 1 and plotted against the % 
transmittance
Proton NMR analysis (Figure 5 2 1 2 3) of 3-amino-7-hydroxycoumann (Figure 
5 2 1 2 2) showed the following chemical shifts A singlet was seen at 5 3 ppm and it 
was assigned to NH2 A doublet and two singlets are seen as a complex mixture at 6 7 
ppm and they are assigned to the two singlet aromatic H ’s and one of the doublet 
aromatic H ’s The doublet at 7 1 ppm is due to the other doublet aromatic H ’s The 
peak at 10 ppm was due to the hydrogen in the hydroxy moiety The peaks at 2 1 ppm 
and 2 5 ppm were due to the dimethylsulphoxide The integration is approximately
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113 2 which would indicate the OH, Aromatic C-H, 3 x aromatic C-H’s, and NH 2 
when related to the structure
Figure 5 2 1 2  2 Structure o f 3-amino-7-hydroxycoumann The hydrogen 
groups and the multiplicity ( te  a single splitting giving a doublet) observed for each 
hydrogen S indicates that there should be a singlet (single peak) and D, that there 
should be a doublet in the NMR spectrum
Figure 5 2 1 2  3 Nuclear magnetic resonance spectrum of 3-amino-7- 
hydroxycoumann Proton NMR analysis o f 3-ammo-7-hydroxycoumann (Figure
5 2 1 2  2 )  showed the following chemical shifts A singlet was seen at 5 3 ppm and it 
was assigned to NH2 A doublet and two singlets are seen as a complex mixture at
6 7 ppm and they are assigned to the two singlet aromatic H*s and one o f the doublet 
aromatic H’s The doublet at 71  ppm is due to the other doublet aromatic H ys The 
peak at 10 ppm was due to the hydrogen in the hydroxy moiety The peaks at 2 1  
ppm and 2 5 ppm were due to the dimethylsulphoxide The integration is 
approximately 1 1 3  2 which would indicate the OH, Aromatic C-H, 3 x aromatic C- 
H*s, and NH2 when related to the structure The nuclear magnetic resonance 
spectrometer used was a Bruker 400 MHz,
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5 2 1 3  Characterisation of thyroglobuhn-7-hydroxycoumann and bovine
serum albumin-7-hydroxycoumann conjugates 
5 2 1 3 1  Ultraviolet (UV) spectral analysis
Control thyroglobulin (see section 2 5 1) and the thyroglobulin-7-hydroxycoumann 
conjugate, formed by the diazotisation of 3-amino-7-hydroxycoumann and its 
subsequent conjugation to a earner protein (see section 2 5 1) were prepared in ultra 
pure water and scanned between 200 nm and 800 nm on a UV spectrophotometer 
Figures 5 2 13 1 (a) and (b) show the UV spectra of control thyroglobulin and 
thyroglobulin-7-hydroxycoumann, respectively Control thyroglobulin had absorbance 
maxima at 200 nm and at 280 nm The brown compound formed had absorbance 
maxima at 200 nm, 280 nm, 330 nm and 480 nm Compounds with azo moieties are 
generally coloured, as observed (absorbances in the visible region) with the protein-drug 
conjugate produced The control thyroglobulin was not coloured (no peak absorbances 
in the visible region) The results for the BSA were similar (results not shown) From 
the UV spectra analysis it was shown that a new compound had been formed that was 
very different from the starting matenal The spectra was also different to that of 7- 
hydroxycoumann which has absorbance maxima at 324 nm and 210 nm (spectra not 
shown)
5 2 1 3 2  Analysis o f conjugates by gel filtration -Sephadex G25 column
A 9 cm X 1 cm Sephadex G25 (Size range 86-258 Jim, fractionation range 100 to 5000 
Da, and the useful pH range was pH 2-13) column was prepared and allowed to 
equilibrate in ultra-pure water The fractionation range of the Sephadex was 100 to 
5000 molecular weight units Thus, any free 7-hydroxycoumann or unconjugated 3- 
amino-7-hydroxycoumann should not elute in the void volume All species with 
molecular weights above 5000 Da should elute in the void volume Blue dextran 
(molecular weight ca 2,000,000 Da) was used to determine the void volume of the 
column The thyroglobulin-7-hydroxycoumann, prepared in water, was then applied 
and the brown band migrated in the void volume indicating that the coloured compound 
was of a large molecular weight The UV scan of the eluting coloured compound was 
recorded (results not shown) and it was found to be the same as that shown in Figure
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5 2 13 1 i e for thyroglobuhn-7-hydroxycoumann No coloured species was observed 
at the top of the Sephadex column indicating that none of the reaction mixture, which 
was a red/brown colour was present after the reaction and dialysis and that the band was 
due only to a large molecular weight species Control thyroglobulm also eluted in the 
void volume (determined by UV analysis of eluted fractions)
(a)
Figures 5 2 1 3 1  (a) and (b) show the UV spectra o f control thyroglobulm and 
thyroglobulm -7-hydroxy coumann. The spectrum were taken between 200 nm and 
800 nm and show peak absorbances at 200 nm, and 280 nm fo r  the control 
thyroglobulin, and at 200 nm, 280 nm, 330 nm and 480 nm fo r  the thyroglobuhn-7- 
hydroxycoumann
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5.2.1.3.3. Analysis o f the conjugates by HPLC
A method was developed for the separation of thyroglobulin and bovine serum albumin 
by HPLC on a Protein-Pak column SW 300 (see section 2.2.3.3.) with UV detection at 
280 nm and analysis of the compounds was also carried out with photodiode array 
detection. It was impossible to differentiate the two molecular weights for thyroglobulin 
and thyroglobulin-7-hydroxycoumarin peaks based on their retention times. The 
protein-pak acts separates species based on their respective molecular weights. Both 
control thyroglobulin and thyroglobulin-7-hydroxycoumarin had retention times of 8.9
min ± 0.02 min. Figure 5.2.1.3.2. shows the overlay of the spectra obtained at four 
different retention times for control thyroglobulin. It is a plot of wavelength (nm) versus 
absorbance (A.U.).
Wavelength 250 -----  600 nm
Figure 5.2.1.3.2. Overlay o f the spectra obtained at fo u r different retention times
fo r control thyroglobulin. The sample was analysed by HPLC with a 100 % ultra- 
pure water mobile phase (flow 0.5 ml/min) with photodiode array detection. (5 nm 
resolution). The spectra were taken at the following times (A) 7.5 min, (B) 8.4 min, 
(C) 9.0 min, and (D) 10.3 min, respectively.
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The times are 7 4 mm, 8 4 mm, 8 9 min and 10 3 nun, respectively The times 
correspond to the chromatogram where (A) there are no other peaks, (B) the side of the 
main peak, (C) the crest of the main peak and (D) after the chromatogram has returned 
to the baseline Figure 5 2 1 3 3 shows the overlay of the spectra obtained at four 
different retention times for thyroglobulin-7-hydroxycoumann The times of each of the 
spectra are the same as in Figure 5 12 3 2
ii
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Figure 5 1 2  3 3 Overlay o f the spectra obtained at four different retention times 
fo r  thyroglobuhn-7-hydroxycoumann The sample was analysed by HPLC with a 
100 % ultra-pure water mobile phase (flow 0 5  ml/mm) with photodiode array 
detection (5 nm resolution) The spectra were taken at the following times (A) 8 0 
min, (B) 8 6 min, (C) 9 0 min, and (D) 10 3 min, respectively
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It is clearly seen that the compound produced by the diazocoupling of the 3-amino-7- 
hydroxycoumann to thyroglobuhn gives a very different profile to that of the control 
thyroglobulin Thus, it was concluded that a new species had been produced that was as 
a result of the diazotisation of 7-hydroxycoumann to thyroglobulin, and similarly for 
bovine serum albumin (results not shown) A plot of contour profile of time versus 
wavelength for the diazocoupled thyroglobulin-7-hydroxycoumann is shown in Figure 
5 2 1 3 4 The peak was scanned from 250 nm to 600 nra from 7 min to 12 min The 
peak maxima are seen at 480 nm, 330 nm and 280 nm
210
Figure 5 2 1 3  4 A plot o f  contour profile o f time versus wavelength fo r the 
diazocoupled thyroglobuhn-7-hydroxycoumann is shown in Figure 5 2 1 3 4  The 
peak was scanned from 250 nm to 600 nmfrom 7 min to 12 min . The peak maxima 
are seen at 480 nm, 330 nm and 280 nm . The sample was analysed by HPLC on a 
Protein pak SW 300 with a 100 % ultra-pure water mobile phase (flow 0 5  milmin) 
with photodiode array detection (5 nm resolution)
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5 3 PRODUCTION AND PURIFICATION OF
ANTI-7-H YDROX Y C 0  UM ARIN ANTIBODIES
5 3 1 Purification of anti-7-hydroxycoumarin antibodies from serum
IgG’s are the most basic of the proteins in serum and they have properties that allow 
their separation from other proteins on the basis of their different physicochemical 
properties e g salt fracnonation, and affinity chromatography (Tyssen, 1985) The anti- 
7-hydroxycoumann antisera was purified by ammonium sulphate precipitation and Affi- 
T affinity chromatography (see section 25 3) Reinartz et a l , (1995) described a 
method for the affinity purification of only anti-7-hydroxycoumann antibodies 
Precipitation by sal ting-out to remove non-specific proteins is highly effective, simple, 
cheap, it avoids direct effects on the protein and concentrates the protein After 
precipitation of the IgG the sample was reconstituted into the running buffer before 
separation and purification by affinity chromatography
Affi-T is a thiophilic agent that binds the thiol- groups present in IgG, thus, allowing a 
separation of all IgG present It does not selectively separate out anti-7- 
hydroxycoumann antibodies The column was allowed to equilibrate in running buffer 
(0 75 M  (NFLO2SO4) and the sample was then applied to the column and fractions were 
taken every 1 ml The absorbance of every fraction was monitored at 280 nm Figure 
5 3 11 shows a plot of the fraction number (1 ml fractions) versus absorbance (A U , 
monitored at 280 nm) for the purification of the polyclonal antisera by Affi-T affinity 
chromatography after ammonium sulphate precipitation When the absorbance had 
decreased to 0 1 A U (absorbance units) the running buffer was replaced with the 
elution buffer (50 m M  tns-HCl, pH 7 4) at the point marked in Figure 5 3 11 The 
fractions (25-30) with the highest absorbances were pooled and dialysed against 0 1 M  
PBS, pH 7 4 at 4 °C The concentration of the resultant compound in solution was 
determined by the Bicinchomnic acid (BCA) assay, and characterised by HPLC to assess 
its molecular weight (see section 5 3 2) and purity
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The antibody titre (section 5 3 3 ) and cross reactivity (section 5 34) was determined 
for the purified antibody After characterisation it was used in an ELISA for the 
determination of free and total 7-hydroxycoumann in unne samples from a volunteer 
who had been treated with coumann
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Figure 5 3 1 1  Plot o f fraction no (1 ml fractions) versus absorbance at 280 
nm (A U ) fo r the purification o f  anti-7-hydroxycoumann antibodies by Affi-T 
affinity chromatography When the absorbance had decreased to 0 1  A U 
(absorbance units) the running buffer was replaced (fraction 21) with the elution 
buffer (50 mM tns-HCl, pH 7 4) The fractions with the highest absorbances (25-30) 
were pooled and dialysed against PBS The method is descnbed in section 2 5 3
5 3 2 Analysis of an anti-7-hydroxycoumarin antibody by HPLC
High-performance liquid chromatography was used to assess the purity of the antibodies 
purified after affinity chromatography The molecular weight of the antibody was also 
determined by this method by comparing the retention times of the antibody to those of 
a set of protein molecular weight standards Figure 5 3 2 1 shows a chromatogram of 
the separation of the purified antibody Purity was determined from a comparison of the 
percentage area occupied by the peak of interest to all other peaks present This is
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determined by System Gold software (see section 4 0) The purity of the antibody in 
this sample was 97 5 %
Time (min)
Figure 5 3 2  1 Chromatogram o f the separation o f an antibody purified by 
salt precipitation and affinity chromatography The sample was analysed by HPLC 
as described in section 2 2 3 3 The retention time was 16 2 min and the punty o f the 
peak was 97 5 % Separation was carried out on a Protein-Pak SW 300 (particle 
diameter 10 jjm ) The flow  rate was 0 5 ml!min and detection was at 280 nm
The molecular weight of the antibody was determined from a plot of the log of the 
molecular weight versus retention times for a set of protein standards / retention time of 
an unretained protein i e blue dextran (Figure 5 3 2 2) The equation of the line was Y 
= 3 03 - 0 31 Log X, R2 = 0 98 The molecular weight protein standards analysed, their 
molecular weights and their respective retention times were- cytochrome c (ca 12,400
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Da) 20 7 min, carbonic anhydrase (ca 29,000 Da) 19 5 min, bovine serum albumin (ca 
66,000 Da) 17 7 min, p-amylase (ca 200,000 Da) 15 9 min, apofemtin (ca 443,000 
Da) 15 3 min and blue dextran (ca 2,000,000 Da) was 11 5 min The retention time for 
the antibody was 16 2 min The molecular weight determined for the antibody was ca 
159,300 Da
10000 100000 1000000 
Log molecular weight
Figure 5 3 2 2 Plot o f the log molecular weight o f protein standards versus 
retention time The proteins analysed, their molecular weights and their respective 
retention times were- cytochrome c (ca  12,400 Da) 20 7 min, carbonic anhydrase 
(ca 29,000 Da) 19 5 min, bovine serum albumin (ca 66,000 Da) 17 7 min, , P- 
amylase (ca 200,000 Da) 15 9 min, apofemtin (ca 443,000 Da) 15 3 min and blue 
dextran (ca 2,000,000 Da) was 11 5 min The graph was used fo r  the determination 
of the molecular weight o f the purified anti-7-hydroxycoumann antibody The 
retention time fo r  the antibody was 16 2 min The molecular weight o f the antibody 
was determined as ca  159¿00 The equation o f the line was y  = 3 03 - 0 31 log X, R2 
= 0 96 The samples were analysed by HPLC as described in section 2 2 3 3
5 3 3. Determination of antibody activity (titre)
The antiserum and punfied antibody were serially diluted (in 1 % (w/v) BSA in 0 14 M  
PBS, pH 7 4 containing 0 05 % (v/v) tween-20) and the activity of the antibody was
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assessed at the different dilutions (Table 5 3 3 1 ) This was tested by preparing the 
ELISA plate as described in section 2 5 4 A range of antisera and antibody dilutions 
were prepared (1/500 - 1/160,000) and these were added to each of six wells No free 
7-hydroxycoumann was added The secondary antibody was then added and the colour 
was developed as described in section 2 5 4 Table 5 3 3 1 are the results for the mean 
absorbances (n=6) ± standard deviation, for the antisera and the purified antibody and 
the respective dilutions prepared
Dilution
Absorbance 
at 405 nm ( A U )  
Antibody analysis in 
unpunfied antisera
Absorbance 
at 405 nm (A U ) 
Antibody analysis after 
purification
1/500 1 01 ± 8E-3
1/1000 0 74 ±0 02
1/1250 0 90 ± 0 02
1/2000 0 42 ± 0 02
1/2500 075 + 001
1/4000 0 25 ± 0 01
1/5000 0 58 ± 0 02
1/8000 0 18 ± 0 01
1/10000 0 39 ± 0 02
1/16000 0 12 ±0 01
1/20000 0261001
1/32000 0 09 ± 4E-31/40000 0 17 ± 0 01
1/64000 0 07 ± IE-31/80000 0 11 ± 0 01
1/128000 0 05 ± 2E-31/160000 0 09 ± 4E-3Negative control 0 07 ± 2E-3 0 05 ± 2E-3
Table 5 3 3 1  Table o f the mean absorbances ±  standard deviation (n=6) as
determined by ELISA (see section 2 5 4 )  and the dilutions o f rabbit antisera and 
purified antibody These absorbances were used to determine the titre o f the 
antibody The negative control was carried out as described in section 2 5 4 except 
there was no bovine serum albumin-7-hydroxy coumann coated on the plate The 
results were plotted against the log o f the reciprocal dilution (see Figure 5 3 3 1 )
The mean absorbances were plotted against the log of the reciprocal dilution (Figure 
5 3 3 1 ) The ELISA on the negative control was earned out as desenbed in section
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2 5 4 except there was no BSA-7-OHC coated on the plate The remaining steps of the 
ELISA were earned out as desenbed in section 2 5 4 For Figure 5 3 3 1 the negative 
control, îe the background reading, absorbance was subtracted from each mean 
absorbance
Log reciprocal dilution
Figure 5 3 3 1  Plot o f log reciprocal dilution versus absorbance at 405 nm 
(A U ) fo r determination of antibody activity (titre) in the antisera and after 
purification The ELISA was earned out as desenbed in section 2 5 4 The dilutions 
and their respective dilutions are tabulated in Table 5 3 3 1
Activity of the anti-7-hydroxycoumann before punfication from the serum l e in the 
antisera, was detectable to a dilution of 1/160,000 The activity of the antibody after 
punfication was detected to a dilution of 1/64,000 The concentration of antibody used 
was 3 mg/ml At a dilution of 1/64,000 there was 47 picograms (4 7E-8 grams) of 
protein present per millilitre A dilution of 1/500 was used for the determination of 7- 
hydroxycoumann in unne
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5 3 4 Cross-reactivity of the anti-7-hydroxycoumarin antibody
The cross-reactivity of the punfied antibody was assessed using an ELISA system as 
described in section 2 5 4 using several structurally related coumann compounds 
instead of 7-hydroxycoumann These were coumann, coumann-3-carboxylic acid, 7- 
hydroxycoumann-glucuronide and 3-amino-7-hydroxycoumann A range of 7- 
hydroxycoumann concentrations (0 -25 |ig/ml) were prepared and an ELISA was 
earned out (see section 2 5 4) The results from this ELISA was compared to the 
results from the ELISA earned out with the other coumanns The ELISA was earned 
out as desenbed in section 2 5 4 The method was adapted by adding a set amount (10 
jig/ml, 20 |xg/ml or 25 |ig/ml) of the compound, being assessed for the antibody cross- 
reactivity, as well as 7-hydroxycoumann to each of three wells In other wells a range 
of concentrations (0, 1,5, 10 and 20 jig/ml) of the compound under examination were 
added without any 7-hydroxycoumann The absorbances after the addition of substrate 
were compared to the control ELISA results The antibody showed no cross-reactivity 
for coumann, coumann 3-carboxyhc acid, or 7-hydroxycoumann-glucuromde but there 
was some cross-reactivity for 3-amino-7-hydroxycoumann (Figure 5 3 4 1 ) The 
activity of the antibody was not inhibited by coumann, 7-hydroxycoumann-glucuromde 
or by coumann-3-carboxylic acid
Cross-reaction will occur for an antibody to a species with one identical determinant 
(see section 5 12 4) The other determinants will not have any affinity for the antigenic 
site The protein-conjugate produced, (see section 5 2 ) for immunisation of the rabbit 
host, involved the preparation of 3-amino-7-hydroxycoumann (see section 5 2 12) 
This was then diazocoupled to thyroglobulin before its use in immunisation of the host 
species The structure of 3-ammo-7-hydroxycoumann is very similar (see section 
5 12 4) to that of 7-hydroxycoumann (Figure 5 3 4 2) l e it will possess similar 
determinants to that of the 7-hydroxycoumann The 7-hydroxycoumann moiety on the 
protein surface is held in the 3-position through the diazo coupling of the ammo group 
to the aromatic amino acids (see section 5 2 )
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Compound concentration (ug/ml)
Figure 5 3 4 1  Assessing the cross-reactivity o f the anti-7-hydroxycoumann
antibody The figure is a plot o f concentration (\iglml) o f the compounds under 
examination versus AfAo There was some cross-reactivity with the 3-ammo-7- 
hydroxycoumann The legend fo r each compound is given on the plot
7-hydroxycoum arin  3 -am ino-7-hydroxycoum arin
Figure 5 3 4 2  Structures o f 7-hydroxycoumann and 3-ammo-7- 
hydroxycoumann
Only the 7-hydroxycoumann moiety on the molecule is ‘free’ to interact with the 
immune system and an antibody will be raised against this determinant The 3-amino- 
moiety of the diazocoupled protein-drug complex cannot elicit an antibody response due 
to its positioning on the protein-drug conjugate Thus, the cross-reactivity observed for
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3-amino-7-hydroxycoumann was attributed to the 7-hydroxycoumann side of the 
molecule
5.3 5 The use of the anti-7-hydroxycoumann antibody for the
determination of 7-hydroxycoumarin
The purified antibody was utilised in an ELISA for the determination of free and total 7- 
hydroxycoumann in unne (see section 5 14 1 and 5 3 5 1 ) It was also used by Deasy 
et a l , (1994) and Lu et a l , (1996) for the determination of free 7-hydroxycoumann 
using electrochemical detection An enzyme-linked electrochemical competitive 
immunoassay was developed by Deasy et al (1994) and is descnbed in section 14 2 Lu et 
al (1996) developed a regeneratable enzyme immunosensor for 7-hydroxycoumann based 
on electrochemical detection (see section 14 2) The methods and applications, utilising the 
purified antibody, are descnbed A bispecific antibody was produced from the anti- 
thyroglobulm-7-hydroxycoumann and an anti-alkaline phosphatase antibody (see section 
1411) The product was used to develop a one-step antigen inhibition ELISA for the 
detection of 7-hydroxycoumann in unne (Reinartz et a l, 1996) A competitive 
immunoassay for the analysis of 7-hydroxycoumann in biological samples was developed, 
based on a commercial biosensor system (see section 14 3) - the BIAcore™ from 
Pharmacia Biosensor (Keating and O’Kennedy, 1995)
5 3 5 1  An ELISA fo r  the determination o f free and total 7-hydroxycoumann
in unne
The punfied antibody was utilised in an ELISA for the determination of free and total 7- 
hydroxycoumann in unne in a volunteer who had been treated with 250 mg of coumann 
(see section 5 14 1 for a descnption of the ELISA, and see section 2 5 4 for the 
method) Samples and 7-hydroxycoumann standards were prepared (see section 2 5 4) 
and analysed by the ELISA method as descnbed by Reinartz et al, (1995) The 
optimum dilution of the punfied antibody prepared for the ELISA was found to be 
1/500 The samples prepared were also analysed by HPLC and by CE 10 (il of sample 
was taken for analysis by ELISA (see section 2 5 4), 20 jil of sample was taken for CE 
analysis (see section 2 3 3 1 ) and the remainder was used for HPLC analysis (adapted
T
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from the gradient elution method descnbed in section 2 2 2 2 2 - the sample was 
analysed after clean-up without the trichloroacetic acid step and without the addition of
4-hydroxycoumann)
The mean absorbances (A) for each of the standards were calculated and divided by the 
maximal absorbance (Ao) [1 e A/A0] and plotted against the log of the concentration of 
7-hydroxycoumann (Figure 5 3 5 1 ) giving a standard curve from which the 
concentrations of 7-hydroxycoumann in the unknown unne samples were determined
Log 7 hydroxycoumann concentration (ug/ml)
Figure 5 3 5 1  Plot o f the log total 7-hydroxycoumann concentration ( 0 - 5 0
\iglml) versus the mean absorbances (A) divided by the maximal absorbance (Ao) 
[i e AfA0]  as determined by ELISA The 7-hydroxycoumann was prepared in unne, 
extracted, reconstituted and analysed by ELISA as descnbed in section 2 5 4  The 
equation o f the line is Y = 0 92 - 0 37 log X, R2 = 0 98 The antibody dilution used 
in the ELISA was If500
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The concentrations of free and total 7-hydroxycoumann determined by each of the 
methods are given in Table 5 3 5 1 There was no statistical difference between each of 
the methods
Sample and 
Time
ELISA CE 
method 1
HPLC
7-hydroxycoumann 7-hydroxycoumann 7-hydroxycoumarm
concentration concentration concentration
(hr) (UR/ml) (Mfi/ml) (Ug/ml)
Total 7-hydroxycoumann
0 30 20 0
2 1882 0 1980 0 1808 0
6 550 4 576 0 560 0
10 600 74 8 65 6
14 23 1 24 2 215
24 33 55 38
Free 7-hydroxycoumann
0 0 0 0
2 58 2 52 1 51 8
6 19 6 19 4 36 1
10 15 2 1 79
14 0 0 10
24 0 0 0
Table 5 3 5 1  Results fo r the determination o f  free and total 7-
hydroxycoumann in unne The samples were extracted into diethyl ether, 
evaporated to dryness and reconstituted into 200 \il o f 25 mM phosphate buffer 10 
\il o f sample was taken fo r  analysis by ELISA (see section 2 5 4 ), 20 \xl o f sample 
was taken fo r  CE analysis (see section 2 3 3 1 )  and the remainder was used for  
HPLC analysis (adapted from the gradient elution method described in section 
2 2 2 2 2 - the sample was analysed after clean-up without the trichloroacetic acid 
step and without the addition o f 4-hydroxycoumann) The results fo r the ELISA 
were determined from  the mean absorbance A/A0 (n=5) The CE and HPLC results 
were determined by single analysis
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Summary
This chapter descnbed the preparation of 7-hydroxycoumann-protein conjugates by the 
diazocoupling of the 3-aimno-7-hydroxycoumann derivative to the earner protein 
molecule le thyroglobuhn and bovine serum albumin These conjugates were 
characterised and the thyroglobuhn conjugate was used for the immunisation of two 
rabbits for the production of anti-7-hydroxycoumann antibodies The antibodies 
produced were screened with bovine serum albumin-7-hydroxycoumann protein 
conjugate The antibodies were characterised and used for the determination of free and 
total 7-hydroxycoumann in unne They were also used by other researchers for the 
prepara Don of a bispecific antibody (anti-7-hydroxycoumann - anti-alkaline 
phosphatase), in the development of electrochemical immunosensors and in an assay on 
a commercial biosensor The conjugates produced and the resultant antibodies were 
shown to be very adaptable and useful for a range of applications
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OVERALL CONCLUSIONS
CHAPTER 6
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The work presented in this thesis has focused on three areas of the novel determination 
of coumann, its metabolites, and their applications Figure 6 1 is a list of the some of 
the advantages and disadvantages of each method
225
Chapter 3 described the development and validation of several capillary electrophoretic 
separation methods for the determination of 7-hydroxycoumann and 7- 
hydroxycoumann-glucuromde for a range of applications 7-hydroxycoumann was 
extracted from unne and serum, as descnbed before (Egan and O’Kennedy, 1992) but 
the analysis time was greatly decreased as compared to HPLC The method developed 
for the determination of 7-hydroxycoumann in unne and serum was then adapted for the 
direct determination of 7-hydroxycoumann after the in vitro metabolism of coumann by 
liver microsomes in a range of different species The method was shown to be fast and 
reliable without the need for stopping the reaction before analysis Multiple runs were 
possible without any visible detenoration in capillary performance A separation method 
was then developed using another phosphate buffer-based electrolyte solution This was 
applied to the direct determination of 7-hydroxycoumann and 7-hydroxycoumann- 
glucuronide in unne without any sample clean-up and also to the study of the in vitro 
undine diphosphate glucuronyl transferase activity in liver homogenate The method 
developed was both fast and reliable and required minimal sample preparation The 
methods developed and descnbed in this chapter were applied to both in vivo and in 
vitro analysis of coumann and 7-hydroxycoumann metabolism
The CE methods developed were shown to be very applicable to these studies and 
comparable to any other analytical methods available Separations are fast, 
reproducibility is very good but the methods were found not to be as sensitive as HPLC 
or antibody detection CE is an excellent tool for the determination of coumanns 
However, with the development of fluorescence and electrochemical detectors the limits 
of sensitivity will, no doubt, make the method very sensitive for low level coumann 
determinations Future ideas for developing CE for the analysis of coumann may be in 
the area of determining inter-organ differences in UDPGT and P-glucuromdase 
activities The use of laser induced fluorescence (LIF) detection may be developed for 
the determination of the fluorescent 7-hydroxycoumann Other in vivo and in vitro 
coumann metabolites may be studied including 7-hydroxycoumann-sulphate and 3- 
hydroxycoumann
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Chapter 4 outlined the development of a HPLC method for the direct determination of 
coumann, 7-hydroxycoumann and 7-hydroxycoumann-glucuronide in urine, plasma and 
serum with minimal sample preparation The HPLC separation method was validated in 
each of the biological fluids Samples of unne and plasma were obtained from 
volunteers who had been treated with coumann and serum samples were obtained from 
patients who were treated with 7-hydroxycoumann The method was also applied to the 
study of UDPGT activity in bovine liver homogenate The second section utilised the 
method of Egan and O’Kennedy (1992) for the study of the metabolism of 7- 
hydroxycoumann in patients with advanced malignancies The serum drug profiles of 59 
patients who had been treated with a range of doses of 7-hydroxycoumann were 
determined HPLC was found to be a very adaptable technique for a range of 
applications with very good reproducibility and sensitivity The system was found to be 
very suitable for large scale determination of coumann and some of its metabolites in 
serum, plasma and drug levels The method developed based on gradient elution had 
not been developed when the serum samples from the study were analysed This newer 
method would have been much less time consuming and less costly with respect to 
sample preparation and matenals used Future studies for the use of HPLC in the 
analysis of coumanns may be to look at other coumann metabolites both in vivo and in 
vitro in different organs and in different species
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7-hydroxycoumann-protein conjugates were prepared and utilised in the preparation of 
anti-7-hydroxycoumann antibodies The methods of preparation and the 
characterisation and utilisation of the antibody is descnbed in Chapter 5 The chapter 
describes the production of 7-hydroxycoumann-thyroglobulin by the conjugation of 7- 
hydroxycoumann utilising haptenic aromatic amino group conversion to a diazonium 
group The characterisation of the product formed and the components produced 
during each of the steps are detailed The conjugate was then used for immunisation to 
produce an anti-7-hydroxycoumann antibody The antibody was punfied, characterised 
and utilised for the determination of 7-hydroxycoumann in unne by ELISA The 
antibody produced was also used by other researchers for the production of bispecific 
antibodies and their use in an antigen-inhibition ELISA, in the development of 
electrochemical immunosensors, and in an assay on a commercial biosensor The 
antibody used for the ELISA developed was sensitive for the determination of 7- 
hydroxycoumann in unne The antibody was found to be cross-reactive for 3-ammo-7- 
hydroxycoumann The antibody was also found to be adaptable for a range of 
applications (i e production of the bispecific antibody etc ) apart from its use unaltered 
le in a basic ELISA The conjugates produced have also been used for the 
immunisation of mouse for the production of monoclonal antibodies and for the 
screening of antibodies made by genetic engineenng and by in vitro immunisation The 
methods descnbed for the preparation of each of the protein-7-hydroxycoumann 
conjugates can be adapted for a range of proteins or for other 7-hydroxycoumann 
denvatives The limit of other applications for the antibody was never reached It is 
possible to develop some other ELISA methods, to utilise antibody fragments for 
treatment and for the elucidation of 7-hydroxycoumann mode of action It may also be 
possible to develop a novel assay on capillary electrophoresis to investigate the 
antibody-antigen interaction
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Capillary Electrophoresis
Advantages Rapid method development 
Rapid analysis time 
Small sample and buffer volumes 
Relatively rapid sample turnover time 
Reproducible and accurate 
Autosampler allows multiple sample 
analysis
Disadvantages Not very sensitive limit of detecuon
Uses
■\
Determination of 7-hydroxycoumarin and 
7-hydroxy coumarm-glucuromde after the 
in vivo and in vitro metabolism of coumarm 
and determination of UDPGT activity m liver 
homogenate
Analysis of serum and unne samples
High Performance Liquid Chromatography
Uses Determination of 7-hydroxycoumarin and
7-hydroxycoumarin-glucuromde after the 
in vivo and in vitro metabolism of coumarm 
and determination of UDPGT activity m liver 
homogenate
Analysis of serum, plasma and urme samples
Enzyme-linked immunosorbent assay
Advantages Relatively fast analysis time 
Sensitive LOD 
Reproducible and accurate 
Autosampler allows 
mutiple analysis
Disadvantages Relauvely large sample 
and solvent volumes 
required
Advantages Very sensitive LOD 
Multiple simultaneous 
sample analysis
Uses Determination of free and total 7-hydroxy coumarm
m urine samples
Disadvantages Time consuming 
Labour intensive 
Care must be taken to 
in the handling and 
storage of antibodies
IFigure 61  Advantages, disadvantages and uses o f  capillary electrophoresis, high
performance liquid chromatography and an enzyme-linked 
immunosorbent assay
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